


**CUMULATIVE
SUPPLEMENT 6
JUNE 2020**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**Cumulative Supplement 6
June 2020**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3 APPLICANT NAME CHANGES.....	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**CUMULATIVE SUPPLEMENT 6
JUNE 2020**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
ACP NIMBLE BUYER INC (ACP NIMBLE)	COSETTE PHARMACEUTICALS INC (COSETTE)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
AMERICAN ANTIBIOTICS INC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)

AMERICAN ANTIBIOTICS LLC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
SUVEN LIFE SCIENCES LTD (SUVEN LIFE)	SUVEN PHARMACEUTICALS LTD (SUVEN PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2019</u>	<u>MAR 2020</u>	<u>JUN 2020</u>	<u>SEP 2020</u>	<u>DEC 2020</u>
DRUG PRODUCTS	20567	20367	20382		
LISTED SINGLE SOURCE	2743 (13.3%)	2635 (12.9%)	2660 (13.1%)		
MULTISOURCE	17824 (86.7%)	17732 (87.1%)	17722 (86.9%)		
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)	17649 (86.6%)		
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)	73 (0.4%)		
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)		
NEW MOLECULAR ENTITIES APPROVED	17	24	25		
NUMBER OF APPLICANTS	1162	1166	1189		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE
AB DR REDDYS LABS LTD 250MG A208416 001 May 18, 2020 May NEWA

ACARBOSE

TABLET;ORAL
ACARBOSE
@ EMCURE PHARMS LTD 25MG A202271 001 Feb 07, 2012 Mar DISC
@ 50MG A202271 002 Feb 07, 2012 Mar DISC
@ 100MG A202271 003 Feb 07, 2012 Mar DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
>A> AA TARO PHARM INDS LTD 300MG;50MG;40MG A213046 001 Jul 01, 2020 Jun NEWA
TABLET;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
@ HIKMA PHARMS 325MG;50MG;40MG A089718 001 Jun 12, 1995 Feb DISC
@ SPECGX LLC 325MG;50MG;40MG A087804 001 Jan 24, 1985 May DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ ACTAVIS LABS FL INC 300MG;5MG A206470 001 Jun 02, 2016 Feb DISC
@ 300MG;7.5MG A206470 002 Jun 02, 2016 Feb DISC
@ 300MG;10MG A206470 003 Jun 02, 2016 Feb DISC
>D> AA GRANULES PHARMS 325MG;5MG A211729 001 Jan 03, 2020 Jun DISC
>A> @ 325MG;5MG A211729 001 Jan 03, 2020 Jun DISC
>D> AA @ 325MG;7.5MG A211729 002 Jan 03, 2020 Jun DISC
>A> @ 325MG;7.5MG A211729 002 Jan 03, 2020 Jun DISC
>D> AA @ 325MG;10MG A211729 003 Jan 03, 2020 Jun DISC
>A> @ 325MG;10MG A211729 003 Jan 03, 2020 Jun DISC
AA @ PAR PHARM 300MG;5MG A205001 001 Jul 05, 2016 May DISC
AA @ 300MG;7.5MG A205001 002 Jul 05, 2016 May DISC
AA @ 300MG;10MG A205001 003 Jul 05, 2016 May DISC
AA @ XIROMED 325MG;5MG A211690 001 Feb 07, 2020 Mar DISC
AA @ 325MG;5MG A211690 001 Feb 07, 2020 Feb CAHN
AA @ 325MG;5MG A211690 001 Feb 07, 2020 Jan NEWA
AA @ 325MG;7.5MG A211690 002 Feb 07, 2020 Mar DISC
AA @ 325MG;7.5MG A211690 002 Feb 07, 2020 Feb CAHN
AA @ 325MG;7.5MG A211690 002 Feb 07, 2020 Jan NEWA
AA @ 325MG;10MG A211690 003 Feb 07, 2020 Mar DISC
AA @ 325MG;10MG A211690 003 Feb 07, 2020 Feb CAHN
AA @ 325MG;10MG A211690 003 Feb 07, 2020 Jan NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
OXYCODONE AND ACETAMINOPHEN
MIKART INC 300MG/5ML;10MG/5ML A202142 001 Nov 27, 2018 Feb CMFD
TABLET;ORAL
OXYCODONE AND ACETAMINOPHEN
@ GRANULES PHARMS 325MG;2.5MG A211708 001 Oct 31, 2019 May DISC
@ 325MG;5MG A211708 002 Oct 31, 2019 May DISC
@ 325MG;7.5MG A211708 003 Oct 31, 2019 May DISC
@ 325MG;10MG A211708 004 Oct 31, 2019 May DISC
@ WATSON LABS 325MG;5MG A040171 001 Oct 30, 1997 Apr DISC
@ 325MG;7.5MG A040535 001 Sep 05, 2003 Apr DISC
@ 325MG;10MG A040535 002 Sep 05, 2003 Apr DISC
@ XIROMED 325MG;5MG A207574 001 Dec 13, 2016 Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN
@ APOTEX 325MG;37.5MG A078778 001 Apr 07, 2014 Feb DISC
@ GRAVITI PHARMS 325MG;37.5MG A076914 001 Jul 26, 2006 Apr CAHN
@ MACLEODS PHARMS LTD 325MG;37.5MG A206885 001 May 02, 2017 May DISC
@ NOSTRUM LABS INC 325MG;37.5MG A078778 001 Apr 07, 2014 Apr CAHN

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Apr NEWA
AB		250MG	A207503	002	Apr 30, 2020	Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	! XGEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Feb CAHN
----	---------------	--------------------	---------	-----	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Mar CAHN
----	-----------------	----	---------	-----	--------------	----------

ACETIC ACID, GLACIAL; HYDROCORTISON

SOLUTION/DROPS;OTIC

HYDROCORTISON AND ACETIC ACID

AT	COSETTE	2%;1%	A040609	001	Feb 06, 2006	May CAHN
----	---------	-------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

@ DAVA PHARMS INC	200MG	A074833	001	Apr 22, 1997	May DISC
-------------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

ACYCLOVIR

AB ! PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan CHRS
-----------------------	----	---------	-----	--------------	----------

AB + BAUSCH	5%	N021478	001	Dec 30, 2002	Jan CHRS
-------------	----	---------	-----	--------------	----------

OINTMENT;TOPICAL

ACYCLOVIR

AB SOLARIS PHARMA CORP	5%	A212495	001	Apr 07, 2020	Mar NEWA
------------------------	----	---------	-----	--------------	----------

AB XIROMED	5%	A201501	001	Jan 29, 2020	Jan NEWA
------------	----	---------	-----	--------------	----------

SUSPENSION;ORAL

ACYCLOVIR

AB HERITAGE PHARMS INC	200MG/5ML	A212718	001	Apr 23, 2020	Apr NEWA
------------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

AB ! HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan CHRS
------------------------	-------	---------	-----	--------------	----------

+ @ MYLAN

+ @

400MG 800MG

N020089	001	Apr 30, 1991	Jan DISC
---------	-----	--------------	----------

N020089	002	Apr 30, 1991	Jan DISC
---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

>A> AP EXELA PHARMA SCS LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun NEWA
-----------------------------	-----------------	---------	-----	--------------	----------

ADAPALENE

GEL;TOPICAL

ADAPALENE

>A> AB ALEOR DERMACEUTICALS	0.3%	A213508	001	Jun 18, 2020	Jun NEWA
-----------------------------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

@ MYLAN LABS LTD	3MG/ML	A078640	001	Mar 21, 2014	Apr DISC
------------------	--------	---------	-----	--------------	----------

>D> AIR POLYMER-TYPE A

>D> FOAM;INTRAUTERINE

>D> EXEM FOAM KIT

>D> +! GISKIT 10ML

>A> + @ 10ML

N212279 001 Nov 07, 2019 Jun DISC

N212279 001 Nov 07, 2019 Jun DISC

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

>A> AB LUPIN LTD 200MG A211636 001 Jun 10, 2020 Jun NEWA

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

ALBUTEROL SULFATE

AB1	CIPILA	EQ 0.09MG BASE/INH	A209959	001	Apr 08, 2020	Mar NFTG
AB2	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CTEC
AB		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Feb NFTG
	PROAIR HFA					
AB2	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar CTEC
AB	+!	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Feb CFTG
	PROVENTIL-HFA					
AB1	+! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar CFTG
AB1	+! KINDEVA	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN
	SOLUTION;INHALATION					
	ALBUTEROL SULFATE					
AN	AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Apr NEWA
AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Apr NEWA
	@ BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb DISC
AN	! NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb CHRS
	TABLET;ORAL					
	ALBUTEROL SULFATE					
AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020	May NEWA
AB		EQ 4MG BASE	A213657	002	May 14, 2020	May NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	VOLMAX					
+ @ MURO		EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar CRLD
+ @		EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar CRLD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ WATSON LABS TEVA EQ 0.083% BASE;0.017%

A077063 001 Dec 31, 2007 Apr DISC

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

@ EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Apr DISC
@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Apr DISC

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

@ DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb DISC	
@	0.5MG	A074174	002	Oct 19, 1993	Feb DISC	
@	1MG	A074174	003	Oct 19, 1993	Feb DISC	
@	2MG	A074174	004	Oct 19, 1993	Feb DISC	
>D> AB	OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jun DISC
>A>	@	0.25MG	A078491	001	Sep 25, 2008	Jun DISC
>D> AB		0.5MG	A078491	002	Sep 25, 2008	Jun DISC
>A>	@	0.5MG	A078491	002	Sep 25, 2008	Jun DISC
>D> AB		1MG	A078491	003	Sep 25, 2008	Jun DISC
>A>	@	1MG	A078491	003	Sep 25, 2008	Jun DISC
>D> AB		2MG	A078491	004	Dec 12, 2008	Jun DISC
>A>	@	2MG	A078491	004	Dec 12, 2008	Jun DISC
	XANAX					
AB	+ UPJOHN	0.25MG	N018276	001		Apr CAHN
AB	+	0.5MG	N018276	002		Apr CAHN
AB	+!	1MG	N018276	003		Apr CAHN
AB	+	2MG	N018276	004	Nov 27, 1985	Apr CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	XANAX XR					
AB	+ UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr CAHN
AB	+	1MG	N021434	002	Jan 17, 2003	Apr CAHN
AB	+	2MG	N021434	003	Jan 17, 2003	Apr CAHN
AB	+!	3MG	N021434	004	Jan 17, 2003	Apr CAHN

ALVIMOPAN

CAPSULE;ORAL

>D>	ALVIMOPAN						
>D> AB	WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun DISC	
>A>	@	12MG	A208295	001	Dec 19, 2019	Jun DISC	
	ENTEREG						
>D> AB	+! CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun CTEC	
>A>	+!	12MG	N021775	001	May 20, 2008	Jun CTEC	

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

>D> AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jun CHRS
>A> AB	!	100MG	A078720	001	May 29, 2008	Jun CHRS
AB	INVATECH	100MG	A210129	001	Mar 02, 2020	Feb NEWA
AB	RUBICON	100MG	A212044	001	May 21, 2020	May NEWA
>D> AB	! SANDOZ	100MG	A071293	001	Feb 18, 1987	Jun CHRS
>A> AB		100MG	A071293	001	Feb 18, 1987	Jun CHRS
	TABLET;ORAL					
	AMANTADINE HYDROCHLORIDE					
AB	INVATECH	100MG	A210215	001	Mar 10, 2020	Feb NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	OSMOLEX ER					
+	OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr NEWA

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP	TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar CMFD
----	-----------------	------------------	---------	-----	--------------	----------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+! FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML; ;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan CHRS
-----------------------	------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb NEWA
----	------------	------------	---------	-----	--------------	----------

AMISULPRIDE

SOLUTION;INTRAVENOUS

BARHEMYSYS

+! ACACIA PHARMA LTD	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb NEWA
----------------------	--------------------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SANDOZ	10MG	A085968	004		Jan CMS1
AB	!	25MG	A085968	002		Jan CMS1
AB		75MG	A085968	006		Jan CMS1
AB		100MG	A085968	003		Jan CMS1
AB		150MG	A085968	005		Jan CMS1
	@ UPSHER SMITH LABS	25MG	A212654	001	Apr 07, 2020	May DISC
AB		25MG	A212654	001	Apr 07, 2020	Mar NEWA

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

+! AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	May CAHN
------------	----------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

@ HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb DISC
@	EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb DISC
@	EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb DISC
@ MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	May DISC

TABLET;ORAL

AMLODIPINE BESYLATE

@		EQ 10MG BASE	A201380	002	Apr 13, 2012	May DISC	
@ WATSON LABS		EQ 2.5MG BASE	A077671	001	Jul 19, 2007	Apr DISC	
@		EQ 5MG BASE	A077671	002	Jul 19, 2007	Apr DISC	
@		EQ 10MG BASE	A077671	003	Jul 19, 2007	Apr DISC	
NORVASC							
>D> AB	+	Pfizer	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jun CAHN
>D> AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jun CAHN
>D> AB	+	!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jun CAHN
>A> AB	+	UPJOHN	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jun CAHN
>A> AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jun CAHN
>A> AB	+	!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jun CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CMFD	
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CMFD	
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CMFD	
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CMFD	
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CMFD	
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CMFD	
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CMFD	
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CMFD	
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CMFD	
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CMFD	
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CMFD	
	CADUET						
AB	+	Pfizer	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	May CAHN
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	May CAHN
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	May CAHN
AB	+	!	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	May CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@ PAR PHARM		EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	May DISC
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	May DISC
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	May DISC
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	May DISC
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	May DISC
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	May DISC

AMLODIPINE BESYLATE; HYDROCHLORTIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLORTIAZIDE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar CPOT
AB	LUPIN LTD	EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar CPOT
AB		EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar CPOT
	PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar CPOT
	@	EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	May DISC

TABLET;ORALAMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLORTIAZIDE

AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar CPOT
	© TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar CPOT
	©	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar CPOT
	©	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar CPOT
	©	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar CPOT
	©	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar CPOT
	© TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar CPOT
	©	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar CPOT
	©	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar CPOT
	©	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar CPOT
	©	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar CPOT
	EXFORGE HCT					
AB	+ NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar CPOT
AB	+	EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar CPOT
AB	+	EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar CPOT
AB	+	EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar CPOT
AB	+!	EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar CPOT

AMLODIPINE BESYLATE; VALSARTANTABLET;ORALAMLODIPINE BESYLATE AND VALSARTAN

>D> AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun DISC
>A>	©	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun DISC
>D> AB		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun DISC
>A>	©	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun DISC
>D> AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun DISC
>A>	©	EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun DISC
>D> AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun DISC
>A>	©	EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun DISC

AMMONIA N-13INJECTABLE; INTRAVENOUSAMMONIA N 13

AP	CARDINAL HLTH 414	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203700	001	Feb 25, 2013	May CAHN
----	-------------------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATECREAM;TOPICALAMMONIUM LACTATE

© WATSON LABS INC EQ 12% BASE

A076829 001 Feb 07, 2006 Apr DISC

LOTION;TOPICALAMMONIUM LACTATE

© WATSON LABS INC EQ 12% BASE

A075575 001 Jun 11, 2002 Apr DISC

AMOXAPINETABLET;ORALAMOXAPINE

© WATSON PHARMS TEVA 25MG

A072418 001 Aug 01, 1989 Jan CMS1

© 50MG

A072419 001 Aug 01, 1989 Jan CMS1

AMOXICILLINTABLET, CHEWABLE;ORALAMOXICILLIN

>A> AB	HIKMA	125MG	A205274	001	Jun 25, 2020	Jun NEWA
>A> AB		250MG	A205274	002	Jun 25, 2020	Jun NEWA
>D>	TEVA	125MG	A064013	002	Sep 11, 1995	Jun CTEC
>A> AB		125MG	A064013	002	Sep 11, 1995	Jun CTEC
>D>	!	250MG	A064013	001	Dec 22, 1992	Jun CTEC
>A> AB	!	250MG	A064013	001	Dec 22, 1992	Jun CTEC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORALDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS INC	1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan CAHN
AB		2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan CAHN
AB		3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan CAHN
AB		5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan CAHN
AB		6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan CAHN
AB		7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan CAHN
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	May CAHN
AB		2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	May CAHN

CAPSULE, EXTENDED RELEASE;ORALDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019	May CAHN
AB		5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019	May CAHN
AB		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	May CAHN
>A> AB	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A211876	001	Jun 24, 2020	Jun NEWA
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A211876	002	Jun 24, 2020	Jun NEWA
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A211876	003	Jun 24, 2020	Jun NEWA
>A> AB		5MG;5MG;5MG;5MG	A211876	004	Jun 24, 2020	Jun NEWA
>A> AB		6.25MG;6.25MG;6.25MG;6.25MG	A211876	005	Jun 24, 2020	Jun NEWA
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A211876	006	Jun 24, 2020	Jun NEWA
>A> AB	@ NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jan DISC
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jan DISC
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jan DISC
>A> AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jan DISC
>A> AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jan DISC
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jan DISC
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Apr CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Apr CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Apr CMFD
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Apr CMFD
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Apr CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Apr CMFD
>A> AB	@ TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Apr DISC
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Apr DISC
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Apr DISC
>A> AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Apr DISC
>A> AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Apr DISC
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Apr DISC
<u>DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE</u>						
>A> AB	@ BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013	Apr DISC
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013	Apr DISC
>A> AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013	Apr DISC
>A> AB		5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013	Apr DISC
>A> AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013	Apr DISC
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013	Apr DISC

TABLET;ORALDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BIONPHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Mar NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Mar NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Mar NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Mar NEWA
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Mar NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Mar NEWA
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018	May CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018	May CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018	May CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018	May CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018	May CAHN
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018	May CAHN

AMPHETAMINE SULFATETABLET;ORALAMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan NEWA
AA		10MG	A212582	002	Feb 04, 2020	Jan NEWA
AA	HAVIX	5MG	A212901	001	May 22, 2020	May NEWA
AA		10MG	A212901	002	May 22, 2020	May NEWA
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb NEWA
AA		10MG	A211861	002	Mar 11, 2020	Feb NEWA

AMPHOTERICIN BINJECTABLE; INJECTIONAMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb CAHN
---	-------------	-----------	---------	-----	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

@ PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 065316	001	Jun 29, 2007	Jan CAHN
@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 065316	002	Jun 29, 2007	Jan CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ DAVA PHARMS INC	EQ 500MG BASE	A 062882	001	Feb 25, 1988	Mar DISC
! SANDOZ	EQ 500MG BASE	A 064082	002	Aug 29, 1995	Mar CHRS

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@ BARR	EQ 0.5MG BASE	A 076530	001	Apr 18, 2005	Apr DISC
@	EQ 1MG BASE	A 076530	002	Apr 18, 2005	Apr DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@ APOTEX INC	1MG	A 200654	001	May 11, 2012	Feb DISC
@ MYLAN	1MG	A 091051	001	Jun 28, 2010	Jan DISC

APIXABAN

TABLET; ORAL

APIXABAN

AB	BIONPHARMA INC	2.5MG	A 210152	001	Apr 08, 2020	Mar NEWA
AB		5MG	A 210152	002	Apr 08, 2020	Mar NEWA
>D> AB	MICRO LABS	2.5MG	A 210013	001	Dec 23, 2019	Jun DISC
>A>	@	2.5MG	A 210013	001	Dec 23, 2019	Jun DISC
>D> AB		5MG	A 210013	002	Dec 23, 2019	Jun DISC
>A>	@	5MG	A 210013	002	Dec 23, 2019	Jun DISC
	@ MYLAN	2.5MG	A 210128	001	Dec 23, 2019	Jan DISC
	@	5MG	A 210128	002	Dec 23, 2019	Jan DISC

APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL

KYNMOBI

+	SUNOVION PHARMS INC	10MG	N 210875	001	May 21, 2020	May NEWA
+		15MG	N 210875	002	May 21, 2020	May NEWA
+		20MG	N 210875	003	May 21, 2020	May NEWA
+		25MG	N 210875	004	May 21, 2020	May NEWA
+!		30MG	N 210875	005	May 21, 2020	May NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	+! HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N 203049	001	Jan 05, 2012	Mar CHRS
AP	+	250MG/2.5ML (100MG/ML)	N 203049	001	Jan 05, 2012	Mar CRLD

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

@ TEVA PHARMS USA	250MG/250ML (1MG/ML)	N 206769	001	Dec 15, 2014	Mar DISC
-------------------	----------------------	----------	-----	--------------	----------

ARTESunate

POWDER; INTRAVENOUS

ARTESunate

+!	AMIVAS	110MG/VIAL	N 213036	001	May 26, 2020	May NEWA
----	--------	------------	----------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCaine

+!	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N 022010	001	Mar 30, 2006	Mar CTEC
+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N 020971	001	Apr 03, 2000	Feb CTEC

ULTACAN

@ HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A 201751	001	Jul 11, 2017	Mar DISC
----------------	----------------------------------------------------	----------	-----	--------------	----------

INJECTABLE; INJECTION

ULTACAN FORTE
© HANSAMED INC 4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML) A201750 001 Jul 11, 2017 Feb DISC

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS
+ ALLERGAN EQ 2.5MG BASE N022117 003 Mar 12, 2015 Jan CMS1

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE AA STRIDES PHARMA 325MG;50MG;40MG A204195 001 Sep 22, 2016 Mar CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN
© HERITAGE PHARMS INC 325MG;200MG
© NOVAST LABS 325MG;200MG
© SANDOZ 325MG;200MG A089594 001 Mar 31, 1989 May DISC
A040832 001 Jan 07, 2010 May DISC
A040116 001 Apr 25, 1996 May DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ASPIRIN >D> AA ACTAVIS LABS FL INC 325MG;4.8355MG A090084 001 Mar 22, 2011 Jun DISC
>A> © 325MG;4.8355MG A090084 001 Mar 22, 2011 Jun DISC

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL
PRAVIGARD PAC (COPACKAGED)
© BRISTOL MYERS SQUIBB 81MG;20MG N021387 001 Jun 24, 2003 May CPOT
© 81MG,N/A;N/A,20MG N021387 001 Jun 24, 2003 May CDFR
© 81MG;40MG N021387 002 Jun 24, 2003 May CPOT
© 81MG,N/A;N/A,40MG N021387 002 Jun 24, 2003 May CDFR
© 81MG;80MG N021387 003 Jun 24, 2003 May CPOT
© 81MG,N/A;N/A,80MG N021387 003 Jun 24, 2003 May CDFR
© 325MG;20MG N021387 004 Jun 24, 2003 May CPOT
© 325MG,N/A;N/A,20MG N021387 004 Jun 24, 2003 May CDFR
© 325MG;40MG N021387 005 Jun 24, 2003 May CPOT
© 325MG,N/A;N/A,40MG N021387 005 Jun 24, 2003 May CDFR
© 325MG;80MG N021387 006 Jun 24, 2003 May CPOT
© 325MG,N/A;N/A,80MG N021387 006 Jun 24, 2003 May CDFR

ATAZANAVIR SULFATE

CAPSULE; ORAL
ATAZANAVIR SULFATE AB AMNEAL EQ 100MG BASE A209717 001 Jun 01, 2020 May NEWA
AB EQ 150MG BASE A209717 002 Jun 01, 2020 May NEWA
AB EQ 200MG BASE A209717 003 Jun 01, 2020 May NEWA
AB EQ 300MG BASE A209717 004 Jun 01, 2020 May NEWA
© MYLAN EQ 150MG BASE A208177 001 Sep 24, 2018 Feb DISC
© EQ 200MG BASE A208177 002 Sep 24, 2018 Feb DISC
© EQ 300MG BASE A208177 003 Sep 24, 2018 Feb DISC
>A> AB ZYDUS PHARMS EQ 150MG BASE A210575 001 Jun 04, 2020 Jun NEWA
>A> AB EQ 200MG BASE A210575 002 Jun 04, 2020 Jun NEWA
>A> AB EQ 300MG BASE A210575 003 Jun 04, 2020 Jun NEWA

ATENOLOL

TABLET; ORAL
ATENOLOL
>A> AB HLTHCARE 25MG A073026 002 May 01, 1992 Jun CMS1
>A> AB 50MG A073026 003 Sep 17, 1991 Jun CMS1

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE
© MYLAN 50MG;25MG A074203 001 Oct 31, 1993 May DISC
© 100MG;25MG A074203 002 Oct 31, 1993 May DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan CMFD
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan CMFD
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan CMFD
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan CMFD
>A> AB	PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020	Jun NEWA
>A> AB		EQ 20MG BASE	A208478	002	Jun 23, 2020	Jun NEWA
	LIPITOR					
>D> AB	+ PFIZER	EQ 10MG BASE	N020702	001	Dec 17, 1996	Jun CAHN
>D> AB	+	EQ 20MG BASE	N020702	002	Dec 17, 1996	Jun CAHN
>D> AB	+	EQ 40MG BASE	N020702	003	Dec 17, 1996	Jun CAHN
>D> AB	!+	EQ 80MG BASE	N020702	004	Apr 07, 2000	Jun CAHN
>A> AB	+ UPJOHN	EQ 10MG BASE	N020702	001	Dec 17, 1996	Jun CAHN
>A> AB	+	EQ 20MG BASE	N020702	002	Dec 17, 1996	Jun CAHN
>A> AB	+	EQ 40MG BASE	N020702	003	Dec 17, 1996	Jun CAHN
>A> AB	!+	EQ 80MG BASE	N020702	004	Apr 07, 2000	Jun CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

@ SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr DISC
@	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Mar CAHN
@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr DISC
@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Mar CAHN
@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr DISC
@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Mar CAHN
!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr DISC
!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Mar CAHN

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

+! ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb CRLD
!	1%	N208151	001	Dec 01, 2016	Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	LEADING PHARMA LLC	0.025MG;2.5MG	A213413	001	Feb 20, 2020	Feb NEWA
AA	MAYNE PHARMA INC	0.025MG;2.5MG	A210789	001	Jun 03, 2020	May NEWA
@	PAR PHARM	0.025MG;2.5MG	A040357	001	May 02, 2000	May DISC

AVAPRITINIB

TABLET;ORAL

AYVAKIT

+	BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan NEWA
+		200MG	N212608	002	Jan 09, 2020	Jan NEWA
!+		300MG	N212608	003	Jan 09, 2020	Jan NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A> AP	EUROLTH INTL SARL	100MG/VIAL	A209337	001	Jun 08, 2020	Jun NEWA
--------	-------------------	------------	---------	-----	--------------	----------

AZATHIOPRINE

TABLET;ORAL

AZATHIOPRINE

AB	ALKEM LABS LTD	25MG	A208687	001	Mar 27, 2020	Mar NEWA
AB		50MG	A208687	002	Mar 27, 2020	Mar NEWA
AB		75MG	A208687	003	Mar 27, 2020	Mar NEWA
AB		100MG	A208687	004	Mar 27, 2020	Mar NEWA
AB	RISING	50MG	A075568	001	Dec 13, 1999	May CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	GLAND PHARMA LTD	0.05%	A210092	001	Feb 25, 2020	Feb NEWA
----	------------------	-------	---------	-----	--------------	----------

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 0.125MG BASE/SPRAY

A212289 001 May 08, 2020 Apr NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

@ TARO EQ 200MG BASE/5ML
@ TEVA PHARMS EQ 100MG BASE/5ML
@ EQ 200MG BASE/5MLA211521 001 Dec 11, 2019 May DISC
A065419 001 Jun 24, 2008 Apr DISC
A065419 002 Jun 24, 2008 Apr DISC

INJECTABLE;INJECTION

AZITHROMYCIN

@ HIKMA EQ 500MG BASE/VIAL
@ MYLAN LABS LTD EQ 500MG BASE/VIALA065265 001 Jan 18, 2007 Mar CAHN
A204732 001 Jan 26, 2017 Mar DISC

TABLET;ORAL

AZITHROMYCIN

AB ALEMBIC PHARMS LTD EQ 250MG BASE
AB EQ 500MG BASE
AB EQ 600MG BASE
@ MYLAN EQ 600MG BASE
>D> AB YUNG SHIN PHARM EQ 600MG BASE
>A> @ EQ 600MG BASE
AB EQ 600MG BASEA211791 001 Jan 28, 2020 Jan NEWA
A211792 001 Jan 28, 2020 Jan NEWA
A211793 001 Jan 27, 2020 Jan NEWA
A065360 001 Jan 08, 2007 Jan DISC
A211068 001 May 08, 2020 Jun DISC
A211068 001 May 08, 2020 Jun DISC
A211068 001 May 08, 2020 Apr NEWABACITRACIN

INJECTABLE;INJECTION

BACIIM

@ X GEN PHARMS 50,000 UNITS/VIAL
BACITRACIN
@ AKORN 50,000 UNITS/VIAL
@ FRESENIUS KABI USA 50,000 UNITS/VIALA064153 001 May 09, 1997 Mar DISC
A206719 001 Oct 20, 2017 Mar DISC
A065116 001 Dec 03, 2002 Mar DISCBACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT + CASPER PHARMA LLC EQ 400 UNITS/GM;EQ 3.5MG
BASE/GM;EQ 10,000 UNITS/GM

N050417 001 May CTNA

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

@ MAIA PHARMS INC 0.5MG/ML
@ 2MG/MLA210048 001 Sep 11, 2019 Mar DISC
A210048 002 Sep 11, 2019 Mar DISC

TABLET;ORAL

BACLOFEN

@ MYLAN 20MG
@ MYLAN PHARMS INC 10MG
@ 20MG
AB RUBICON 5MG
AB ZYDUS 5MGA077121 002 Jul 29, 2005 Jan DISC
A090334 001 Feb 18, 2010 Apr DISC
A090334 002 Feb 18, 2010 Apr DISC
A209102 001 Nov 28, 2017 Apr CTEC
A211659 003 Apr 17, 2020 Apr NEWABARIUM SULFATE

SUSPENSION;ORAL

ENTERO VU 24%

>A> +! BRACCO 24% (144GM/600ML)

N208143 008 May 29, 2020 Jun NEWA

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+ JANSSEN THERAP EQ 20MG BASE

N204384 002 May 27, 2020 May NEWA

BEMPEDOIC ACID

TABLET;ORAL

NEXLETOL

+! ESPERION THERAPS INC 180MG

N211616 001 Feb 21, 2020 Feb NEWA

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL

NEXLIZET

+! ESPERION THERAPS INC 180MG;10MG

N211617 001 Feb 26, 2020 Feb NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Feb CAHN
AB		10MG	A077128	002	Mar 08, 2006	Feb CAHN
AB		20MG	A077128	003	Mar 08, 2006	Feb CAHN
AB		40MG	A077128	004	Mar 08, 2006	Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D> AB	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	Jun DISC
>A>	@	5MG;6.25MG	A078794	001	Aug 21, 2014	Jun DISC
>D> AB		10MG;12.5MG	A078794	002	Aug 21, 2014	Jun DISC
>A>	@	10MG;12.5MG	A078794	002	Aug 21, 2014	Jun DISC
>D> AB		20MG;12.5MG	A078794	003	Aug 21, 2014	Jun DISC
>A>	@	20MG;12.5MG	A078794	003	Aug 21, 2014	Jun DISC
>D> AB		20MG;25MG	A078794	004	Aug 21, 2014	Jun DISC
>A>	@	20MG;25MG	A078794	004	Aug 21, 2014	Jun DISC

BENOXINATE HYDROCHLORIDE; FLUORESCIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLUORESCIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%;0.3%

N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

@	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Mar DISC
@	SPECGX LLC	50MG	A040773	001	Apr 25, 2007	Apr DISC
@	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

@	MYLAN	1.5%	A206220	001	Mar 18, 2019	Feb DISC
+!	BEPREVE		N022288	001	Sep 08, 2009	Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	! GLENMARK GENERICS	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Feb CHRS
	DIPROLENE AF		N019555	001	Apr 27, 1987	Feb DISC
+!	MERCK SHARP DOHME	EQ 0.05% BASE				
	LOTION;TOPICAL					
	BETAMETHASONE DIPROPIONATE					
	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281	001	Jul 31, 1985	Apr DISC
	SPRAY;TOPICAL					
	BETAMETHASONE DIPROPIONATE					
>A>	@ TARO PHARMS	EQ 0.05% BASE/SPRAY	A211722	001	Jun 17, 2020	Jun DISC
>A> AB		EQ 0.05% BASE/SPRAY	A211722	001	Jun 17, 2020	Jun NFTG
	SERNIVO					
>D>	+! ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Jun CFTG
>A>	+!	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Jun CTEC
>A> AB	+!	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Jun CFTG

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TOLMAR	0.064%;0.005%	A210765	001	May 11, 2020	Apr NFTG
	TACLONEX					

AB	+! LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Apr CFTG
----	------------------	---------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	!	AMNEAL PHARM	5MG	A040855	001	Nov 21, 2007	Jan CHRS
AA	!		10MG	A040855	002	Nov 21, 2007	Jan CHRS
AA	!		25MG	A040855	003	Nov 21, 2007	Jan CHRS
	@	IMPAK LABS	25MG	A040721	003	Nov 01, 2006	Jan CMS1
	URECHOLINE						
	@	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985	Jan DISC
	@		10MG	A088440	001	May 29, 1984	Jan DISC
	@		25MG	A088441	001	May 29, 1984	Jan DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		ANI PHARMS INC	75MG	A209861	001	May 08, 2018	Jan CAHN
>A> AB		HIKMA	75MG	A203663	001	Jun 16, 2020	Jun NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

@ MYLAN

50MG

A079185 001 Jul 06, 2009 Jan DISC

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

+! ALLERGAN INC

10MCG

N211911 001 Mar 04, 2020 Mar NEWA

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

@ TEVA PHARMS

5MG

A075644 001 Jun 26, 2001 Apr DISC

@

10MG

A075644 002 Jun 26, 2001 Apr DISC

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

@ APOTEX

250MG/VIAL

A204876 001 Jul 06, 2017 Feb DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan NEWA
>D> AB		CIPLA	62.5MG	A210342	001	Jan 03, 2020	Jun DISC
>A>	@		62.5MG	A210342	001	Jan 03, 2020	Jun DISC
>D> AB			125MG	A210342	002	Jan 03, 2020	Jun DISC
>A>	@		125MG	A210342	002	Jan 03, 2020	Jun DISC
	@	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan DISC
	@		125MG	A205173	002	Jan 15, 2020	Jan DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

QOLIANA

>D> AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Jun CRLD
>A> AT	+!		0.15%	N021764	001	May 22, 2006	Jun CHRS
>A> AT	+		0.15%	N021764	001	May 22, 2006	Jun CRLD

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2		GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar NEWA
-----	--	------------------	---------------	---------	-----	--------------	----------

BROMOCRIPTINE MESYLATE

TABLET;ORAL

BROMOCRIPTINE MESYLATE

>D>	AB	MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Jun DISC
>A>		@	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Jun DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	LANNETT CO INC	2MG/5ML;10MG/5ML;30MG/5ML	A213125	001	Apr 17, 2020	Apr NEWA	
>A>	AA	WES PHARMA INC	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Jun NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

+! SALIX

2MG/ACTUATION

N205613 001 Oct 07, 2014 Feb CAHN

BUMETANIDE

TABLET;ORAL

BUMETANIDE

AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jan CAHN
AB		1MG	A212019	002	Dec 12, 2019	Jan CAHN
AB		2MG	A212019	003	Dec 12, 2019	Jan CAHN

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB	AMNEAL PHARMS LLC	5MCG/HR	A211586	001	Apr 14, 2020	Mar NEWA
AB		7.5MCG/HR	A211586	002	Apr 14, 2020	Mar NFTG
AB		10MCG/HR	A211586	003	Apr 14, 2020	Mar NEWA
AB		15MCG/HR	A211586	004	Apr 14, 2020	Mar NEWA
AB		20MCG/HR	A211586	005	Apr 14, 2020	Mar NEWA

	BUTRANS					
AB	+ PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar CFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

>D>						
>D>	+ BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun DISC
>A>	+ @	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun DISC
>D>	+	EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun DISC
>A>	+ @	EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun DISC
>D>	+!	EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun DISC
>A>	+ @	EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun DISC

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	MYLAN TECHNOLOGIES	EQ 2MG BASE;EQ 0.5MG BASE	A211785	001	Apr 17, 2020	Apr NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A211785	002	Apr 17, 2020	Apr NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Mar NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Mar NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan NEWA
AB		100MG	A208606	002	Jan 16, 2020	Jan NEWA
AB	MICRO LABS	75MG	A207403	001	Apr 17, 2020	Apr NEWA
AB		100MG	A207403	002	Apr 17, 2020	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@ JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb DISC
@	150MG	A202774	002	Oct 11, 2013	Feb DISC
@	150MG	A202775	001	Oct 11, 2013	Feb DISC
@	150MG	A207459	001	Jun 30, 2017	Feb DISC
@	200MG	A202774	003	Oct 11, 2013	Feb DISC
@	300MG	A207459	002	Jun 30, 2017	Feb DISC
@ WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr DISC
@	150MG	A077455	002	Mar 12, 2008	Apr DISC
@	200MG	A077455	003	Jul 19, 2010	Apr DISC

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>D>	@ YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Jun CMFD
>A> AB1		100MG	A211347	001	Oct 16, 2018	Jun CMFD
>D>	@	150MG	A211347	002	Oct 16, 2018	Jun CMFD
>A> AB1		150MG	A211347	002	Oct 16, 2018	Jun CMFD
>D>	@	200MG	A211347	003	Oct 16, 2018	Jun CMFD
>A> AB1		200MG	A211347	003	Oct 16, 2018	Jun CMFD
>A> AB3	ZHEJIANG JUTAI PHARM	150MG	A211200	002	Apr 29, 2020	Jun NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CONTRAVE
+! NALPROPION 90MG;8MG

N200063 001 Sep 10, 2014 Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	7.5MG	A078246	005	Feb 21, 2020	Jun NEWA
>D> AB	MYLAN	7.5MG	A075467	002	Mar 28, 2001	Jun CHRS
>A> AB	!	7.5MG	A075467	002	Mar 28, 2001	Jun CHRS

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Apr CTNA
	@ MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb DISC

BUTABARBITAL SODIUM

TABLET;ORAL
BUTISOL SODIUM
+ @ MYLAN SPECIALITY LP 30MG

N000793 004 May DISC

CABERGOLINE

TABLET;ORAL
CABERGOLINE
@ MYLAN 0.5MG

A202947 001 Dec 02, 2013 Jan DISC

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Mar CMFD
AB		0.5MCG	A204556	002	Feb 21, 2019	Mar CMFD
	INJECTABLE;INJECTION CALCITRIOL					
AP	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
AP	GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan NEWA

CALCIUM ACETATE

CAPSULE;ORAL
CALCIUM ACETATE
@ LOTUS PHARM CO LTD 667MG

A203298 001 Jul 26, 2016 Jan DISC

CAPECITABINE

TABLET;ORAL
CAPECITABINE
AB RELIANCE LIFE 150MG

A211724 001 Apr 27, 2020 Apr NEWA

AB		500MG	A211724	002	Apr 27, 2020	Apr NEWA
----	--	-------	---------	-----	--------------	----------

CAPMATINIB HYDROCHLORIDE

TABLET;ORAL
TABRECTA
+ NOVARTIS PHARM EQ 150MG BASE
+! EQ 200MG BASE

N213591 001 May 06, 2020 May NEWA
N213591 002 May 06, 2020 May NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION
CAPREOMYCIN SULFATE
@ HISUN PHARM HANGZHOU EQ 1GM BASE/VIAL

A204796 001 Oct 18, 2018 Mar DISC

CAPTOPRIL

TABLET;ORAL

Captopril

@ COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb CAHN
@	25MG	A074737	002	Oct 28, 1998	Feb CAHN
@	50MG	A074737	003	Oct 28, 1998	Feb CAHN
@	100MG	A074737	004	Oct 28, 1998	Feb CAHN
@ SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	May DISC
@	25MG	A212223	002	Oct 30, 2019	May DISC
@	50MG	A212223	003	Oct 30, 2019	May DISC
@	100MG	A212223	004	Oct 30, 2019	May DISC
@ TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr DISC
@	25MG	A074322	002	Feb 13, 1996	Apr DISC
@	50MG	A074322	003	Feb 13, 1996	Apr DISC
@	100MG	A074322	004	Feb 13, 1996	Apr DISC
@ WATSON LABS	12.5MG	A074386	001	May 23, 1996	Apr DISC
@	25MG	A074386	002	May 23, 1996	Apr DISC
@	50MG	A074386	003	May 23, 1996	Apr DISC
@	100MG	A074386	004	May 23, 1996	Apr DISC

CARBAMAZEPINECAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	May CMFD
AB		200MG	A076697	002	May 20, 2011	May CMFD
AB		300MG	A076697	003	May 20, 2011	May CMFD

TABLET;ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar CTEC
AB	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar NEWA
AB		200MG	A207798	002	Apr 15, 2020	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	UNIQUE PHARM	100MG	A211623	001	Apr 24, 2020	Apr NEWA
AB		200MG	A211623	002	Apr 24, 2020	Apr NEWA
AB		400MG	A211623	003	Apr 24, 2020	Apr NEWA

CARBIDOPATABLET;ORAL
CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan CAHN
----	----------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPATABLET, EXTENDED RELEASE;ORAL
SINemet CR

+ @ MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan DISC
-----------------------	------------	---------	-----	--------------	----------

CARBOPLATININJECTABLE; INTRAVENOUS
CARBOPLATIN

@ EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar DISC
@	150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar DISC
@	450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar DISC
@ PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	Apr DISC
@	150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	Apr DISC
@	450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	Apr DISC
@	600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	Apr DISC
@ TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May DISC
@	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May DISC
@	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May DISC
@	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May DISC

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

AP	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Mar NFTG
AP		60MG/VIAL	A209425	001	Mar 16, 2020	Mar NEWA
AP	KYPROLIS		N202714	002	Jun 03, 2016	Mar CFTG
AP	+ ONYX THERAP	30MG/VIAL				

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	@ HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb DISC
	OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997	Apr CMFD

CEFIXIME

FOR SUSPENSION;ORAL

SUPRAX

@ LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan DISC
----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

SUPRAX

@ LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan DISC
----------------	-------	---------	-----	--------------	----------

CEFOXITIN SODIUM

INJECTABLE;INJECTION

MEFOXIN IN PLASTIC CONTAINER

@ MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Mar DISC
@	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Mar DISC

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

@ TEVA PHARMS	125MG/5ML	A065236	001	Dec 08, 2005	Apr DISC
@	250MG/5ML	A065236	002	Dec 08, 2005	Apr DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	NANJING	200MG	A213598	001	May 13, 2020	Apr NEWA
	@ QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	May DISC
	@	100MG	A208856	002	Aug 07, 2019	May DISC
	@	200MG	A208856	003	Aug 07, 2019	May DISC
	@	400MG	A208856	004	Aug 07, 2019	May DISC
AB	TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb NEWA
AB		100MG	A207872	002	Feb 25, 2020	Feb NEWA
AB		200MG	A207872	003	Feb 25, 2020	Feb NEWA
AB		400MG	A207872	004	Feb 25, 2020	Feb NEWA
AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan CDFR
AB		100MG	A210628	002	Nov 27, 2019	Jan CDFR
AB		200MG	A210628	003	Nov 27, 2019	Jan CDFR
AB		400MG	A210628	004	Nov 27, 2019	Jan CDFR
AB	YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Feb NEWA
AB		100MG	A211412	002	Mar 06, 2020	Feb NEWA
AB		200MG	A211412	003	Mar 06, 2020	Feb NEWA
AB		400MG	A211412	004	Mar 06, 2020	Feb NEWA

SOLUTION;ORAL

ELYXYB

>D>	+! DR REDDYS	25MG/ML	N212157	001	May 05, 2020	Jun CAHN
>A>	+!	25MG/ML	N212157	001	May 05, 2020	Jun CAHN
	+!	25MG/ML	N212157	001	May 05, 2020	May NEWA

CENOBAMATE

TABLET;ORAL

XCOPRI

+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Mar NEWA
+		25MG	N212839	002	Mar 10, 2020	Mar NEWA
+		50MG	N212839	003	Mar 10, 2020	Mar NEWA
+		100MG	N212839	004	Mar 10, 2020	Mar NEWA
+		150MG	N212839	005	Mar 10, 2020	Mar NEWA
+		200MG	N212839	006	Mar 10, 2020	Mar NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

>A>	+! BAUSCH	5MG;2.5MG	N012750	001		Jun CAHN
>D>	+! VALEANT PHARMS	5MG;2.5MG	N012750	001		Jun CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

	+ @ SANOFI AVENTIS US	500MG	N 006002	001		Apr CPOT
	CHLOROQUINE PHOSPHATE					
	@ HIKMA PHARMS	EQ 150MG BASE	A 083082	001		Feb DISC
	@	250MG	A 083082	001		Apr CPOT
AA		500MG	A 083082	002	Sep 17, 1999	Apr CPOT
	@ IMPAX LABS	250MG	A 080880	001		Apr CPOT
	@	500MG	A 040516	001	Aug 29, 2003	Apr CPOT
AA	IPCA LABS LTD	250MG	A 090610	001	Dec 03, 2009	Apr CPOT
AA		500MG	A 090249	001	Dec 03, 2009	Apr CPOT
	@ MD PHARM	250MG	A 087228	001		Apr CPOT
AA	! NATCO PHARMA LTD	EQ 150MG BASE	A 091621	001	Jan 21, 2011	Feb CHRS
AA	!	250MG	A 091621	001	Jan 21, 2011	Apr CPOT
AA	!	500MG	A 090612	001	Jan 21, 2011	Apr CPOT
	@ PUREPAC PHARM	250MG	A 080886	001		Apr CPOT
	@ TEVA	250MG	A 087504	001	Jan 13, 1982	Apr CPOT
	@ WATSON LABS	250MG	A 087979	001	Dec 21, 1982	Apr CPOT
	@	500MG	A 088030	001	Dec 21, 1982	Apr CPOT

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ZYDUS	10MG	A 213368	001	Jan 17, 2020	Jan NEWA
AB		25MG	A 213368	002	Jan 17, 2020	Jan NEWA
AB		50MG	A 213368	003	Jan 17, 2020	Jan NEWA
AB		100MG	A 213368	004	Jan 17, 2020	Jan NEWA
AB		200MG	A 213368	005	Jan 17, 2020	Jan NEWA

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	ALKEM LABS LTD	25MG	A 213412	001	Feb 11, 2020	Jan NEWA
AB		50MG	A 213412	002	Feb 11, 2020	Jan NEWA
AB	VISTAPHARM	25MG	A 211063	001	Feb 26, 2019	Feb CAHN
AB		50MG	A 211063	002	Feb 26, 2019	Feb CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>D>	@ AUROLIFE PHARMA LLC	500MG	A 089853	001	May 04, 1988	Jun CMFD
>A> AA		500MG	A 089853	001	May 04, 1988	Jun CMFD
AB	GLENMARK PHARMS LTD	375MG	A 212185	001	May 26, 2020	May NEWA
AB		750MG	A 212185	002	May 26, 2020	May NEWA
>A> AB	TEVA PHARMS USA INC	375MG	A 212898	001	Jun 17, 2020	Jun NEWA
>A> AB		750MG	A 212898	002	Jun 17, 2020	Jun NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A 211119	001	Apr 06, 2020	Mar NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A 211119	002	Apr 06, 2020	Mar NEWA
	LOCHOLEST					
	@ ALLIED	EQ 4GM RESIN/PACKET	A 074561	001	Aug 15, 1996	Feb CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A 074561	002	Aug 15, 1996	Feb CAHN
	@ INVATECH	EQ 4GM RESIN/PACKET	A 074561	001	Aug 15, 1996	Jan CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A 074561	002	Aug 15, 1996	Jan CAHN
	LOCHOLEST LIGHT					
	@ ALLIED	EQ 4GM RESIN/PACKET	A 074562	001	Aug 15, 1996	Feb CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A 074562	002	Aug 15, 1996	Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>A> AB	MICRO LABS	EQ 45MG FENOFIBRIC ACID	A 213450	001	Jun 16, 2020	Jun NEWA
>A> AB		EQ 135MG FENOFIBRIC ACID	A 213450	002	Jun 16, 2020	Jun NEWA
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A 210469	001	Jul 05, 2019	Mar CMFD
AB		EQ 135MG FENOFIBRIC ACID	A 210469	002	Jul 05, 2019	Mar CMFD

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE
@ DAVA PHARMS INC

EQ 300MG BASE/2ML

A074428 001 Apr 25, 1996 May DISC

CINACALCET HYDROCHLORIDE

TABLET; ORAL
CINACALCET HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 30MG BASE	A211892	001	May 15, 2020	May NEWA
AB		EQ 60MG BASE	A211892	002	May 15, 2020	May NEWA
AB		EQ 90MG BASE	A211892	003	May 15, 2020	May NEWA
AB	ACME LABS	EQ 30MG BASE	A213325	001	May 18, 2020	May NEWA
AB		EQ 60MG BASE	A213325	002	May 18, 2020	May NEWA
AB		EQ 90MG BASE	A213325	003	May 18, 2020	May NEWA
@ LUPIN LTD		EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan DISC
@		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan DISC
@		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
CISATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Apr NEWA
AP	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan CMFD
AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

@ JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar DISC
@	EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar DISC
@	EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar DISC

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL
PHEXXI

+! EVOFEM INC 1%;1.8%;0.4%

N208352 001 May 22, 2020 May NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL
CLINDAMYCIN PHOSPHATE

@ TARO PHARM IND LTD	1%	A210004	001	Mar 11, 2020	May DISC
	1%	A210004	001	Mar 11, 2020	Feb NEWA
SOLUTION; TOPICAL					
CLINDAMYCIN PHOSPHATE					
>D> AT VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	Jun DISC
>A>	@ EQ 1% BASE	A203343	001	May 29, 2015	Jun DISC

CLOBAZAM

SUSPENSION; ORAL
CLOBAZAM

AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb NEWA
AB	LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr NEWA
@ TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr DISC	
	2.5MG/ML	A211032	001	Jan 31, 2020	Jan NEWA	
AB	TABLET; ORAL					
	CLOBAZAM					
>A> AB APOTEX	10MG	A209853	001	Jun 09, 2020	Jun NEWA	
>A> AB	20MG	A209853	002	Jun 09, 2020	Jun NEWA	

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan NEWA
	CLOBETASOL PROPIONATE (EMOLLIENT)					
>A> AB2 ANI PHARMS INC	0.05%	A075733	001	Aug 22, 2001	Jun CAHN	
>D> AB2 INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	Jun CAHN	
AB2	0.05%	A075733	001	Aug 22, 2001	May CAHN	
LOTION; TOPICAL						
IMPEKLO						
>A> +! MYLAN	0.05%	N213691	001	May 19, 2020	Jun CAHN	
>D> +! MYLAN LABS INC	0.05%	N213691	001	May 19, 2020	Jun CAHN	

LOTION;TOPICAL

IMPEKLO

+! 0.05%

N213691 001 May 19, 2020 May NEWA

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB ALEOR DERMACEUTICALS 0.05%

A213290 001 May 18, 2020 May NEWA

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

@ ALEOR DERMACEUTICALS 0.05%

A211191 001 Oct 02, 2019 Jan DISC

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

AB TARO 0.1%

A206370 001 Apr 21, 2020 Apr NFTG

AB +! EPI HLTH 0.1%

N017765 001 Apr CFTG

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB LEADING PHARMA LLC 25MG

A211364 001 Feb 07, 2020 Jan NEWA

AB 50MG

A211364 002 Feb 07, 2020 Jan NEWA

AB 75MG

A211364 003 Feb 07, 2020 Jan NEWA

AB MANKIND PHARMA 25MG

A211767 001 Apr 08, 2019 Jan CMFD

AB 50MG

A211767 002 Apr 08, 2019 Jan CMFD

AB 75MG

A211767 003 Apr 08, 2019 Jan CMFD

>A> AB MICRO LABS 25MG

A213219 001 Jun 22, 2020 Jun NEWA

>A> AB 50MG

A213219 002 Jun 22, 2020 Jun NEWA

>A> AB 75MG

A213219 003 Jun 22, 2020 Jun NEWA

@ TEVA 25MG

A074958 001 Aug 26, 1997 Feb DISC

@ 50MG

A074958 002 Aug 26, 1997 Feb DISC

@ 75MG

A074958 003 Aug 26, 1997 Feb DISC

AB TULEX PHARMS INC 25MG

A210653 001 Apr 03, 2020 Mar NEWA

AB 50MG

A210653 002 Apr 03, 2020 Mar NEWA

AB 75MG

A210653 003 Apr 03, 2020 Mar NEWA

>A> AB VGYAAN 25MG

A213221 001 Jun 22, 2020 Jun NEWA

>A> AB 50MG

A213221 002 Jun 22, 2020 Jun NEWA

>A> AB 75MG

A213221 003 Jun 22, 2020 Jun NEWA

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

@ MYLAN 0.5MG

A075150 001 Oct 05, 1998 May DISC

1MG

A075150 002 Oct 05, 1998 Jun DISC

>A> @ 1MG

A075150 002 Oct 05, 1998 Jun DISC

@ 2MG

A075150 003 Oct 05, 1998 May DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP XGEN PHARMS 1MG/10ML (0.1MG/ML)

A203167 001 Oct 29, 2013 Feb CAHN

AP 5MG/10ML (0.5MG/ML)

A203167 002 Oct 29, 2013 Feb CAHN

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD 0.1MG

A070886 002 Aug 31, 1988 May CAHN

@ 0.2MG

A070886 001 Aug 31, 1988 May CAHN

@ 0.3MG

A070886 003 Aug 31, 1988 May CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1 UPSHER SMITH LABS 0.1MG

A211433 001 Oct 12, 2018 Feb CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB ! APOTEX INC EQ 300MG BASE

A076274 002 Mar 04, 2014 May CHRS

CELLTRION EQ 75MG BASE

A202266 001 Aug 14, 2012 Jun DISC

@ EQ 75MG BASE

A202266 001 Aug 14, 2012 Jun DISC

EQ 300MG BASE

A202266 002 Nov 20, 2012 Jun DISC

@ EQ 300MG BASE

A202266 002 Nov 20, 2012 Jun DISC

AB GRAVITI PHARMS EQ 75MG BASE

A204359 001 Feb 02, 2017 Apr CAHN

	TABLET;ORAL PLAVIX					
AB	+ SANOFI AVENTIS US	EQ 300MG BASE		N 020839	002 Sep 20, 2007	May CHRS
	<u>CLORAZEPATE DIPOTASSIUM</u>					
	CAPSULE;ORAL CLORAZEPATE DIPOTASSIUM			A 072112	002 Aug 26, 1988	Feb CMS1
	@ AUROLIFE PHARMA LLC 3.75MG			A 072112	003 Aug 26, 1988	Feb CMS1
	@ 7.5MG					
	<u>COCAINE HYDROCHLORIDE</u>					
	SOLUTION;NASAL NUMBRINO			N 209575	001 Jan 10, 2020	Jan NEWA
	CODY LABS INC 4%					
	<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>					
	SYRUP;ORAL PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE					
>A> AA	PHARM ASSOC 10MG/5ML;5MG/5ML;6.25MG/5ML			A 040660	001 Dec 07, 2006	Jun CAHN
>D> AA	VINTAGE 10MG/5ML;5MG/5ML;6.25MG/5ML			A 040660	001 Dec 07, 2006	Jun CAHN
	PROMETH VC W/ CODEINE					
>D> AA	! ACTAVIS MID ATLANTIC 10MG/5ML;5MG/5ML;6.25MG/5ML			A 088764	001 Oct 31, 1984	Jun CAHN
>A> AA	! NOSTRUM LABS INC 10MG/5ML;5MG/5ML;6.25MG/5ML			A 088764	001 Oct 31, 1984	Jun CAHN
	<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>					
	SYRUP;ORAL PROMETHAZINE WITH CODEINE					
>A>	@ PHARM ASSOC 10MG/5ML;6.25MG/5ML			A 040650	001 Jan 31, 2006	Jun CAHN
>D>	@ VINTAGE 10MG/5ML;6.25MG/5ML			A 040650	001 Jan 31, 2006	Jun CAHN
	@ 10MG/5ML;6.25MG/5ML			A 040650	001 Jan 31, 2006	Apr DISC
	<u>COLCHICINE</u>					
	TABLET;ORAL COLCHICINE					
AB	AMNEAL PHARMS 0.6MG			A 204711	001 Sep 28, 2016	Jan CMFD
AB	GRANULES PHARMS 0.6MG			A 210425	001 Feb 05, 2020	Jan NEWA
	<u>COLESEVELAM HYDROCHLORIDE</u>					
>D>	BAR, CHEWABLE;ORAL					
>D>	WELCHOL					
>D>	+! DAIICHI SANKYO INC 3.75GM			N 210895	001 Apr 03, 2019	Jun DISC
>A>	+ @ 3.75GM			N 210895	001 Apr 03, 2019	Jun DISC
	TABLET;ORAL COLESEVELAM HYDROCHLORIDE					
AB	INVAGEN PHARMS 625MG			A 212602	001 Apr 20, 2020	Apr NEWA
	<u>COLISTIMETHATE SODIUM</u>					
	INJECTABLE;INJECTION COLISTIMETHATE SODIUM					
AP	XGEN PHARMS EQ 150MG BASE/VIAL			A 064216	001 Feb 26, 1999	Feb CAHN
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>					
	TABLET;ORAL CYCLOBENZAPRINE HYDROCHLORIDE					
>D> AB	! MYLAN PHARMS INC 10MG			A 073144	001 May 30, 1991	Jun CHRS
>A> AB	10MG			A 073144	001 May 30, 1991	Jun CHRS
>D> AB	RUBICON 10MG			A 208170	003 May 31, 2017	Jun CHRS
>A> AB	! 10MG			A 208170	003 May 31, 2017	Jun CHRS
	<u>CYCLOPHOSPHAMIDE</u>					
	CAPSULE;ORAL CYCLOPHOSPHAMIDE					
AB	ANI PHARMS INC 25MG			A 207014	001 Mar 19, 2018	Jan CAHN
AB	50MG			A 207014	002 Mar 19, 2018	Jan CAHN
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>					
	TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE					
AA	APPCO 4MG			A 206553	001 Nov 29, 2016	Mar CAHN
	@ PAR PHARM 4MG			A 087129	001	May DISC

CYSTEAMINE BITARTRATE

GRANULE;ORAL
PROSYSBI
+ HORIZON PHARMA USA EQ 75MG BASE/PACKET N213491 001 Feb 14, 2020 Feb NEWA
+! EQ 300MG BASE/PACKET N213491 002 Feb 14, 2020 Feb NEWA

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
NOURESS
+ @ AVADEL LEGACY 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019 May CRLD
@ 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019 May DISC

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE
>A> AP HONG KONG 20MG/ML A206189 001 Jun 26, 2020 Jun NEWA

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL
DABIGATRAN ETEXILATE MESYLATE
AB ALKEM LABS LTD EQ 75MG BASE A208040 001 Mar 11, 2020 Feb NFTG
AB EQ 150MG BASE A208040 002 Mar 11, 2020 Feb NFTG
AB HETERO LABS LTD III EQ 75MG BASE A207961 001 May 06, 2020 Apr NEWA
AB EQ 150MG BASE A207961 002 May 06, 2020 Apr NEWA
PRADAXA
AB + BOEHRINGER INGELHEIM EQ 75MG BASE N022512 001 Oct 19, 2010 Feb CFTG
AB +! EQ 150MG BASE N022512 002 Oct 19, 2010 Feb CFTG

DACTINOMYCIN

INJECTABLE;INJECTION
DACTINOMYCIN
AP XGEN PHARMS 0.5MG/VIAL A203999 001 May 20, 2019 Feb CAHN

DANTROLENE SODIUM

INJECTABLE;INJECTION
REVONTO
>D> AP US WORLDMEDS 20MG/VIAL A078378 001 Jul 24, 2007 Jun CAHN
>A> AP USWM 20MG/VIAL A078378 001 Jul 24, 2007 Jun CAHN

DAPSONE

GEL;TOPICAL
ACZONE
>D> +! ALMIRALL 7.5% N207154 001 Feb 24, 2016 Jun CTEC
>A> AB +! 7.5% N207154 001 Feb 24, 2016 Jun CTEC
DAPSONE
AB TARO PHARMS 7.5% A210191 001 Jun 26, 2019 Feb NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE
@ ALAN LABS INC EQ 7.5MG BASE A209571 002 Oct 22, 2019 Apr DISC
@ EQ 15MG BASE A209571 001 Oct 22, 2019 Apr DISC
@ ANCHEN PHARMS EQ 7.5MG BASE A091190 001 Mar 13, 2015 Feb DISC
@ EQ 15MG BASE A091190 002 Mar 13, 2015 Feb DISC

DEFERASIROX

TABLET;ORAL
DEFERASIROX
>A> AB ALEMBIC PHARMS LTD 180MG A211824 003 Jun 15, 2020 Jun NEWA
AB ALKEM LABS LTD 90MG A210555 001 Mar 30, 2020 Mar NEWA
AB 360MG A210555 002 Mar 30, 2020 Mar NEWA
AB AMNEAL 90MG A210727 001 Dec 27, 2019 Feb CAHN
>A> AB 180MG A210727 003 Jun 15, 2020 Jun NEWA
AB 360MG A210727 002 Dec 27, 2019 Feb CAHN
AB CIPLA 90MG A211852 001 Feb 11, 2020 Jan NEWA
>A> AB 180MG A211852 003 Jun 15, 2020 Jun NEWA
AB 360MG A211852 002 Feb 11, 2020 Jan NEWA
>A> AB MSN 180MG A210945 003 Jun 16, 2020 Jun NEWA
>A> AB PIRAMAL HLTHCARE UK 180MG A212995 003 Jun 15, 2020 Jun NEWA
>A> AB SUN PHARM 180MG A211641 003 Jun 15, 2020 Jun NEWA
AB TEVA PHARMS USA 180MG A209223 003 Apr 24, 2020 Apr NEWA

	TABLET;ORAL DEFERASIROX						
>A> AB	ZYDUS PHARMS	180MG		A211383	003	Jun 15, 2020	Jun NEWA
	TABLET, FOR SUSPENSION;ORAL DEFERASIROX						
AB	ZYDUS PHARMS	125MG		A208882	001	May 05, 2020	Apr NEWA
AB		250MG		A208882	002	May 05, 2020	Apr NEWA
AB		500MG		A208882	003	May 05, 2020	Apr NEWA
	<u>DEFERIPRONE</u>						
	SOLUTION;ORAL FERRIPROX						
+ !	CHIESI	80MG/ML		N208030	002	Apr 20, 2018	Mar CAHN
+ !		100MG/ML		N208030	001	Sep 09, 2015	Mar CAHN
	TABLET;ORAL FERRIPROX						
+ !	CHIESI	500MG		N021825	001	Oct 14, 2011	Mar CAHN
+ !		1GM		N021825	002	Jul 25, 2019	Mar CAHN
+ !		1GM		N212269	001	May 19, 2020	May NEWA
	<u>DELAVIRDINE MESYLATE</u>						
	TABLET;ORAL RESCRIPTOR						
+ @	VIV HLTHCARE	200MG		N020705	002	Jul 14, 1999	Mar DISC
	<u>DESMOPRESSIN ACETATE</u>						
	INJECTABLE; INJECTION DESMOPRESSIN ACETATE						
AP	UBI	0.004MG/ML		A210218	001	Feb 14, 2020	Feb NEWA
	<u>DESOGESTREL; ETHINYLN ESTRADIOL</u>						
	TABLET;ORAL-28 DESOGESTREL AND ETHINYLN ESTRADIOL						
>D> AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG		A209170	001	Jun 05, 2017	Jun CAHN
>D>	@	0.15MG;0.03MG		A207067	001	Sep 13, 2018	Jun CAHN
>A> AB	NAARI PTE LTD	0.15MG,N/A;0.02MG,0.01MG		A209170	001	Jun 05, 2017	Jun CAHN
>A>	@	0.15MG;0.03MG		A207067	001	Sep 13, 2018	Jun CAHN
	EMOQUETTE						
	@ VINTAGE PHARMS LLC	0.15MG;0.03MG		A076675	001	Feb 25, 2011	Apr DISC
	SIMILIYA						
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG		A206853	001	Mar 22, 2017	Mar CTNA
	<u>DESONIDE</u>						
	GEL;TOPICAL DESONATE						
AB	+! LEO PHARMA AS	0.05%		N021844	001	Oct 20, 2006	Apr CFTG
AB	TERESINA	0.05%		A202470	001	May 11, 2020	Apr NFTG
	<u>DESOXIMETASONE</u>						
	CREAM;TOPICAL DESOXIMETASONE						
AB	CADILA	0.25%		A205620	001	Sep 28, 2018	Mar CMFD
AB	COSETTE	0.25%		A209595	001	Mar 04, 2020	Feb NEWA
	<u>DESVENLAFAKINE SUCCINATE</u>						
	TABLET, EXTENDED RELEASE;ORAL DESVENLAFAKINE SUCCINATE						
>D>	@ MYLAN	EQ 50MG BASE		A204095	001	Jun 29, 2015	Feb DISC
>D>	@ YICHANG HUMANWELL	EQ 50MG BASE		A210014	001	Oct 01, 2018	Jun CMFD
>A> AB		EQ 50MG BASE		A210014	001	Oct 01, 2018	Jun CMFD
>D>	@	EQ 100MG BASE		A210014	002	Oct 01, 2018	Jun CMFD
>A> AB		EQ 100MG BASE		A210014	002	Oct 01, 2018	Jun CMFD
	<u>DEXAMETHASONE SODIUM PHOSPHATE</u>						
	INJECTABLE; INJECTION DEXAMETHASONE SODIUM PHOSPHATE						
>A> AP	AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML		A210966	001	Jun 05, 2020	Jun NEWA

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX ST

+! EYEVANCE

0.05%;0.3%

N050818 001 Feb 13, 2009 Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

>D> DEXMEDETOMIDINE

>D> AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun CTNA
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan CTNA
	DEXMEDETOMIDINE HYDROCHLORIDE					
AP	AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551	001	May 20, 2020	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551	002	May 20, 2020	May NEWA
AP	GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307	001	Jun 03, 2020	May NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307	002	Jun 03, 2020	May NEWA
AP	HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan NEWA
>A> AP	JIANGSU HENGRUI MED	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A209065	002	Jun 12, 2020	Jun NEWA
>A> AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun CTNA
>A> AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209065	003	Jun 12, 2020	Jun NEWA
>A> AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209065	004	Jun 12, 2020	Jun NEWA
	PRECEDEX					
>A>	+! HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	Jun NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Mar NEWA
AB		10MG	A209754	002	Mar 24, 2020	Mar NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

@ PII	5MG	A205077	001	Jun 21, 2019	Jan DISC
@	10MG	A205077	002	Jun 21, 2019	Jan DISC
@	15MG	A205077	003	Jun 21, 2019	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	! SLATE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Mar CMFD
@		15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Feb CAHN
	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA	AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Mar CMFD
@ HI TECH PHARMA		15MG/5ML; 6.25MG/5ML	A040027	001	Jul 31, 1996	Mar DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D> AP	FRESENIUS KABI USA	2.5GM/100ML; 450MG/100ML	A211190	001	Dec 20, 2019	Jun DISC
>A>	@	2.5GM/100ML; 450MG/100ML	A211190	001	Dec 20, 2019	Jun DISC

DIAZEPAM

SPRAY;NASAL

VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan NEWA
+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan NEWA
+		10MG/SPRAY	N211635	003	Jan 10, 2020	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

+ @ NOSTRUM LABS INC 75MG

N012546 001

Mar CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB	CIPPLA	0.5MG/SPRAY	A212907	001	May 20, 2020	May NEWA
AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb NFTG
	MIGRANAL					

AB	+! BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb CFTG
----	-----------	-------------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2	ACCORD HLTHCARE	120MG	A206997	001	Apr 28, 2020	Apr NEWA
AB2		180MG	A206997	002	Apr 28, 2020	Apr NEWA
AB2		240MG	A206997	003	Apr 28, 2020	Apr NEWA
AB2	APOTEX	120MG	A074943	003	Dec 19, 2000	Apr CTEC
	DILTZAC					
@	APOTEX	120MG	A076395	001	Feb 01, 2006	Apr DISC
@		180MG	A076395	002	Feb 01, 2006	Apr DISC
@		240MG	A076395	003	Feb 01, 2006	Apr DISC
@		300MG	A076395	004	Feb 01, 2006	Apr DISC
@		360MG	A076395	005	Feb 01, 2006	Apr DISC

DISULFIRAM

TABLET;ORAL

DISULFIRAM

@ HIKMA 250MG

@ 500MG

A202652 001 Feb 05, 2014 Feb DISC

A202652 002 Feb 05, 2014 Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

AB	AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb NEWA
@	MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan DISC

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ MYLAN EQ 125MG VALPROIC ACID

@ EQ 250MG VALPROIC ACID

@ EQ 500MG VALPROIC ACID

A090062 001 Mar 17, 2009 Jan DISC

A090062 002 Mar 17, 2009 Jan DISC

A090062 003 Mar 17, 2009 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ LUPIN LTD EQ 250MG VALPROIC ACID

@ EQ 500MG VALPROIC ACID

A209286 001 Oct 18, 2019 Apr DISC

A209286 002 Oct 18, 2019 Apr DISC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan CMFD
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan CMFD
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan CMFD

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

>A> AB	ACCORD HLTHCARE	0.125MG	A213338	001	Jun 19, 2020	Jun NEWA
>A> AB		0.25MG	A213338	002	Jun 19, 2020	Jun NEWA
>A> AB		0.5MG	A213338	003	Jun 19, 2020	Jun NEWA
AB	MSN	0.125MG	A213220	001	Jan 29, 2020	Jan NEWA
AB		0.25MG	A213220	002	Jan 29, 2020	Jan NEWA
AB		0.5MG	A213220	003	Jan 29, 2020	Jan NEWA

DOLUTEGRAVIR SODIUM

>A>	TABLET, FOR SUSPENSION;ORAL					
>A>	TIVICAY PD					
>A>	+! VII VHLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020	Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	GRAVITI PHARMS	5MG	A202114	001	Jul 05, 2013	Apr CAHN
AB		10MG	A202114	002	Jul 05, 2013	Apr CAHN
@	MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011	Mar DISC
@		10MG	A090521	002	May 31, 2011	Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	MICRO LABS	EQ 2.0% BASE; EQ 0.5% BASE	A204777	001	May 28, 2020	May NEWA
----	------------	----------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

>D> AB	+!	PFIZER	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jun CAHN
>D> AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jun CAHN
>D> AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jun CAHN
>D> AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jun CAHN
>A> AB	+!	UPJOHN	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jun CAHN
>A> AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jun CAHN
>A> AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jun CAHN
>A> AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jun CAHN
		DOXAZOSIN MESYLATE					
	@	ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan DISC
	@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan DISC
	@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan DISC
	@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan DISC

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

>D>	+	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jun CAHN
>D>	+		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jun CAHN
>A>	+	UPJOHN	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jun CAHN
>A>	!+		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jun CAHN

DOXEPIН HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIН HYDROCHLORIDE

>A> AB	TARO PHARM IND'S LTD	EQ 10MG BASE	A213063	001	Jul 01, 2020	Jun NEWA
>A> AB		EQ 25MG BASE	A213063	002	Jul 01, 2020	Jun NEWA
>A> AB		EQ 50MG BASE	A213063	003	Jul 01, 2020	Jun NEWA
>A> AB		EQ 75MG BASE	A213063	004	Jul 01, 2020	Jun NEWA
>A> AB		EQ 100MG BASE	A213063	005	Jul 01, 2020	Jun NEWA

CONCENTRATE; ORAL

DOXEPIН HYDROCHLORIDE

AA	! LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	May CHRS
	@ TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987	May DISC

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb CAHN
AP	NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@	MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan DISC
---	------------------	---------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar NEWA
AB		EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar NEWA

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	AJANTA PHARMA LTD	EQ 75MG BASE	A211584	001	Jun 01, 2020	May NEWA
AB		EQ 150MG BASE	A211584	002	Jun 01, 2020	May NEWA
AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb NEWA
>A> AB		EQ 75MG BASE	A211744	001	Jun 30, 2020	Jun NEWA

TABLET; ORAL

	AB		EQ 100MG BASE	A210536	001	May 14, 2020	May NEWA
>A>	AB		EQ 150MG BASE	A211744	002	Jun 30, 2020	Jun NEWA
	AB	OAKLOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar NEWA
TABLET, DELAYED RELEASE;ORAL							
	DORYX						
	+ MAYNE PHARMA		EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar CMFD
	DOXYCYCLINE HYCLATE						
	AB	PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb NEWA

DRONABINOL

CAPSULE; ORAL
DRONABINOL

AB	ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan NEWA
AB		5MG	A207421	002	Feb 07, 2020	Jan NEWA
AB		10MG	A207421	003	Feb 07, 2020	Jan NEWA
MARINOL						
AB	+ ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan CAHN
AB	+!	5MG	N018651	002	May 31, 1985	Jan CAHN
AB	+	10MG	N018651	003	May 31, 1985	Jan CAHN
SOLUTION;ORAL SYNDROS						
+!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	ALLIED TABLET;ORAL-28	3MG;0.02MG DROSPIRENONE AND ETHINYL ESTRADIOL	A203291	001	Jul 18, 2017	Jan CAHN	
>D>	AB	ACCORD HLTHCARE	3MG;0.03MG	A207245	001	Nov 22, 2016	Jun CAHN
AB	HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan NEWA	
>A>	AB	NAARI PTE LTD	3MG;0.03MG	A207245	001	Nov 22, 2016	Jun CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

④	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	May	DISC
④		EQ 30MG BASE	A210599	002	Apr 17, 2019	May	DISC
④		EQ 60MG BASE	A210599	003	Apr 17, 2019	May	DISC
④	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar	DISC
④		EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar	DISC
④		EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar	DISC

DUTASTERIDE

CAPSULE; ORAL
DUTASTERIDE

	© ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan DISC
	© APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb DISC
AB	AUROBINDO PHARMA LTD	0.5MG	A202660	001	Nov 20, 2015	May CAHN
	© HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb DISC
	© STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018	Mar CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET: OBAT

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR

AB	LAURUS LABS LTD	400MG;300MG;300MG	A213038	001	May 14, 2020	May NFTG
AB		600MG;300MG;300MG	A212786	001	May 14, 2020	May NFTG
	SYMFI					
AB	+! MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	May CFTG
	SYMFI LO					
AB	+! MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018	May CFTG

ELACOTIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELACOTIX SODIUM

CAPSULE:OBAT

ORTAHNN (CORPACKAGED)

+! ABBVIE INC EQ 300MG BASE,1MG,0.5MG; EQ 300MG N213388 001 May 29, 2020 May NEWA
BASE

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIJARDY XR

+ BOEHRINGER INGELHEIM	5MG;2.5MG;1GM
+	10MG;5MG;1GM
+	12.5MG;2.5MG;1GM
+!	25MG;5MG;1GM

N212614	001	Jan 27, 2020	Jan NEWA
N212614	002	Jan 27, 2020	Jan NEWA
N212614	003	Jan 27, 2020	Jan NEWA
N212614	004	Jan 27, 2020	Jan NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	May NEWA
@ MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb DISC
AB ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

EPANED

+! AZURITY	1MG/ML
------------	--------

N208686	001	Sep 20, 2016	May CAHN
---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@ MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan DISC
@	1MG	A206226	002	Mar 26, 2019	Jan DISC
AB SUNSHINE LAKE	0.5MG	A211978	001	May 20, 2020	May NEWA
AB	1MG	A211978	002	May 20, 2020	May NEWA
@ YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Apr DISC
@	1MG	A212201	002	Nov 04, 2019	Apr DISC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EMERPHED

+! NEXUS PHARMS	50MG/10ML (5MG/ML)
-----------------	--------------------

N213407	001	Apr 17, 2020	Apr NEWA
---------	-----	--------------	----------

EPINEPHRINESOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ADRENALIN

AP +! PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr CFTG
AP INTL MEDICATION SYS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A211880	001	Apr 24, 2020	Apr NFTG

EPLERENONE

TABLET;ORAL

EPLERENONE

AB COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb CAHN
AB	50MG	A078482	002	Jul 30, 2008	Feb CAHN

EPROSARTAN MESYLATE

TABLET;ORAL

EPROSARTAN MESYLATE

@ MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011	Apr DISC
@	EQ 600MG BASE	A202012	002	Nov 16, 2011	Apr DISC

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar NEWA
AP	75MG/100ML	A207864	002	Mar 20, 2020	Mar NEWA

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS

XERAVA

>A> +! TETRAPHASE PHARMS	EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020	Jun NEWA
--------------------------	--------------------	---------	-----	--------------	----------

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB	ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr NEWA
AB		EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr NEWA
AB		EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan CAHN
AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr CHRS
	LEXAPRO					
+ @	ALLERGAN	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr DISC
	TABLET;ORAL					
	ESCITALOPRAM OXALATE					
@	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	May DISC
@		EQ 10MG BASE	A202210	002	Sep 11, 2012	May DISC
@		EQ 20MG BASE	A202210	003	Sep 11, 2012	May DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	HETERO LABS LTD III	EQ 20MG BASE	A211977	001	Jun 02, 2020	May NEWA
AB		EQ 40MG BASE	A211977	002	Jun 02, 2020	May NEWA
	FOR SUSPENSION, DELAYED RELEASE;ORAL					
	ESOMEPRAZOLE MAGNESIUM					
AB	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar NFTG
AB		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar NFTG
AB		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar NFTG
	NEXIUM					
AB	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar CFTG
AB	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar CFTG
AB	+!	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A204206	001	Feb 18, 2020	Feb NEWA
AB		EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Feb NEWA
	VIMOVO					
AB	+ HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb CTEC
AB	+!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar NEWA
AP		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+ @	BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar CAHN
+ @		49.3MG	N202342	002	Aug 06, 2013	Mar CAHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

AO	+! PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr CTEC
	ESTRADIOL VALERATE					
AO	HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr NEWA
AO		20MG/ML	A203723	002	Apr 21, 2020	Apr NEWA
AO		40MG/ML	A203723	003	Apr 21, 2020	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

>D>	@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Jun CAHN
>A>	@ NAARI PTE LTD	1MG;0.5MG	A210233	001	Feb 28, 2018	Jun CAHN
	@ TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Jan DISC

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

@ MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan DISC
@	1.5MG	A040359	002	Aug 26, 1999	Jan DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ HIKMA	1MG	A091153	001	Apr 15, 2014	Feb DISC
@	2MG	A091153	002	Apr 15, 2014	Feb DISC
@	3MG	A091153	003	Apr 15, 2014	Feb DISC

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

>A> AP	VPI PHARMS INC	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Jun NEWA
--------	----------------	-------------------	---------	-----	--------------	----------

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB	UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

ETHINYLM ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

+! AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020	Feb NEWA
----------	-------------------------	---------	-----	--------------	----------

TABLET;ORAL

BALCOLTRA

+! AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CHRS
+	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CRLD

FAYOSIM

@ LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03M G,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar DISC
-------------	--------------------------------------------------------	---------	-----	--------------	----------

TABLET;ORAL-28

ELIFEMME

@ XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075M G,0.125MG	A202507	001	Dec 04, 2015	Mar DISC
-----------	----------------------------------------------	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYLM ESTRADIOL

@ MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075M G,0.125MG	A202970	001	Mar 23, 2018	Feb DISC
------------------	----------------------------------------------	---------	-----	--------------	----------

ORSYTHIA

>D> AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011	Jun DISC
---------	--------------------	--------------	---------	-----	--------------	----------

>A>	@	0.02MG;0.1MG	A077099	001	May 11, 2011	Jun DISC
-----	---	--------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

LEVONORGESTREL AND ETHINYLM ESTRADIOL

>D>	+! EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020	Jun CTNA
>D>	+!	0.02MG;0.1MG	N209405	001	Mar 30, 2020	Mar NEWA

>A>	TYBLUME		N209405	001	Mar 30, 2020	Jun CTNA
-----	---------	--	---------	-----	--------------	----------

>A>	+! EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020	Jun CTNA
-----	--------------------	--------------	---------	-----	--------------	----------

ETHINYLM ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYLM ESTRADIOL

>D> AB	ACCORD HLTHCARE	0.035MG;1MG	A206864	001	Apr 28, 2017	Jun CAHN
--------	-----------------	-------------	---------	-----	--------------	----------

>A> AB	NAARI PTE LTD	0.035MG;1MG	A206864	001	Apr 28, 2017	Jun CAHN
--------	---------------	-------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYLM ESTRADIOL AND FERROUS FUMARATE

>D> AB	ACCORD HLTHCARE	0.035MG;0.4MG	A207066	001	Mar 29, 2017	Jun CAHN
--------	-----------------	---------------	---------	-----	--------------	----------

>A> AB	NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	Jun CAHN
--------	---------------	---------------	---------	-----	--------------	----------

TABLET;ORAL
EVEROLIMUS

>D> AB		7.5MG	A210050	003	Dec 09, 2019	Jun DISC
>A> AB		7.5MG	A210050	003	Dec 09, 2019	Jun CMFD
>A>	@	7.5MG	A210050	003	Dec 09, 2019	Jun DISC
>D> AB		10MG	A210050	004	Dec 09, 2019	Jun DISC
>A>	@	10MG	A210050	004	Dec 09, 2019	Jun DISC

EXEMESTANE

TABLET;ORAL EXEMESTANE						
AB	@ MAYNE PHARMA INC QILU	25MG 25MG	A208764	001	Aug 08, 2019	Jan DISC
			A213547	001	Apr 13, 2020	Mar NEWA

EZETIMIBE

TABLET;ORAL EZETIMIBE						
	@ MYLAN @ TEVA PHARMS USA	10MG 10MG	A201790	001	Apr 26, 2019	Feb DISC
			A078724	001	Jun 12, 2017	Mar DISC

FAMOTIDINE

TABLET;ORAL FAMOTIDINE						
AB	! AUROBINDO PHARMA LTD @ MYLAN @ TEVA @ PEPCID + @ VALEANT PHARMS NORTH + @	40MG 20MG 20MG 40MG 20MG 40MG	A206530	002	Dec 22, 2015	Jan CHRS
			A075704	001	Apr 16, 2001	Feb DISC
			A075311	001	Apr 16, 2001	Mar DISC
			A075311	002	Apr 16, 2001	Mar DISC
			N019462	001	Oct 15, 1986	Jan DISC
			N019462	002	Oct 15, 1986	Jan DISC

FEBUXOSTAT

TABLET;ORAL FEBUXOSTAT						
AB	SUNSHINE LAKE	40MG	A213069	001	Jun 02, 2020	May NEWA
AB		80MG	A213069	002	Jun 02, 2020	May NEWA

>A> FENFLURAMINE HYDROCHLORIDE

>A>	SOLUTION;ORAL					
>A>	FINTEPLA					
>A>	+! ZOGENIX INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun NEWA

FENOFRIBRATE

CAPSULE;ORAL FENOFRIBRATE (MICRONIZED)						
AB	ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan CAHN
AB		134MG	A209504	002	Apr 30, 2018	Jan CAHN
AB		200MG	A209504	003	Apr 30, 2018	Jan CAHN
	@ MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013	Mar DISC
	@	130MG	A202579	002	Jan 10, 2013	Mar DISC
TABLET;ORAL FENOFRIBRATE						
AB	ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan NEWA
AB		160MG	A213252	002	Jan 17, 2020	Jan NEWA
AB	APPCO	54MG	A210670	001	Sep 06, 2019	Jan CAHN
AB		160MG	A210670	002	Sep 06, 2019	Jan CAHN
AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar NEWA
AB		54MG	A210606	001	Aug 17, 2018	Jan CMFD
AB		145MG	A211122	002	Mar 18, 2020	Mar NEWA
AB		160MG	A210606	002	Aug 17, 2018	Jan CMFD
>A> AB	MANKIND PHARMA	54MG	A213864	001	Jun 12, 2020	Jun NEWA
>A> AB		160MG	A213864	002	Jun 12, 2020	Jun NEWA

FENTANYL CITRATE

INJECTABLE;INJECTION FENTANYL CITRATE PRESERVATIVE FREE						
AP	+! HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN

FERRIC DERISOMALTOSE

SOLUTION; INTRAVENOUS
MONOFERRIC

>D>	+!	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jun DISC
>A>	+ @		100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jun DISC
	+!		100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan NEWA
>D>	+!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jun DISC
>A>	+ @		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jun DISC
	+!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan NEWA
	+!		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION; INTRAVENOUS
TRIFERIC AVNU

+!	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar NEWA
----	----------------------	-----------------------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL
FESOTERODINE FUMARATE
@ DR REDDYS LABS LTD 4MG
@ 8MG

A204975	001	Aug 13, 2019	Feb DISC
A204975	002	Aug 13, 2019	Feb DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE
@ BARR 30MG
@ 60MG
@ 180MG

A076191	001	Aug 31, 2005	Mar DISC
A076191	002	Aug 31, 2005	Mar DISC
A076191	003	Aug 31, 2005	Mar DISC

FIDAXOMICIN

FOR SUSPENSION; ORAL
DIFICID
+! CUBIST PHARMS LLC 40MG/ML

N213138	001	Jan 24, 2020	Jan NEWA
---------	-----	--------------	----------

FINASTERIDE

TABLET; ORAL
FINASTERIDE
@ TEVA 1MG

A076905	001	Nov 05, 2013	Mar DISC
---------	-----	--------------	----------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE
>D> AB BIOCON LTD EQ 0.5MG BASE
>A> @ EQ 0.5MG BASE
>A> AB GLENMARK PHARMS LTD EQ 0.5MG BASE
AB HETERO LABS LTD V EQ 0.5MG BASE
>A> AB STRIDES PHARMA EQ 0.5MG BASE

A207979	001	Dec 04, 2019	Jun DISC
A207979	001	Dec 04, 2019	Jun DISC
A207985	001	Jun 18, 2020	Jun NEWA
A207933	001	May 18, 2020	May NEWA
A207971	001	Jun 29, 2020	Jun NEWA

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS
TAUVID
+! AVID RADIOPHARMS INC 30ML (8.1-51mCi/ML)
+! 50ML (8.1-51mCi/ML)

N212123	001	May 28, 2020	May NEWA
N212123	002	May 28, 2020	May NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL
FLUCONAZOLE
@ HIKMA 50MG/5ML
@ 200MG/5ML

A076246	001	Jul 29, 2004	Feb DISC
A076246	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
@ HIKMA FARMACEUTICA 200MG/100ML (2MG/ML)
@ 400MG/200ML (2MG/ML)
@ HOSPIRA 200MG/100ML (2MG/ML)
@ 400MG/200ML (2MG/ML)
@ WOODWARD 200MG/100ML (2MG/ML)
@ 400MG/200ML (2MG/ML)

A078764	001	Jan 30, 2012	Mar DISC
A078764	002	Jan 30, 2012	Mar DISC
A076304	001	Jul 29, 2004	Mar DISC
A076304	002	Jul 29, 2004	Mar DISC
A077988	001	May 26, 2010	Mar DISC
A077988	002	May 26, 2010	Mar DISC

TABLET; ORAL

FLUCONAZOLE
@ MYLAN 50MG
@ 100MG

A076351	001	Jul 29, 2004	Jan DISC
A076351	002	Jul 29, 2004	Jan DISC

TABLET;ORAL
FLUCONAZOLE

@	150MG	A076351	003	Jul 29, 2004	Jan DISC
@	200MG	A076351	004	Jul 29, 2004	Jan DISC
@ TEVA	50MG	A074681	001	Jul 29, 2004	Mar DISC
@	100MG	A074681	002	Jul 29, 2004	Mar DISC
@	150MG	A074681	003	Jul 29, 2004	Mar DISC
@	200MG	A074681	004	Jul 29, 2004	Mar DISC

FLUCYTOSINE

CAPSULE;ORAL
FLUCYTOSINE

AB	AUROBINDO PHARMA LTD	250MG	A213665	001	May 01, 2020	Apr NEWA
AB		500MG	A213665	002	May 01, 2020	Apr NEWA
AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Apr NEWA
AB		500MG	A212632	002	Apr 17, 2020	Apr NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	@ UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020	May DISC
		20-200mCi/ML	A210265	001	Feb 06, 2020	Jan NEWA

FLUNISOLIDE

SPRAY, METERED;NASAL
FLUNISOLIDE

!	APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar CHRS
		0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar CMFD

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

AB1	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Apr CMFD
AB	CADILA	0.1%	A208989	001	Feb 10, 2020	Feb CAHN
AB	ZYDUS PHARMS	0.1%	A208989	001	Feb 10, 2020	Jan NEWA
	SOLUTION;TOPICAL					
	FLUOCINONIDE					
@ TEVA		0.05%	A072511	001	Feb 07, 1989	Mar DISC

FLUOROESTRADIOL F-18

SOLUTION; INTRAVENOUS
CERIANNA

+!	ZIONEXA	50ML (4-100mCi/ML)	N212155	001	May 20, 2020	May NEWA
----	---------	--------------------	---------	-----	--------------	----------

FLUOROURACIL

INJECTABLE;INJECTION
FLUOROURACIL

@ INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	Apr DISC
@	500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Apr DISC
@	1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	Apr DISC
@	2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	Apr DISC

SOLUTION;TOPICAL
FLUOROURACIL

AT	! TARO	5%	A076526	002	Nov 05, 2003	Mar CHRS
----	--------	----	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

@ BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar DISC
@	EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar DISC
@ SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002	May DISC
@	EQ 20MG BASE	A075658	002	Jan 29, 2002	May DISC

SOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar CMFD
	@ SPECGX LLC	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	May DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar NEWA
AB		EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar NEWA
>A> AB		EQ 60MG BASE	A213265	001	Jun 10, 2020	Jun NEWA
	@ G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Mar DISC

TABLET;ORAL

SARAFEM

+ APIL	EQ 15MG BASE	N 021860	002	May 19, 2006	Apr CTEC
SELFEMRA					
@ TEVA PHARMS USA	EQ 10MG BASE	A 200151	001	Feb 03, 2014	Apr DISC
@	EQ 15MG BASE	A 200151	002	Feb 03, 2014	Apr DISC
@	EQ 20MG BASE	A 200151	003	Feb 03, 2014	Apr DISC

FLUPHENAZINE HYDROCHLORIDETABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

@ SANDOZ	1MG	A 089586	002	Oct 16, 1987	Mar DISC
@	2.5MG	A 089586	003	Oct 16, 1987	Mar DISC
@	5MG	A 089586	004	Oct 16, 1987	Mar DISC
@	10MG	A 089586	001	Oct 16, 1987	Mar DISC

FLUTICASONE PROPIONATEPOWDER;INHALATION

ARMONAIR DIGIHALER

+ TEVA PHARM	0.055MG/INH	N 208798	004	Feb 20, 2020	Mar NEWA
+	0.113MG/INH	N 208798	005	Feb 20, 2020	Mar NEWA
+!	0.232MG/INH	N 208798	006	Feb 20, 2020	Mar NEWA

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE;ORAL
FLUVOXAMINE MALEATE

AB	BIONPHARMA INC	150MG	A 212182	001	May 11, 2020	Apr NEWA
	TABLET;ORAL					
	FLUVOXAMINE MALEATE					
	@ TEVA	25MG	A 075893	001	Sep 10, 2002	Mar DISC
	@	50MG	A 075893	002	Sep 10, 2002	Mar DISC
	@	100MG	A 075893	003	Sep 10, 2002	Mar DISC

FOLIC ACIDINJECTABLE;INJECTION
FOLIC ACID

AP	X-GEN PHARMS INC	5MG/ML	A 202522	001	Nov 06, 2019	Jan CAHN
AP	XGEN PHARMS	5MG/ML	A 202522	001	Nov 06, 2019	Feb CAHN
	TABLET;ORAL					
	FOLIC ACID					
>D> AA	VINTAGE	1MG	A 040756	001	Jun 04, 2010	Jun DISC
>A>	@	1MG	A 040756	001	Jun 04, 2010	Jun DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	! AUROBINDO PHARMA	20MG;12.5MG	A 079245	002	Jul 09, 2009	Apr CHRS
	@ EMCURE PHARMS LTD	10MG;12.5MG	A 079025	001	Sep 17, 2010	Apr DISC
	@	20MG;12.5MG	A 079025	002	Sep 17, 2010	Apr DISC

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDEPOWDER;INTRAVENOUS

AKYNZEOTM

+! HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N 210493	001	Apr 19, 2018	May CMS1
---------------------	-------------------------------------------	----------	-----	--------------	----------

SOLUTION;INTRAVENOUS

AKYNZEOTM

+! HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N 210493	002	May 27, 2020	May NEWA
---------------------	-----------------------------------------------------------------------------------------	----------	-----	--------------	----------

FULVESTRANTINJECTABLE;INTRAMUSCULAR

FULVESTRANT

AO	CHIA TAI TIANQING	50MG/ML	A 211422	001	Feb 07, 2020	Jan NEWA
----	-------------------	---------	----------	-----	--------------	----------

FUROSEMIDEINJECTABLE;INJECTION

FUROSEMIDE

>A> AP	GLAND PHARMA LTD	10MG/ML	A 213902	001	Jul 01, 2020	Jun NEWA
--------	------------------	---------	----------	-----	--------------	----------

TABLET;ORAL
FUROSEMIDE

@ AVET	20MG	N 018413 001 Nov 30, 1983	Jan DISC
@	40MG	N 018413 002 Nov 30, 1983	Jan DISC

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

AB	CSPC OUYI	100MG	A 075477 001 Mar 23, 2005	Jan CMFD
AB		300MG	A 075477 002 Mar 23, 2005	Jan CMFD
AB		400MG	A 075477 003 Mar 23, 2005	Jan CMFD
	@ JIANGSU HENGRUI MED	100MG	A 091008 001 Oct 26, 2017	May DISC
	@	300MG	A 091008 002 Oct 26, 2017	May DISC
	@	400MG	A 091008 003 Oct 26, 2017	May DISC
	@ TEVA PHARMS	100MG	A 075435 001 Oct 08, 2004	Mar DISC
	@	300MG	A 075435 002 Oct 08, 2004	Mar DISC
	@	400MG	A 075435 003 Oct 08, 2004	Mar DISC

NEURONTIN

>D> AB	+	PFIZER PHARMS	100MG	N 020235 001 Dec 30, 1993	Jun CAHN
>D> AB	+		300MG	N 020235 002 Dec 30, 1993	Jun CAHN
>D> AB	+!		400MG	N 020235 003 Dec 30, 1993	Jun CAHN
>A> AB	+	UPJOHN	100MG	N 020235 001 Dec 30, 1993	Jun CAHN
>A> AB	+		300MG	N 020235 002 Dec 30, 1993	Jun CAHN
>A> AB	+!		400MG	N 020235 003 Dec 30, 1993	Jun CAHN

SOLUTION;ORAL

GABAPENTIN

	@ VISTAPHARM	250MG/5ML	A 211330 001 Dec 03, 2019	May DISC
	NEURONTIN			

>D> AA	+!	PARKE DAVIS	250MG/5ML	N 021129 001 Mar 02, 2000	Jun CAHN
>A> AA	+!	UPJOHN	250MG/5ML	N 021129 001 Mar 02, 2000	Jun CAHN

TABLET;ORAL

GABAPENTIN

	@ MYLAN PHARMS INC	600MG	A 090335 001 Jun 01, 2010	Mar DISC
	@	800MG	A 090335 002 Jun 01, 2010	Mar DISC
	@ TEVA PHARMS USA	600MG	A 205807 001 Mar 10, 2017	Mar DISC
	@	800MG	A 205807 002 Mar 10, 2017	Mar DISC

GRALISE

BX	+!	ALMATICA	300MG	N 022544 001 Jan 28, 2011	Jan CAHN
BX	+!		600MG	N 022544 002 Jan 28, 2011	Jan CAHN
		NEURONTIN			
>D> AB	+	PFIZER PHARMS	600MG	N 020882 001 Oct 09, 1998	Jun CAHN
>D> AB	+!		800MG	N 020882 002 Oct 09, 1998	Jun CAHN
>A> AB	+	UPJOHN	600MG	N 020882 001 Oct 09, 1998	Jun CAHN
>A> AB	+!		800MG	N 020882 002 Oct 09, 1998	Jun CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

	@ HIKMA	EQ 4MG BASE	A 077608 001 Feb 11, 2009	Feb DISC
	@	EQ 8MG BASE	A 077608 002 Feb 11, 2009	Feb DISC
	@	EQ 12MG BASE	A 077608 003 Feb 11, 2009	Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

	@ APOTEX	200MG/5.26ML (38MG/ML)	A 206776 001 May 23, 2017	Feb DISC
	@	1GM/26.3ML (38MG/ML)	A 206776 002 May 23, 2017	Feb DISC
	@	2GM/52.6ML (38MG/ML)	A 206776 003 May 23, 2017	Feb DISC
	@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A 200145 002 Jul 25, 2011	May DISC
	@	EQ 2GM BASE/VIAL	A 200145 003 Jul 25, 2011	Mar DISC
AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A 207575 001 Feb 22, 2019	Jan CMFD
AP		EQ 1GM BASE/VIAL	A 207575 002 Feb 22, 2019	Jan CMFD
	@ TEVA PHARMS	EQ 200MG BASE/VIAL	A 077983 002 Jan 25, 2011	Mar DISC
	@	EQ 1GM BASE/VIAL	A 077983 001 Jan 25, 2011	Mar DISC

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	CADILA	600MG	A 204189 001 Aug 28, 2018	Feb CAHN
	@ TEVA	600MG	A 074256 001 Oct 31, 1993	Feb DISC

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE
@ HOSPIRA

EQ 10MG BASE/ML

A062612 004 Feb 20, 1986 Mar DISC

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE
@ MYLAN 1MG
@ 2MG
@ 4MG

A077624 001 Nov 28, 2005 Apr DISC
A077624 002 Nov 28, 2005 Apr DISC
A077624 003 Nov 28, 2005 Apr DISC

GLYBURIDE

TABLET; ORAL
GLYBURIDE

AB1 ORIENT PHARMA CO LTD 1.25MG
AB1 2.5MG
AB1 5MG
GLYBURIDE (MICRONIZED)
@ MYLAN 1.5MG
@ 3MG
@ 6MG

A206483 001 Feb 22, 2019 May CMFD
A206483 002 Feb 22, 2019 May CMFD
A206483 003 Feb 22, 2019 May CMFD
A074792 001 Jun 26, 1998 Jan DISC
A074792 002 Jun 26, 1998 Jan DISC
A074792 003 Aug 17, 1999 Jan DISC

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP RICONPHARMA LLC 0.2MG/ML
POWDER; INHALATION
SEEBRI
+ @ NOVARTIS 15.6MCG/INH
+ @ SUNOVION PHARMS INC 15.6MCG/INH
SOLUTION; INTRAMUSCULAR, INTRAVENOUS
GLYRX-PF
EXELA PHARMA SCS LLC 1MG/5ML (0.2MG/ML)

A210083 001 Feb 21, 2020 Feb NEWA
N207923 001 Oct 29, 2015 Mar CAHN
N207923 001 Oct 29, 2015 Mar DISC
N210997 003 Apr 09, 2020 Apr NEWA

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION
UTIBRON
+ @ NOVARTIS 15.6MCG/INH; 27.5MCG/INH
+ @ SUNOVION PHARMS INC 15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 Mar CAHN
N207930 001 Oct 29, 2015 Mar DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

@ MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
@ EQ 1MG BASE/ML (EQ 1MG BASE/ML)
@ EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
AP PUNISKA EQ 0.1IMG BASE/ML (EQ 0.1IMG
BASE/ML)
AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)
AP @ YUNG SHIN PHARM EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
EQ 0.1IMG BASE/ML (EQ 0.1IMG
BASE/ML)
AP EQ 0.1IMG BASE/ML (EQ 0.1IMG
BASE/ML)
>A> AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)
>A> AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

A203454 001 Apr 04, 2017 Apr DISC
A203454 002 Apr 04, 2017 Apr DISC
A203453 001 Jan 31, 2017 Mar DISC
A078262 001 Dec 31, 2007 May CAHN
A078258 001 Jun 30, 2008 May CAHN
A078258 002 Jun 30, 2008 May CAHN
A202647 001 Mar 06, 2020 Apr DISC
A202647 001 Mar 06, 2020 Feb NEWA
A202648 001 Jun 29, 2020 Jun NEWA
A202648 002 Jun 29, 2020 Jun NEWA

TABLET; ORAL
GRANISETRON HYDROCHLORIDE
@ MYLAN EQ 1MG BASE

A078725 001 Jan 30, 2008 Jan DISC

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL
GRISEOFULVIN

AB COSETTE 125MG/5ML

A065438 001 Oct 08, 2010 May CAHN

HALCINONIDE

SOLUTION;TOPICAL

HALOG

! SUN PHARM INDNS INC 0.1%

N017823 001

Mar CMFD

HALOBETASOL PROPIONATE

LOTION;TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	PERRIGO ISRAEL	0.05%	A211464	001	Jun 03, 2020	Jun DISC
>A>	@		0.05%	A211464	001	Jun 03, 2020	Jun DISC
AB			0.05%	A211464	001	Jun 03, 2020	May NFTG
		ULTRAVATE					
>D>	AB	+! SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	Jun CTEC
>A>	+!		0.05%	N208183	001	Nov 06, 2015	Jun CTEC
AB	+!		0.05%	N208183	001	Nov 06, 2015	May CFTG

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

>D>	AB	APPCO	0.5MG	A211061	001	Jan 08, 2020	Jun CAHN
>D>	AB		1MG	A211061	002	Jan 08, 2020	Jun CAHN
>D>	AB		2MG	A211061	003	Jan 08, 2020	Jun CAHN
>D>	AB		5MG	A211061	004	Jan 08, 2020	Jun CAHN
>D>	AB		10MG	A211061	005	Jan 08, 2020	Jun CAHN
>D>	AB		20MG	A211061	006	Jan 08, 2020	Jun CAHN
>A>	AB	UPSHER SMITH LABS	0.5MG	A211061	001	Jan 08, 2020	Jun CAHN
>A>	AB		1MG	A211061	002	Jan 08, 2020	Jun CAHN
>A>	AB		2MG	A211061	003	Jan 08, 2020	Jun CAHN
>A>	AB		5MG	A211061	004	Jan 08, 2020	Jun CAHN
>A>	AB		10MG	A211061	005	Jan 08, 2020	Jun CAHN
>A>	AB		20MG	A211061	006	Jan 08, 2020	Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@ TEVA PHARMS USA EQ 5MG BASE/ML

A076035 001 Aug 29, 2001 Mar DISC

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		GLAND PHARMA LTD	1,000 UNITS/ML	A205323	002	Nov 18, 2019	Apr NEWA
AP		NANJING KING-FRIEND	20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb NEWA
>D>	+!	PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jun DISC
>A>	+ @		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jun DISC
		HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020	Apr NEWA
		HEPARIN SODIUM PRESERVATIVE FREE					
AP	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar CTEC
AP		NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@ NOSTRUM LABS INC 1.5MG/5ML;5MG/5ML

A210663 001 Jun 11, 2019 Apr CAHN

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA ! NOVEL LABS INC 1.5MG;5MG
TUSSIGON
@ KING PHARMS 1.5MG;5MG

A091528 001 Apr 20, 2011 Jan CHRS

A088508 001 Jul 30, 1985 Jan DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP XGEN PHARMS 20MG/ML
TABLET;ORAL
HYDRALAZINE HYDROCHLORIDE
@ STRIDES PHARMA 10MG

A203110 001 Jun 29, 2015 Feb CAHN

A200770 004 Jun 25, 2019 Jan DISC

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

@ IVAX SUB TEVA PHARMS 12.5MG

A077005 001 Jul 13, 2005 Mar DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ MYLAN PHARMS INC 25MG

A040735 002 Jan 23, 2007 Jan DISC

@ 50MG

A040735 003 Jan 23, 2007 Jan DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

@ COREPHARMA 12.5MG;10MG

A076674 001 Oct 05, 2004 Feb CAHN

@ 12.5MG;20MG

A076674 002 Oct 05, 2004 Feb CAHN

@ 25MG;20MG

A076674 003 Oct 05, 2004 Feb CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMS INC 12.5MG;7.5MG

A202150 001 Mar 07, 2014 Apr DISC

@ 12.5MG;15MG

A202150 002 Mar 07, 2014 Apr DISC

@ 25MG;15MG

A202150 003 Mar 07, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	May CMFD
	@	12.5MG;20MG	A208847	001	Sep 17, 2019	Mar DISC
AB		12.5MG;40MG	A208847	003	Sep 17, 2019	May CMFD
	@	12.5MG;40MG	A208847	003	Sep 17, 2019	Mar DISC
AB		25MG;40MG	A208847	002	Sep 17, 2019	May CMFD
	@	25MG;40MG	A208847	002	Sep 17, 2019	Mar DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@ MACLEODS PHARMS LTD 12.5MG;40MG

A204169 001 Nov 02, 2015 May DISC

@ 12.5MG;80MG

A204169 002 Nov 02, 2015 May DISC

@ 25MG;80MG

A204169 003 Nov 02, 2015 May DISC

@ MYLAN 12.5MG;40MG

A091648 001 Feb 25, 2014 Apr DISC

@ 12.5MG;80MG

A091648 002 Feb 25, 2014 Apr DISC

@ 25MG;80MG

A091648 003 Feb 25, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb CAHN
	@ DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999	Mar DISC

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ PLIVA 25MG;37.5MG

A074026 001 Apr 26, 1996 Mar DISC

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB	ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan NFTG
AB		15MG	A206986	002	Jan 21, 2020	Jan NFTG
AB		20MG	A206986	003	Jan 21, 2020	Jan NFTG
AB		30MG	A206986	004	Jan 21, 2020	Jan NFTG
AB		40MG	A206986	005	Jan 21, 2020	Jan NFTG
AB		50MG	A206986	006	Jan 21, 2020	Jan NFTG
	ZOHYDRO ER					
AB	+! PERSION	10MG	N202880	001	Oct 25, 2013	Jan CFTG
AB	+	15MG	N202880	002	Oct 25, 2013	Jan CFTG
AB	+	20MG	N202880	003	Oct 25, 2013	Jan CFTG
AB	+	30MG	N202880	004	Oct 25, 2013	Jan CFTG
AB	+	40MG	N202880	005	Oct 25, 2013	Jan CFTG
AB	+	50MG	N202880	006	Oct 25, 2013	Jan CFTG

HYDROCORTISONE

ENEMA;RECTAL

HYDROCORTISONE

@ TEVA PHARMS

100MG/60ML

A074171 001 May 27, 1994 Mar DISC

LOTION;TOPICAL

HYDROCORTISONE

@ FOUGERA PHARMS

2.5%

A040351 001 Jul 25, 2000 Apr DISC

STIE-CORT

AT ! PERRIGO CO

2.5%

A089074 001 Nov 26, 1985 Apr CHRS

OINTMENT;TOPICAL

HYDROCORTISONE

@ ACTAVIS MID ATLANTIC

1%

A087796 001 Oct 13, 1982 Mar DISC

TABLET;ORAL

HYDROCORTISONE

AB STRIDES PHARMA

5MG

A207029 001 Apr 27, 2017 Feb CAHN

AB 10MG

A207029 002 Apr 27, 2017 Feb CAHN

AB 20MG

A207029 003 Apr 27, 2017 Feb CAHN

HYDROCORTISONE ACETATE

CREAM;TOPICAL

HYDROCORTISONE ACETATE

>D> @ FERNDALE LABS

2.5%

A040259 001 Jul 29, 1999 Jun CAHN

>A> @ IMPERIUM

2.5%

A040259 001 Jul 29, 1999 Jun CAHN

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB COSETTE

0.2%

A211764 001 Mar 04, 2020 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

+! FRESENIUS KABI USA

0.2MG/ML

N019034 006 Jan 16, 2020 Jan NEWA

HYDROMORPHONE HYDROCHLORIDE

@ BARR

10MG/ML

A076444 001 Apr 25, 2003 Mar DISC

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

AA LANNETT CO INC

5MG/5ML

A207108 001 Apr 22, 2020 Apr NEWA

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB NOSTRUM LABS INC

8MG

A076723 001 Oct 18, 2005 Feb CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB ACCORD HLTHCARE

200MG

A213342 001 Apr 07, 2020 Mar NEWA

AB APPCO

200MG

A210441 001 May 01, 2018 Mar CAHN

AB HAVIX

200MG

A212902 001 May 14, 2020 May NEWA

AB LAURUS LABS LTD

200MG

A210959 001 Jan 15, 2019 Mar CMFD

AB LUPIN LTD

200MG

A210543 001 Jul 06, 2018 Mar CMFD

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP1 @ AM REGENT

1250MG/5ML (250MG/ML)

A210724 001 Aug 09, 2019 Feb DISC

1250MG/5ML (250MG/ML)

A210724 001 Aug 09, 2019 Jan CMS1

HYDROXYUREA

CAPSULE;ORAL

HYDROXYUREA

AB LEADING PHARMA LLC

500MG

A213438 001 Apr 08, 2020 Mar NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

@ VINTAGE PHARMS

10MG/5ML

A040391 001 Apr 10, 2002 May DISC

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD

10MG

A087871 002 Dec 20, 1982 May CAHN

@

25MG

A087871 003 Dec 20, 1982 May CAHN

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE
@ 50MG

A 087871 001 Dec 20, 1982 May CAHN

IBUPROFEN

TABLET;ORAL
IBUPROFEN

AB	AUROBINDO PHARMA LTD	400MG	A 213794 001 May 08, 2020	Apr NEWA
AB		600MG	A 213794 002 May 08, 2020	Apr NEWA
AB		800MG	A 213794 003 May 08, 2020	Apr NEWA

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP	XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A 202402 001 Mar 30, 2016	Feb CAHN
----	-------------	------------------------------------	---------------------------	----------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

COMBUNOX

+ @ FOREST LABS	400MG;5MG	N 021378 001 Nov 26, 2004	Apr CRLD
OXYCODONE HYDROCHLORIDE AND IBUPROFEN			
ACTAVIS ELIZABETH	400MG;5MG	A 078769 001 Jan 04, 2008	Apr CTEC
@ BARR LABS INC	400MG;5MG	A 078316 001 Nov 29, 2007	Apr DISC

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS
ICATIBANT ACETATE

>A> AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 208317 001 Jun 18, 2020	Jun NEWA
AP	JIANGSU HANSOH PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 211021 001 Mar 09, 2020	Feb NEWA

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	HIKMA	1GM	A 209457 001 May 21, 2020	May NFTG
	VASCEPA			
AB	+! AMARIN PHARMS	1GM	N 202057 001 Jul 26, 2012	May CFTG

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

AB	ZYDUS PHARMS	EQ 100MG BASE	A 210658 001 Apr 08, 2020	Mar NEWA
AB		EQ 400MG BASE	A 210658 002 Apr 08, 2020	Mar NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	OXFORD PHARMS	10MG	A 040751 003 Feb 28, 2008	Apr CMFD
AB		25MG	A 040751 002 Feb 28, 2008	Apr CMFD
AB		50MG	A 040751 001 Feb 28, 2008	Apr CMFD

INDACATEROL MALEATE

POWDER;INHALATION
ARCAPTA NEOHALER

+ @ NOVARTIS	EQ 75MCG BASE	N 022383 001 Jul 01, 2011	Mar CAHN
+ @ SUNOVION PHARMS INC	EQ 75MCG BASE	N 022383 001 Jul 01, 2011	Mar DISC

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A 075201 001 Dec 04, 1998	Jan CAHN
AB		2.5MG	A 075201 002 Dec 04, 1998	Jan CAHN

INDINAVIR SULFATE

CAPSULE;ORAL

CRIXIVAN

+ @ MERCK SHARP DOHME	EQ 200MG BASE	N 020685 003 Mar 13, 1996	Mar DISC
-----------------------	---------------	---------------------------	----------

INDOMETHACIN

	CAPSULE;ORAL INDOMETHACIN						
AB	HERITAGE	25MG	N 018851	001	May 18, 1984	Jan CAHN	
AB		50MG	N 018851	002	May 18, 1984	Jan CAHN	
	@ HERITAGE PHARMA	25MG	A 070719	001	Feb 12, 1986	Apr DISC	
	@	50MG	A 070756	001	Feb 12, 1986	Mar DISC	
	CAPSULE, EXTENDED RELEASE;ORAL INDOMETHACIN						
	@ MYLAN	75MG	A 202139	001	Mar 20, 2014	May DISC	

INGENOL MEBUTATE

	GEL;TOPICAL						
>D>	INGENOL MEBUTATE						
>D> AB	PERRIGO UK FINCO	0.015%	A 209018	001	Jan 07, 2019	Jun DISC	
>A>	@	0.015%	A 209018	001	Jan 07, 2019	Jun DISC	
>D> AB		0.05%	A 209019	001	Jan 09, 2019	Jun DISC	
>A>	@	0.05%	A 209019	001	Jan 09, 2019	Jun DISC	
	PICATO						
>D> AB	+! LEO LABS	0.015%	N 202833	001	Jan 23, 2012	Jun CTEC	
>A>	+!	0.015%	N 202833	001	Jan 23, 2012	Jun CTEC	
>D> AB	+!	0.05%	N 202833	002	Jan 23, 2012	Jun CTEC	
>A>	+!	0.05%	N 202833	002	Jan 23, 2012	Jun CTEC	

IPRATROPIUM BROMIDE

	SOLUTION;INHALATION						
	IPRATROPIUM BROMIDE						
	@ WATSON LABS	0.02%	A 076291	001	May 09, 2005	Apr DISC	
	SPRAY, METERED;NASAL						
	IPRATROPIUM BROMIDE						
AB	APOTEX INC	0.021MG/SPRAY	A 076156	001	Apr 18, 2003	Jan CMFD	

IRBESARTAN

	TABLET;ORAL						
	IRBESARTAN						
	@ HIKMA	75MG	A 090201	001	Oct 15, 2012	Feb DISC	
	@	150MG	A 090201	002	Oct 15, 2012	Feb DISC	
	@	300MG	A 090201	003	Oct 15, 2012	Feb DISC	

IRINOTECAN HYDROCHLORIDE

	INJECTABLE;INJECTION						
	IRINOTECAN HYDROCHLORIDE						
	@ CIPLA LTD	40MG/2ML (20MG/ML)	A 077219	001	Feb 20, 2008	Apr DISC	
	@	100MG/5ML (20MG/ML)	A 077219	002	Feb 20, 2008	Apr DISC	
	@ PLIVA LACHEMA	40MG/2ML (20MG/ML)	A 078122	001	Oct 31, 2008	Apr DISC	
	@	100MG/5ML (20MG/ML)	A 078122	002	Oct 31, 2008	Apr DISC	

ISOSORBIDE MONONITRATE

	TABLET, EXTENDED RELEASE;ORAL						
	ISOSORBIDE MONONITRATE						
	@ HIKMA INTL PHARMS	30MG	A 076813	002	Mar 30, 2006	Feb DISC	
	@	60MG	A 076813	001	Jan 07, 2005	Feb DISC	

ISOTRETINOIN

	CAPSULE;ORAL						
	ABSORICA LD						
>D>	+ SUN PHARM	20MG	N 211913	003	Nov 05, 2019	Jun DISC	
>A>	+ @	20MG	N 211913	003	Nov 05, 2019	Jun DISC	
>D>	+	28MG	N 211913	005	Nov 05, 2019	Jun DISC	
>A>	+ @	28MG	N 211913	005	Nov 05, 2019	Jun DISC	

ITRACONAZOLE

	SOLUTION;ORAL						
	ITRACONAZOLE						
	@ APOTEX	10MG/ML	A 208481	001	Aug 02, 2019	Feb DISC	

IVACAFTOR

TABLET;ORAL

KALYDECO

>D>	+ VERTEX PHARMS	75MG	N 203188	002	May 20, 2019	Jun DISC
>A>	+ @	75MG	N 203188	002	May 20, 2019	Jun DISC

IVERMECTIN

CREAM;TOPICAL

IVERMECTIN

AB	PERRIGO UK FINCO	1%	A 210225	001	Apr 13, 2020	Mar NEWA
AB	LOTION;TOPICAL					
	IVERMECTIN					
AB	TARO	0.5%	A 210720	001	May 06, 2020	Apr NFTG
	SKLICE					
AB	+! ARBOR PHARMS LLC	0.5%	N 202736	001	Feb 07, 2012	Apr CFTG

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

AB	HAVIX	200MG	A 075912	001	Jan 10, 2002	Apr CMFD
----	-------	-------	----------	-----	--------------	----------

KETOROLAC TROMETHAMINE

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB	MYLAN	10MG	A 074761	001	May 16, 1997	Feb CHRS
	@ PLIVA	10MG	A 075284	001	Jun 23, 1999	Apr DISC
AB	! TEVA	10MG	A 074754	001	May 16, 1997	Feb CHRS

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

NORMODYNE

+ @ SCHERING

5MG/ML

N 018686 001 Aug 01, 1984 Jan CRLD

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	HERITAGE PHARMA	100MG	A 074787	001	Aug 03, 1998	Feb CMFD
AB		200MG	A 074787	002	Aug 03, 1998	Feb CMFD

LACTITOL

FOR SOLUTION;ORAL

PIZENSY

+! BRAINTREE LABS

10GM

N 211281 001 Feb 12, 2020 Feb NEWA

+

10GM/PACKET

N 211281 001 Feb 12, 2020 Feb NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TEMIXYS

+! CELLTRION

300MG;300MG

N 211284 001 Nov 16, 2018 May CHRS

+

300MG;300MG

N 211284 001 Nov 16, 2018 May CRLD

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

@ MYLAN LABS LTD

150MG;300MG

A 079079 001 Aug 12, 2019 Apr CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@ MYLAN

25MG

A 077420 001 Jan 27, 2009 Mar DISC

@

100MG

A 077420 002 Jan 27, 2009 Mar DISC

@

150MG

A 077420 003 Jan 27, 2009 Mar DISC

@

200MG

A 077420 004 Jan 27, 2009 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	DR REDDYS LABS LTD	250MG	A 202383	006	Sep 06, 2018	Mar NEWA
AB	ZYDUS PHARMS	25MG	A 207763	001	Apr 01, 2020	Mar NEWA
AB		50MG	A 207763	002	Apr 01, 2020	Mar NEWA
AB		100MG	A 207763	003	Apr 01, 2020	Mar NEWA
AB		200MG	A 207763	004	Apr 01, 2020	Mar NEWA
AB		250MG	A 207763	005	Apr 01, 2020	Mar NEWA
AB		300MG	A 207763	006	Apr 01, 2020	Mar NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	HETERO LABS LTD III	15MG	A203083	001	May 18, 2020	May NEWA
AB		30MG	A203083	002	May 18, 2020	May NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL
REYVOW
+ ELI LILLY AND CO 50MG
+! 100MG

N211280	001	Jan 31, 2020	Jan NEWA
N211280	002	Jan 31, 2020	Jan NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST
@ AUROBINDO PHARMA LTD 0.005%
XALATAN

>D> AT	+!	PHARMACIA AND UPJOHN	0.005%	A206519	001	Sep 03, 2019	Mar DISC
>A> AT	+!	UPJOHN	0.005%	N020597	001	Jun 05, 1996	Jun CAHN

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE
@ BARR 10MG
@ 20MG
AB LUPIN LTD 10MG
AB 20MG
@ TEVA PHARMS 10MG
@ 20MG

A077083	001	Sep 13, 2005	Apr DISC
A077083	002	Sep 13, 2005	Apr DISC
A211863	001	Feb 04, 2020	Jan NEWA
A211863	002	Feb 04, 2020	Jan NEWA
A077084	001	Sep 13, 2005	Apr DISC
A077084	002	Sep 13, 2005	Apr DISC

LEMBOREXANT

TABLET;ORAL
DAYVIGO
+ EISAI INC 5MG
+! 10MG

N212028	001	Apr 07, 2020	Apr NEWA
N212028	002	Apr 07, 2020	Apr NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE
@ JIANGSU HENGRI MED 2.5MG

A202716	001	May 16, 2013	May DISC
---------	-----	--------------	----------

LEUCOVORIN CALCIUM

TABLET;ORAL
LEUCOVORIN CALCIUM
AB EPIC PHARMA LLC EQ 5MG BASE
AB EQ 25MG BASE

A074544	001	Aug 28, 1997	Mar CMFD
A074544	002	Aug 28, 1997	Mar CMFD

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LUPRON DEPOT-PED KIT
+ @ ABBVIE ENDOCRINE INC 3.75MG/VIAL, 7.5MG/VIAL
+ @ 7.5MG/VIAL, 7.5MG/VIAL
+! 7.5MG/VIAL
+! 11.25MG/VIAL
+! 11.25MG/VIAL
+! 15MG/VIAL
+! 30MG/VIAL

N020263	003	Apr 16, 1993	May CTNA
N020263	004	Apr 16, 1993	May CTNA
N020263	002	Apr 16, 1993	May CTNA
N020263	005	Jan 21, 1994	May CTNA
N020263	007	Aug 15, 2011	May CTNA
N020263	006	Jan 21, 1994	May CTNA
N020263	008	Aug 15, 2011	May CTNA

INJECTABLE;SUBCUTANEOUS

ELIGARD KIT
+! TOLMAR THERAP 7.5MG/VIAL
+! 22.5MG/VIAL
+! 30MG/VIAL
+! 45MG/VIAL

N021343	001	Jan 23, 2002	May CTNA
N021379	001	Jul 24, 2002	May CTNA
N021488	001	Feb 13, 2003	May CTNA
N021731	001	Dec 14, 2004	May CTNA

POWDER;INTRAMUSCULAR
LUPRON DEPOT-PED KIT

+ @ ABBVIE ENDOCRINE INC 3.75MG, 7.5MG
+ @ 3.75MG/VIAL, 7.5MG/VIAL
+! 7.5MG
+! 7.5MG/VIAL
+ @ 7.5MG, 7.5MG
+ @ 7.5MG/VIAL, 7.5MG/VIAL

N020263	003	Apr 16, 1993	May CPOT
N020263	003	Apr 16, 1993	May CDFR
N020263	002	Apr 16, 1993	May CPOT
N020263	002	Apr 16, 1993	May CDFR
N020263	004	Apr 16, 1993	May CPOT
N020263	004	Apr 16, 1993	May CDFR

POWDER; INTRAMUSCULAR
LUPRON DEPOT-PED KIT

+!	11.25MG	N 020263	005	Jan 21, 1994	May CPOT
+!	11.25MG/VIAL	N 020263	005	Jan 21, 1994	May CDFR
+!	11.25MG	N 020263	007	Aug 15, 2011	May CPOT
+!	11.25MG/VIAL	N 020263	007	Aug 15, 2011	May CDFR
+!	15MG	N 020263	006	Jan 21, 1994	May CPOT
+!	15MG/VIAL	N 020263	006	Jan 21, 1994	May CDFR
+!	30MG	N 020263	008	Aug 15, 2011	May CPOT
+!	30MG/VIAL	N 020263	008	Aug 15, 2011	May CDFR

POWDER; SUBCUTANEOUS
ELIGARD KIT

+! TOLMAR THERAP	7.5MG	N 021343	001	Jan 23, 2002	May CPOT
+!	7.5MG/VIAL	N 021343	001	Jan 23, 2002	May CDFR
+!	22.5MG	N 021379	001	Jul 24, 2002	May CPOT
+!	22.5MG/VIAL	N 021379	001	Jul 24, 2002	May CDFR
+!	30MG	N 021488	001	Feb 13, 2003	May CPOT
+!	30MG/VIAL	N 021488	001	Feb 13, 2003	May CDFR
+!	45MG	N 021731	001	Dec 14, 2004	May CPOT
+!	45MG/VIAL	N 021731	001	Dec 14, 2004	May CDFR
FENSOLVI KIT					
+! TOLMAR	45MG	N 213150	001	May 01, 2020	May NEWA

LEVAMLODIPINE MALEATE

TABLET; ORAL					
CONJUPRI					
+ @ CSPC OUYI	EQ 1.25MG BASE	N 212895	001	Dec 19, 2019	May DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS
LEVETIRACETAM

AP XGEN PHARMS	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Feb CAHN
----------------	----------------------	----------	-----	--------------	----------

SOLUTION; ORAL
LEVETIRACETAM

>D> @ ACI HEALTHCARE LTD	100MG/ML	A 078582	001	Jan 15, 2009	Jun CMFD
>A> AA	100MG/ML	A 078582	001	Jan 15, 2009	Jun CMFD

TABLET; ORAL
LEVETIRACETAM

@ TEVA PHARMS	250MG	A 078101	001	Jan 15, 2009	Apr DISC
@	500MG	A 078101	002	Jan 15, 2009	Apr DISC
@	750MG	A 078101	003	Jan 15, 2009	Apr DISC
@	1GM	A 078101	004	Jan 15, 2009	Apr DISC

>D> AB VINTAGE PHARMS 250MG

>D> AB 500MG

>D> AB 750MG

>D> AB 1GM

AB VIWIT PHARM	250MG	A 078869	001	Mar 13, 2009	Mar CAHN
----------------	-------	----------	-----	--------------	----------

AB	250MG	A 078869	001	Mar 13, 2009	Mar CAHN
----	-------	----------	-----	--------------	----------

AB	500MG	A 078869	002	Mar 13, 2009	Mar CAHN
----	-------	----------	-----	--------------	----------

AB	500MG	A 078869	002	Mar 13, 2009	Mar CAHN
----	-------	----------	-----	--------------	----------

AB	750MG	A 078869	003	Mar 13, 2009	Mar CAHN
----	-------	----------	-----	--------------	----------

AB	750MG	A 078869	003	Mar 13, 2009	Mar CAHN
----	-------	----------	-----	--------------	----------

AB	1GM	A 078869	004	Mar 13, 2009	Mar CAHN
----	-----	----------	-----	--------------	----------

AB	1GM	A 078869	004	Mar 13, 2009	Mar CAHN
----	-----	----------	-----	--------------	----------

>A> AB ZHEJIANG JINGXIN 250MG

>A> AB 500MG

>A> AB 750MG

>A> AB 1GM

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM					
@ ACTAVIS ELIZABETH	500MG	A 091557	001	Sep 12, 2011	Apr DISC
@	750MG	A 091557	002	Sep 12, 2011	Apr DISC

>A> AB OVERSEAS 750MG

>A> AB @ TEVA PHARMS 500MG

@	750MG	A 212688	001	Jun 11, 2020	Jun NEWA
---	-------	----------	-----	--------------	----------

A 091430	001	Sep 12, 2011	Apr DISC
----------	-----	--------------	----------

A 091430	002	Sep 12, 2011	Apr DISC
----------	-----	--------------	----------

LEVOSETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL					
LEVOSETIRIZINE DIHYDROCHLORIDE					
@ APOTEX	2.5MG/5ML	A 202915	001	Aug 21, 2014	Feb DISC

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE
© APOTEX 5MG

A203027 001 Feb 13, 2015 Feb DISC

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVOFLOXACIN

AP	GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A205540 001 Apr 22, 2020	Apr NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205540 002 Apr 22, 2020	Apr NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

AP	! INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623 001 May 03, 2018	Apr CHRS
AP	! Sandoz Inc	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623 002 May 03, 2018	Apr CHRS
		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563 002 Mar 09, 2015	Apr DISC

LEVORPHANOL TARTRATE

TABLET;ORAL
LEVORPHANOL TARTRATE

>A> AB	NOVITIUM PHARMA	2MG	A213479 001 Jul 01, 2020	Jun NEWA
--------	-----------------	-----	--------------------------	----------

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP	DR REDDYS	100MCG/VIAL	A208837 001 Mar 27, 2020	Mar NEWA
----	-----------	-------------	--------------------------	----------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
THYRO-TABS

AB2, + AB4	ALVOGEN	0.3MG	N021116 009 Oct 24, 2002	Jan CHRS
------------	---------	-------	--------------------------	----------

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT	MACLEODS PHARMS LTD	5%	A211697 001 Mar 16, 2020	Mar NEWA
	© SUNGEN PHARMA	5%	A212486 001 Oct 17, 2019	Mar DISC
AT	© TEVA PHARMS USA	5%	A212486 001 Oct 17, 2019	Mar CPOT
		5%	A210256 001 Jan 16, 2018	Apr DISC
	PATCH;TOPICAL			
	LIDOCAINE			
AB	RHODES PHARMS	5%	A209190 001 Apr 30, 2020	Apr NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP	HUONS	1%	A212821 001 May 07, 2020	Apr NEWA
AP	WEST-WARD PHARMS INT	1%	A080407 001	Mar CMFD
AP		2%	A080407 002	Mar CMFD
	LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE		
AP	WEST-WARD PHARMS INT	1%	A084625 001	Mar CMFD
AP		2%	A084625 002	Mar CMFD
	SOLUTION;TOPICAL			
	LIDOCAINE HYDROCHLORIDE			

>D>	© WOCKHARDT BIO AG	4%	A087881 001 Nov 18, 1982	Jun CMFD
>A> AT		4%	A087881 001 Nov 18, 1982	Jun CMFD

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION
LINCOMYCIN

AP	XGEN PHARMS	EQ 300MG BASE/ML	A201746 001 Jun 04, 2015	Feb CAHN
----	-------------	------------------	--------------------------	----------

LINEZOLID

TABLET;ORAL

LINEZOLID

@ GATE PHARMS

600MG

A091210 001 Feb 05, 2016

Apr DISC

@ TEVA PHARMS USA

600MG

A078061 001 May 18, 2015

May DISC

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

LIOTHYRONINE SODIUM

AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb CAHN
AB	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan CMFD
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan CMFD
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan CMFD

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+! AZURITY

1MG/ML

N208401 001 Jul 29, 2016

May CAHN

TABLET;ORAL

LISINOPRIL

AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb CAHN
AB		5MG	A076102	002	Sep 30, 2002	Feb CAHN
AB		10MG	A076102	003	Sep 30, 2002	Feb CAHN
AB		20MG	A076102	004	Sep 30, 2002	Feb CAHN
AB		30MG	A076102	005	Sep 30, 2002	Feb CAHN
AB		40MG	A076102	006	Sep 30, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	+ HIKMA	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+	300MG	N017812	001		Jan CAHN
AB	+!	600MG	N017812	003	Jan 28, 1987	Jan CAHN
	@ MYLAN	150MG	A076243	002	Feb 24, 2003	Jan DISC
	@	300MG	A076243	001	Jun 27, 2002	Jan DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+! HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
----	----------	------------------------	---------	-----	--	----------

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

>D>	+! US WORLDMEDS LLC	EQ 0.18MG BASE	N209229	001	May 16, 2018	Jun CAHN
>A>	+! USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Jun CAHN

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+ AMRYT

EQ 5MG BASE

N203858 001 Dec 21, 2012

May CAHN

+

EQ 10MG BASE

N203858 002 Dec 21, 2012

May CAHN

+

EQ 20MG BASE

N203858 003 Dec 21, 2012

May CAHN

+

EQ 30MG BASE

N203858 004 Apr 23, 2015

May CAHN

+

EQ 40MG BASE

N203858 005 Apr 23, 2015

May CAHN

+!

EQ 60MG BASE

N203858 006 Apr 23, 2015

May CAHN

LORAZEPAM

TABLET;ORAL

LORAZEPAM

@ MYLAN

0.5MG

A077657 001 Mar 16, 2006

Mar DISC

@

1MG

A077657 002 Mar 16, 2006

Mar DISC

@

2MG

A077657 003 Mar 16, 2006

Mar DISC

LORCASERIN HYDROCHLORIDE

TABLET;ORAL
BELVIQ
+ @ EISAI INC 10MG N022529 001 Jun 27, 2012 Feb DISC
TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR
+ @ EISAI INC 20MG N208524 001 Jul 15, 2016 Feb DISC

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM
@ HIKMA 25MG A077459 001 Oct 06, 2010 Feb DISC
@ 50MG A077459 002 Oct 06, 2010 Feb DISC
@ 100MG A077459 003 Oct 06, 2010 Feb DISC

LOVASTATIN

TABLET;ORAL
LOVASTATIN
AB COREPHARMA 10MG A077748 001 Feb 28, 2007 Feb CAHN
AB 20MG A077748 002 Feb 28, 2007 Feb CAHN
AB 40MG A077748 003 Feb 28, 2007 Feb CAHN

>A> LURBINECTEDIN

>A> POWDER; INTRAVENOUS
>A> ZEPZELCA
>A> +! JAZZ 4MG/VIAL N213702 001 Jun 15, 2020 Jun NEWA

MAFENIDE ACETATE

CREAM;TOPICAL
SULFAMYLYON
+! RISING EQ 85MG BASE/GM N016763 001 May CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER
AP BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML) A211966 001 Jun 01, 2020 May NEWA
AP 4GM/50ML (80MG/ML) A211966 002 Jun 01, 2020 May NEWA
AP 4GM/100ML (40MG/ML) A211966 003 Jun 01, 2020 May NEWA

MAZINDOL

TABLET;ORAL
SANOREX
+ @ NOVARTIS 1MG N017247 001 Jan CAHN
+ @ 2MG N017247 002 Jan CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
MECLIZINE HYDROCHLORIDE
>D> INDICUS PHARMA 50MG A205136 003 Feb 22, 2019 Jun CTEC
>A> AA @ MYLAN PHARMS INC 50MG A205136 003 Feb 22, 2019 Jun CTEC
12.5MG A202640 001 Sep 17, 2012 Jan DISC
@ 25MG A202640 002 Sep 17, 2012 Jan DISC
>A> AA ZYDUS 12.5MG A213957 001 Jun 23, 2020 Jun NEWA
>A> AA 25MG A213957 002 Jun 23, 2020 Jun NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL
MEFLOQUINE HYDROCHLORIDE
! BARR 250MG A076392 001 Dec 29, 2003 Feb CTEC
@ HIKMA 250MG A076523 001 Oct 01, 2004 Feb DISC

MEGESTROL ACETATE

SUSPENSION;ORAL
MEGESTROL ACETATE
@ HIKMA 40MG/ML A075997 001 Feb 15, 2002 Feb DISC
AB ! PAR PHARM 40MG/ML A075671 001 Jul 25, 2001 Feb CHRS
@ TEVA PHARMS 40MG/ML A075681 001 May 05, 2003 Apr DISC

MELOXICAM

	CAPSULE;ORAL						
	MELOXICAM						
AB	LUPIN LTD	5MG		A209487	001	Jun 01, 2020	May NFTG
AB		10MG		A209487	002	Jun 01, 2020	May NFTG
	VIVLODEX						
AB	+ ZYLA	5MG		N207233	001	Oct 22, 2015	May CFTG
AB	+!	10MG		N207233	002	Oct 22, 2015	May CFTG
	SOLUTION;INTRAVENOUS						
	ANJESO						
+!	BAUDAX	30MG/ML (30MG/ML)		N210583	001	Feb 20, 2020	Feb NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL						
	QMIIZ ODT						
+ @	TERSCERA THERAPS LLC	7.5MG		N211210	001	Oct 19, 2018	Apr DISC
+ @		15MG		N211210	002	Oct 19, 2018	Apr DISC

MELPHALAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	MELPHALAN HYDROCHLORIDE						
AP	@ ALVOGEN INC	EQ 50MG BASE/VIAL		A204817	001	May 17, 2019	May DISC
AP	BPI LABS LLC	EQ 50MG BASE/VIAL		A209197	001	May 08, 2020	Apr NEWA
AP	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL		A210947	001	Feb 18, 2020	Feb NEWA
	@ PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL		A204773	001	Aug 22, 2016	Feb DISC
	@ TWI PHARMS	EQ 50MG BASE/VIAL		A211463	001	Sep 13, 2019	Jan DISC
>D>	@ US WORLDMEDS LLC	EQ 50MG BASE/VIAL		A207032	001	May 03, 2019	Jun CAHN
>A>	@ USWM	EQ 50MG BASE/VIAL		A207032	001	May 03, 2019	Jun CAHN
	POWDER;INTRAVENOUS						
	EVOMELA						
AP	+! ACROTECH	EQ 50MG BASE/VIAL		N207155	001	Mar 10, 2016	Mar CTEC
AP	+!	EQ 50MG BASE/VIAL		N207155	001	Mar 10, 2016	Feb CFTG
	MELPHALAN HYDROCHLORIDE						
AP	@ ACTAVIS LLC	EQ 50MG BASE/VIAL		A209323	001	Mar 06, 2020	Mar DISC
AP		EQ 50MG BASE/VIAL		A209323	001	Mar 06, 2020	Feb NFTG

MEMANTINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	MEMANTINE HYDROCHLORIDE						
AB	ANI PHARMS INC	7MG		A205365	001	Feb 28, 2020	Feb NEWA
AB		14MG		A205365	002	Feb 28, 2020	Feb NEWA
AB		21MG		A205365	003	Feb 28, 2020	Feb NEWA
AB		28MG		A205365	004	Feb 28, 2020	Feb NEWA
	TABLET;ORAL						
	MEMANTINE HYDROCHLORIDE						
AB	@ CHARTWELL	5MG		A090244	001	Jul 11, 2018	Mar CAHN
	@	10MG		A090244	002	Jul 11, 2018	Mar CAHN
AB	HIKMA	5MG		A208173	001	Feb 28, 2020	Feb NEWA
AB		10MG		A208173	002	Feb 28, 2020	Feb NEWA
AB	NINGBO	5MG		A212947	001	Apr 03, 2020	Apr CAHN
AB		5MG		A212947	001	Apr 03, 2020	Mar NEWA
AB		10MG		A212947	002	Apr 03, 2020	Apr CAHN
AB		10MG		A212947	002	Apr 03, 2020	Mar NEWA
	@ TEVA PHARMS	5MG		A090052	001	Oct 25, 2011	Apr DISC
	@	10MG		A090052	002	Oct 25, 2011	Apr DISC

MEPERIDINE HYDROCHLORIDE

	TABLET;ORAL						
	MEPERIDINE HYDROCHLORIDE						
AA	! EPIC PHARMA	50MG		A040331	001	May 28, 1999	Feb CHRS
AA	!	100MG		A040331	002	May 28, 1999	Feb CHRS
	@ HIKMA	50MG		A040110	001	Mar 12, 1997	Feb DISC
	@	100MG		A040110	002	Mar 12, 1997	Feb DISC

MESALAMINE

	SUPPOSITORY;RECTAL						
	MESALAMINE						
AB	ANNORA PHARMA	1GM		A213377	001	Mar 19, 2020	Mar NEWA
AB	ZYDUS PHARMS	1GM		A208953	001	Feb 12, 2020	Jan NEWA

METAXALONE

TABLET;ORAL

METAXALONE

AB	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar CTEC
AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB	SEPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb NFTG
	RIOMET					
AB	+! RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
	+!	500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

@ HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar DISC
@	850MG	A075978	002	Jan 25, 2002	Mar DISC
@	1GM	A075978	003	Nov 05, 2002	Mar DISC
@ MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	May DISC
@	850MG	A205330	002	Oct 31, 2017	May DISC
@	1GM	A205330	003	Oct 31, 2017	May DISC
@ MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
@	850MG	A075976	002	Jan 24, 2002	Jan DISC
@	1GM	A075976	003	Jan 24, 2002	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar NEWA
AB2		1GM	A213651	002	Apr 09, 2020	Mar NEWA
	@ APOTEX	750MG	A076706	002	Dec 29, 2005	May DISC
	@ BARR	750MG	A076863	001	Oct 14, 2004	Apr DISC
	@ MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	May DISC
	@	750MG	A206955	002	Dec 07, 2016	May DISC
>D>	@ YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Jun CMFD
>A> AB1		500MG	A211052	001	Sep 24, 2018	Jun CMFD
>D>	@	750MG	A211052	002	Sep 24, 2018	Jun CMFD
>A> AB		750MG	A211052	002	Sep 24, 2018	Jun CMFD

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA	SPECGX LLC	10MG/ML	A207368	001	Aug 22, 2019	May CAHN
	SOLUTION;ORAL					

METHADONE HYDROCHLORIDE

AA	SPECGX LLC	5MG/5ML	A207537	001	Oct 02, 2019	May CAHN
AA		10MG/5ML	A207537	002	Oct 01, 2019	May CAHN

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

>D> AA	+! HIKMA	5MG	N006134	002		Jun DISC
>A>	+ @	5MG	N006134	002		Jun DISC
>D> AA	+!	10MG	N006134	010		Jun DISC
>A>	+ @	10MG	N006134	010		Jun DISC

METHADONE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar CAHN
AA		5MG	A210484	001	Aug 02, 2018	Mar CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
AA	ROXANE	5MG	A088108	001	Mar 08, 1983	May CMFD

AA		10MG	A088109	001	Mar 08, 1983	May CMFD
>D> AA	SPECGX LLC	5MG	A040517	001	Apr 27, 2004	Jun CHRS
>A> AA	!	5MG	A040517	001	Apr 27, 2004	Jun CHRS
>D> AA		10MG	A040517	002	Apr 27, 2004	Jun CHRS

>A> AA	!	10MG	A040517	002	Apr 27, 2004	Jun CHRS
AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar NEWA
	METHADOSE					
@	SPECGX LLC	5MG	A040050	001	Apr 15, 1993	May DISC

@		10MG	A040050	002	Apr 15, 1993	May DISC
---	--	------	---------	-----	--------------	----------

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

@ HIKMA INTL PHARMS 500MG
@ 750MGA085159 001
A085123 001Feb DISC
Feb DISCMETHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

@ MYLAN LABS LTD EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A201529 001 Mar 29, 2012 Jan DISC
@ EQ 100MG BASE/4ML (EQ 25MG BASE/ML) A201529 002 Mar 29, 2012 Jan DISC
@ EQ 200MG BASE/8ML (EQ 25MG BASE/ML) A201529 003 Mar 29, 2012 Jan DISC
PHARMACHEMIE BV EQ 100MG BASE/4ML (EQ 25MG BASE/ML) A040843 003 Feb 27, 2012 Jan CTEC

TABLET;ORAL

METHOTREXATE SODIUM

AB ACCORD HLTHCARE EQ 2.5MG BASE A213343 001 Jan 24, 2020 Jan NEWA
+ @ DAVA PHARMS INC EQ 2.5MG BASE N008085 002 Mar DISC
AB EUGIA PHARMA EQ 2.5MG BASE A210454 001 Jan 30, 2020 Jan NEWA
AB ! HIKMA EQ 2.5MG BASE A040054 001 Aug 01, 1994 Mar CHRSMETHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

AA BAYSHORE PHARMS LLC 2.5MG A200602 001 Sep 24, 2012 Apr CTEC
AA ! 5MG A200602 002 Sep 24, 2012 Apr CTEC
AA BRECKENRIDGE PHARM 2.5MG A040642 001 Dec 06, 2011 Apr CMFD
AA 5MG A040642 002 Dec 06, 2011 Apr CMFDMETHYLDOPA

TABLET;ORAL

METHYLDOPA

@ HERITAGE PHARMA 250MG A070098 001 Feb 20, 1986 Apr DISC
@ 500MG A070343 001 Feb 20, 1986 Apr DISC
@ WATSON LABS 500MG A070625 001 Jun 06, 1986 Apr DISCMETHYLENE BLUE

SOLUTION;INTRAVENOUS

PROVAYBLUE

>A> +! PROVEPHARM SAS 10MG/2ML (5MG/ML) N204630 002 Jul 18, 2019 Jun NEWA

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB TULEX PHARMS INC 0.2MG A212233 001 May 01, 2020 Apr NEWA

METHYLPHENIDATETABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT>D> + NEOS THERAPS INC 8.6MG N205489 001 Jun 19, 2017 Jun CFTG
>A> AB + 8.6MG N205489 001 Jun 19, 2017 Jun CFTG
>D> + 17.3MG N205489 002 Jun 19, 2017 Jun CFTG
>A> AB + 17.3MG N205489 002 Jun 19, 2017 Jun CFTG
>D> + 25.9MG N205489 003 Jun 19, 2017 Jun CHRS
>A> AB +! 25.9MG N205489 003 Jun 19, 2017 Jun CFTG
>A> +! 25.9MG N205489 003 Jun 19, 2017 Jun CHRS
>A> METHYLPHENIDATE N205489 003 Jun 19, 2017 Jun CHRS
>A> AB ACTAVIS ELIZABETH 8.6MG A210924 001 Jun 19, 2020 Jun NFTG
>A> AB 17.3MG A210924 002 Jun 19, 2020 Jun NFTG
>A> AB 25.9MG A210924 003 Jun 19, 2020 Jun NFTGMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE@ BARR LABS INC 10MG A079031 004 Oct 15, 2014 Apr DISC
@ 20MG A079031 001 Jul 13, 2012 Apr DISC
@ 30MG A079031 002 Jul 13, 2012 Apr DISC
@ 40MG A079031 003 Jul 13, 2012 Apr DISC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar NEWA
AA		10MG/5ML	A211647	002	Mar 30, 2020	Mar NEWA
AA	PATRIN PHARMA INC	5MG/5ML	A210764	001	Apr 10, 2020	Mar NEWA
AA		10MG/5ML	A210764	002	Apr 10, 2020	Mar NEWA
>A> AA	QUAGEN	5MG/5ML	A213567	001	Jun 04, 2020	Jun NEWA
>A> AA		10MG/5ML	A213567	002	Jun 04, 2020	Jun NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ WATSON LABS	5MG	A040220	001	Aug 29, 1997	Apr DISC
@	10MG	A040220	002	Aug 29, 1997	Apr DISC
@	20MG	A040220	003	Aug 29, 1997	Apr DISC

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Mar DISC
@	27MG	A076772	002	Mar 22, 2018	Mar DISC
@	36MG	A076772	003	Mar 22, 2018	Mar DISC
@	54MG	A076655	001	Mar 21, 2018	Mar DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@ DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar DISC
-----------------------	-----	---------	-----	--------------	----------

METOCLOPRAMIDE HYDROCHLORIDE

>A>	SPRAY, METERED;NASAL					
>A>	GIMOTI					
>A>	+! EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Jun NEWA

METOLAZONE

TABLET;ORAL

METOLAZONE

@ ANI PHARMS INC	2.5MG	A075543	001	Jan 06, 2004	May CMS1
@	5MG	A075543	002	Mar 01, 2004	May CMS1

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@ ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar DISC
@	EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar DISC
@	EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar DISC
@	EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar DISC
@ ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC
@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan DISC
@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan DISC
AB PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar NEWA
AB	EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar NEWA
AB	EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar NEWA
AB	EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@ HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb DISC
@	100MG	A074141	002	Jan 31, 1995	Feb DISC
AB YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan NEWA
AB	50MG	A208955	002	Feb 05, 2020	Jan NEWA
AB	100MG	A208955	003	Feb 05, 2020	Jan NEWA

METRONIDAZOLE

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>D> AP MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Jun DISC
>A> @	500MG/100ML	A205531	001	May 09, 2017	Jun DISC

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

>D> @ ANI PHARMS INC	150MG	A074450	001	May 16, 1996	Jun CMFD
>A> AB @	150MG	A074450	001	May 16, 1996	Jun CMFD
>D> @	200MG	A074450	002	May 16, 1996	Jun CMFD

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

>A> AB	200MG	A074450	002	May 16, 1996	Jun CMFD
>D> @	250MG	A074450	003	May 16, 1996	Jun CMFD
>A> AB	250MG	A074450	003	May 16, 1996	Jun CMFD
>D> TEVA	150MG	A074377	001	May 16, 1995	Jun CTEC
>A> AB	150MG	A074377	001	May 16, 1995	Jun CTEC
>D>	200MG	A074377	002	May 16, 1995	Jun CTEC
>A> AB	200MG	A074377	002	May 16, 1995	Jun CTEC
>D> !	250MG	A074377	003	May 16, 1995	Jun CTEC
>A> AB !	250MG	A074377	003	May 16, 1995	Jun CTEC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan DISC
@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan DISC

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

AP MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr CAHN
AP NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL					
ZILXI					
+! FOAMIX	EQ 1.5% BASE	N213690	001	May 28, 2020	May NEWA
CAPSULE, EXTENDED RELEASE;ORAL					
XIMINO					
JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Feb CAHN
@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Feb CAHN
	EQ 90MG BASE	N201922	003	Jul 11, 2012	Feb CAHN
@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Feb CAHN
	EQ 135MG BASE	N201922	005	Jul 11, 2012	Feb CAHN
TABLET;ORAL					
MINOCYCLINE HYDROCHLORIDE					
AB AUROBINDO PHARMA LTD	EQ 50MG BASE	A213662	001	May 01, 2020	Apr NEWA
AB	EQ 75MG BASE	A213662	002	May 01, 2020	Apr NEWA
AB	EQ 100MG BASE	A213662	003	May 01, 2020	Apr NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL					
MIRABEGRON					
@ SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan DISC
MYRBETRIQ					
+! APGDI	25MG	N202611	001	Jun 28, 2012	Jan CTEC

MITOMYCIN

POWDER;PYELOCALYCEAL					
JELMYTO					
+! UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020	Apr NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL					
MOMETASONE FUROATE					
AB AMNEAL PHARMS	0.05MG/SPRAY	A207989	001	Apr 03, 2017	Mar CPOT
AB APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	Mar CPOT
NASONEX					
AB +! MERCK SHARP DOHME	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Mar CPOT

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL					
BAFIERTAM					
+! BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020	Apr NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB	AUROBINDO PHARMA LTD	EQ 4MG BASE/PACKET	A213471	001	Feb 18, 2020	Feb NEWA
	TABLET;ORAL					
	MONTELUKAST SODIUM					
AB	GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	May CAHN
	@ HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012	Feb DISC
	TABLET, CHEWABLE;ORAL					
	MONTELUKAST SODIUM					
AB	GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr CAHN
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr CAHN
	@ JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan DISC
	@	EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

+ ALLERGAN	70MG	N020616	010	Jul 09, 2012	Apr CTEC
MORPHINE SULFATE					
@ TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Apr DISC
@	30MG	A202718	002	Dec 29, 2014	Apr DISC
@	40MG	A202718	007	Jun 03, 2015	Apr DISC
@	50MG	A202718	003	Dec 29, 2014	Apr DISC
@	60MG	A202718	004	Dec 29, 2014	Apr DISC
@	70MG	A202718	008	Jun 03, 2015	Apr DISC
@	80MG	A202718	005	Dec 29, 2014	Apr DISC
@	100MG	A202718	006	Dec 29, 2014	Apr DISC

INJECTABLE;INJECTION

DURAMORPH PF

AP	+! HIKMA	0.5MG/ML	N018565	001	Sep 18, 1984	Feb CAHN
AP	+!	1MG/ML	N018565	002	Sep 18, 1984	Feb CAHN
	INFUMORPH					
AP	+! HIKMA	10MG/ML	N018565	003	Jul 19, 1991	Feb CAHN
AP	+!	25MG/ML	N018565	004	Jul 19, 1991	Feb CAHN
	MORPHINE SULFATE					
AP	HIKMA	4MG/ML	A205758	001	May 21, 2015	Feb CAHN
AP		8MG/ML	A205758	002	May 21, 2015	Feb CAHN
AP		10MG/ML	A205758	003	May 21, 2015	Feb CAHN
	@ HOSPIRA	1MG/ML	A071850	001	May 11, 1988	May DISC
+ @	ICU MEDICAL INC	1MG/ML	N019916	001	Oct 30, 1992	May DISC
>D>	+! MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990	Jun CDFR

>A> SOLUTION;INTRAMUSCULAR

>A> MORPHINE SULFATE

>A>	+! MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990	Jun CDFR
	MORPHINE SULFATE (AUTOINJECTOR)					
>A>	+! MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Jun CPOT

>A> +! MERIDIAN MEDCL TECHN 15MG/ML

	TABLET, EXTENDED RELEASE;ORAL					
	MORPHINE SULFATE					
	@ NESHER PHARMS	15MG	A076733	001	May 19, 2004	Mar DISC
	@	100MG	A077855	001	Sep 27, 2007	Mar DISC
	@	200MG	A077855	002	Sep 27, 2007	Mar DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1	GLAND PHARMA LTD	EQ 0.5% BASE	A208778	001	Mar 30, 2020	Mar NEWA
AT1	MYLAN	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Mar NEWA
	TABLET;ORAL					
	AVELOX					
+ @	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Apr DISC
	MOXIFLOXACIN HYDROCHLORIDE					
AB	! DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr CTEC
AB		TARO	EQ 2% BASE	A207116	001	Apr 27, 2020	Apr NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	VINTAGE PHARMS LLC	250MG	A090111	001	Dec 22, 2009	Jun DISC
>A>		@	250MG	A090111	001	Dec 22, 2009	Jun DISC

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

@	TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014	Mar DISC
@		360MG	A202720	002	Oct 30, 2014	Mar DISC

NABILONE

CAPSULE;ORAL

CESAMET

+! BAUSCH

1MG

N018677 001 Dec 26, 1985 Mar CAHN

NADOLOL

TABLET;ORAL

CORGARD

>D>	AB	+	US WORLDMEDS LLC	20MG	N018063	005	Oct 28, 1986	Jun CAHN
>D>	AB	+		40MG	N018063	001		Jun CAHN
>D>	AB	+!		80MG	N018063	002		Jun CAHN
>D>		@		120MG	N018063	003		Jun CAHN
>D>		@		160MG	N018063	004		Jun CAHN
>A>	AB	+	USWM	20MG	N018063	005	Oct 28, 1986	Jun CAHN
>A>	AB	+		40MG	N018063	001		Jun CAHN
>A>	AB	+!		80MG	N018063	002		Jun CAHN
>A>		@		120MG	N018063	003		Jun CAHN
>A>		@		160MG	N018063	004		Jun CAHN
			NADOLOL					
		@	VGYAAN	20MG	A212856	001	Sep 13, 2019	Mar DISC
		@		40MG	A212856	002	Sep 13, 2019	Mar DISC
		@		80MG	A212856	003	Sep 13, 2019	Mar DISC

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	May NEWA
----	--	-----------	-------------------	---------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Feb DISC
@		10MG/ML	A207595	001	Jan 11, 2019	Feb DISC
@		20MG/ML	A206506	002	Feb 06, 2019	Feb DISC
@		20MG/ML	A207595	002	Jan 11, 2019	Feb DISC

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP		DR REDDYS	1MG/ML	A213209	001	Mar 16, 2020	Mar NEWA
AP	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Mar CTEC
AP		PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jan NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

@	MYLAN	250MG	A074121	001	Dec 21, 1993	Jan DISC	
@		375MG	A074121	002	Dec 21, 1993	Jan DISC	
@		500MG	A074121	003	Dec 21, 1993	Jan DISC	
AB		SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb NEWA
AB			375MG	A212517	002	Feb 21, 2020	Feb NEWA
AB			500MG	A212517	003	Feb 21, 2020	Feb NEWA

TABLET, DELAYED RELEASE;ORAL NAPROXEN						
@ PLIVA	375MG	A075337	001	May 26, 1999	Mar	DISC
@	500MG	A075337	002	May 26, 1999	Mar	DISC
<u>NAPROXEN SODIUM</u>						
TABLET;ORAL NAPROXEN SODIUM						
@ TEVA	EQ 250MG BASE	A074198	001	Dec 21, 1993	Mar	DISC
@	EQ 500MG BASE	A074198	002	Dec 21, 1993	Mar	DISC
<u>NATEGLINIDE</u>						
TABLET;ORAL NATEGLINIDE						
@ ALVOGEN	60MG	A205055	001	Dec 11, 2015	Mar	DISC
@	120MG	A205055	002	Dec 11, 2015	Mar	DISC
<u>NEOMYCIN SULFATE</u>						
TABLET;ORAL NEOMYCIN SULFATE						
AA @ BRECKENRIDGE	500MG	A065468	001	Mar 29, 2010	Apr	DISC
AA XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb	CAHN
<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
SOLUTION;IRRIGATION NEOMYCIN AND POLYMYXIN B SULFATE						
AT WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar	CMFD
AT XGEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb	CAHN
AT	EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb	CAHN
<u>NETARSUDIL MESYLATE</u>						
SOLUTION/DROPS;OPHTHALMIC RHOPRESSA						
+! AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb	CAIN
<u>NIACIN</u>						
TABLET, EXTENDED RELEASE;ORAL NIACIN						
@ MYLAN	500MG	A203742	001	Feb 22, 2019	Jan	DISC
@	750MG	A203742	002	Feb 22, 2019	Jan	DISC
@	1GM	A203742	003	Feb 22, 2019	Jan	DISC
<u>NICARDIPINE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION NICARDIPINE HYDROCHLORIDE						
AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	May	CMFD
INJECTABLE;INTRAVENOUS NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE						
EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	May	CMFD
	40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	May	CMFD
<u>NIMODIPINE</u>						
SOLUTION;ORAL NYMALIZE						
+ @ ARBOR PHARMS LLC	3MG/ML	N203340	001	May 10, 2013	Apr	DISC
+!	3MG/ML	N203340	001	May 10, 2013	Apr	CPOT
+!	6MG/ML	N203340	002	Apr 08, 2020	Apr	NEWA
<u>NIRAPARIB TOSYLATE</u>						
CAPSULE;ORAL ZEJULA						
+! GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN
<u>NITROGLYCERIN</u>						
FILM, EXTENDED RELEASE;TRANSDERMAL NITRO-DUR						
BX +! USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
BX +!	0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
BX +!	0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
BX +!	0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

@ ACTAVIS LABS FL INC	0.3MG
@	0.4MG
@	0.6MG

A203693	001	Oct 16, 2017	Mar DISC
A203693	002	Oct 16, 2017	Mar DISC
A203693	003	Oct 16, 2017	Mar DISC

NIZATIDINECAPSULE;ORAL

NIZATIDINE

@ MYLAN PHARMS INC	150MG
@	300MG

A075806	001	Jul 05, 2002	May DISC
A075806	002	Jul 05, 2002	May DISC
A075616	002	Jul 09, 2002	May CHRS

AB ! WATSON LABS 300MG

NORETHINDRONETABLET;ORAL-28

NOR-QD

AB1 +! TEVA BRANDED PHARM	0.35MG
NORETHINDRONE	
>D> AB1 ACCORD HLTHCARE	0.35MG
>A> AB1 NAARI PTE LTD	0.35MG

N017060	001		Jan CAHN
A206807	001	Dec 13, 2016	Jun CAHN
A206807	001	Dec 13, 2016	Jun CAHN

NUSINERSEN SODIUMSOLUTION;INTRATHECAL

SPINRAZA

>D>	+! BIOGEN IDEC	12MG/5ML (2.4MG/ML)
>A>	+!	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)

N209531	001	Dec 23, 2016	Jun CPOT
N209531	001	Dec 23, 2016	Jun CPOT

NYSTATINPOWDER;TOPICAL

NYSTATIN

AT XGEN PHARMS	100,000 UNITS/GM
SUSPENSION;ORAL	
AA SOCORRO	100,000 UNITS/ML

A065175	001	Dec 17, 2004	Feb CAHN
A062832	001	Dec 27, 1991	May CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDEOINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A> AT CADILA	100,000 UNITS/GM;0.1%
@ VITRUVIAS THERAP	100,000 UNITS/GM;0.1%
@	100000 UNITS/GM;0.1%
>D> AT ZYDUS PHARMS	100,000 UNITS/GM;0.1%
AT	100,000 UNITS/GM;0.1%

A207764	001	Nov 08, 2018	Jun CAHN
A207316	001	Nov 18, 2019	May CPOT
A207316	001	Nov 18, 2019	May DISC
A207764	001	Nov 08, 2018	Jun CAHN
A207764	001	Nov 08, 2018	Mar CMFD

OCTREOTIDE ACETATE

>A> CAPSULE, DELAYED RELEASE;ORAL
>A> MYCAPSSA

>A> +! CHIASMA	EQ 20MG BASE
----------------	--------------

N208232	001	Jun 26, 2020	Jun NEWA
---------	-----	--------------	----------

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

@ HERITAGE PHARMS INC	EQ 0.05MG BASE/ML
@	EQ 0.1MG BASE/ML
@	EQ 0.5MG BASE/ML

A204669	001	Dec 27, 2018	Feb DISC
A204669	002	Dec 27, 2018	Feb DISC
A204669	003	Dec 27, 2018	Feb DISC

SANDOSTATIN

+ @ NOVARTIS	EQ 0.2MG BASE/ML
+ @	EQ 1MG BASE/ML

N019667	004	Jun 12, 1991	May DISC
N019667	005	Jun 12, 1991	May DISC

SOLUTION;SUBCUTANEOUS

BYNFEZIA PEN

+! SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)
--------------	----------------------------------------

N213224	001	Jan 28, 2020	Jan NEWA
---------	-----	--------------	----------

OLANZAPINETABLET;ORAL

OLANZAPINE

@ IVAX PHARMS INC	20MG
@ JIANGSU HANSOH PHARM	2.5MG
@	5MG
@	10MG
@ TEVA PHARMS	2.5MG
@	5MG
@	7.5MG

A077301	001	Apr 29, 2015	Mar DISC
A209399	001	Sep 24, 2018	May DISC
A209399	002	Sep 24, 2018	May DISC
A209399	003	Sep 24, 2018	May DISC
A076000	001	Oct 24, 2011	Jan DISC
A076000	002	Oct 24, 2011	Jan DISC
A076000	003	Oct 24, 2011	Jan DISC

TABLET;ORAL
OLANZAPINE

@	10MG	A076000	004	Oct 24, 2011	Jan DISC
@	15MG	A076000	005	Oct 24, 2011	Jan DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

AB	INVENTIA	5MG	A208659	001	May 18, 2020	May NEWA
AB		20MG	A208659	002	May 18, 2020	May NEWA
AB		40MG	A208659	003	May 18, 2020	May NEWA
	@ JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb DISC
	@	20MG	A205482	002	Apr 24, 2017	Feb DISC
	@	40MG	A205482	003	Apr 24, 2017	Feb DISC
AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar NEWA
AB		20MG	A090237	002	Apr 13, 2020	Mar NEWA
AB		40MG	A090237	003	Apr 13, 2020	Mar NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

	@ CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar DISC
	@	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar DISC
	@ WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar DISC
AT		EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb NFTG
	PAZEZO					
AT	+! NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar CTEC
AT	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb CFTG
	SPRAY, METERED;NASAL					
	OLOPATADINE HYDROCHLORIDE					
AB	AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020	Apr NEWA
>A> AB	PURACAP PHARM LLC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210093	001	Jun 15, 2020	Jun NEWA
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

@	MYLAN	10MG	A205070	001	Jun 29, 2018	Feb DISC
@		20MG	A075876	002	May 29, 2003	Jan DISC
@		20MG	A205070	002	Jun 29, 2018	Feb DISC
@		40MG	A205070	003	Jun 29, 2018	Feb DISC
@	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017	May DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Apr NEWA
AB		40MG;1.1GM	A212587	002	Apr 30, 2020	Apr NEWA

ONDANSETRON

FILM;ORAL
ZUPLENZ

+!	FORTOVIA	4MG	N022524	001	Jul 02, 2010	May CAHN
+!		8MG	N022524	002	Jul 02, 2010	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

@	BARR	4MG	A076693	001	Jun 25, 2007	Mar DISC
@		8MG	A076693	002	Jun 25, 2007	Mar DISC
@	TEVA	4MG	A076810	001	Jun 25, 2007	Mar DISC
@		8MG	A076810	002	Jun 25, 2007	Mar DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	@ ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan NEWA
AA	@ HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb DISC
AA	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@ NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar DISC
@	10MG	A077290	002	Dec 08, 2005	Mar DISC
@	15MG	A077290	003	Dec 08, 2005	Mar DISC
@	20MG	A077290	004	Dec 08, 2005	Mar DISC
@	30MG	A077290	005	Dec 08, 2005	Mar DISC
ROXYBOND					
@ OHMO LIFE	5MG	N209777	001	Apr 20, 2017	May CAHN
@	15MG	N209777	002	Apr 20, 2017	May CAHN
@	30MG	N209777	003	Apr 20, 2017	May CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

@ ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar DISC
@	7.5MG	A079046	001	Dec 13, 2010	Mar DISC
@	10MG	A079046	004	Jul 11, 2013	Mar DISC
@	15MG	A079046	002	Dec 13, 2010	Mar DISC
@	20MG	A079046	005	Jul 11, 2013	Mar DISC
@	30MG	A079046	006	Jul 11, 2013	Mar DISC
@	40MG	A079046	007	Jul 11, 2013	Mar DISC
@ SPECGX LLC	5MG	A202946	001	Jun 27, 2014	May DISC
@	7.5MG	A202946	002	Jun 27, 2014	May DISC
@	10MG	A202946	003	Jun 27, 2014	May DISC
@	15MG	A202946	004	Jun 27, 2014	May DISC
@	20MG	A202946	005	Jun 27, 2014	May DISC
@	30MG	A202946	006	Jun 27, 2014	May DISC
@	40MG	A202946	007	Jun 27, 2014	May DISC

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+ CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar NEWA
+	0.46MG	N209899	002	Mar 25, 2020	Mar NEWA
+!	0.92MG	N209899	003	Mar 25, 2020	Mar NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May NEWA
----	--------------------	----------------------------------------	---------	-----	--------------	----------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

@ TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar DISC
@	90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar DISC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

>A> AB	SUN PHARM	EQ 40MG BASE	A213725	001	Jun 30, 2020	Jun NFTG
>D>	+! WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jun CFTG

>A> AB	+	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jun CFTG
--------	---	--------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

@ MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	May DISC
@	EQ 40MG BASE	A200821	002	Feb 16, 2012	May DISC
@ TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007	May DISC
@	EQ 40MG BASE	A077056	002	Aug 02, 2007	May DISC

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

@ JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan DISC
@	EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan DISC
@	EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan DISC
@	EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan DISC

PASIREOTIDE DIASPARTATESOLUTION;SUBCUTANEOUS
SIGNIFOR

+ RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb CAHN
+	EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb CAHN
+!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb CAHN

PASIREOTIDE PAMOATEFOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT

+ RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb CAHN
+	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb CAHN
+	EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb CAHN
+	EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb CAHN
+!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

+ @ NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan CRLD
--------------	---------------	---------	-----	--------------	----------

PEMETREXEDSOLUTION;INTRAVENOUS
PEMFEXY

+! EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020	Feb NEWA
-----------------	----------------------	---------	-----	--------------	----------

PEMIGATINIB

TABLET;ORAL

PEMAZYRE

+ INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020	Apr NEWA
+	9MG	N213736	002	Apr 17, 2020	Apr NEWA
+!	13.5MG	N213736	003	Apr 17, 2020	Apr NEWA

PENICILLAMINE

CAPSULE;ORAL

PENICILLAMINE

AB ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan CAHN
AB APOTEX	250MG	A213310	001	Apr 28, 2020	Apr NEWA
TABLET;ORAL					
PENICILLAMINE					

AB TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Feb NEWA
--------------------	-------	---------	-----	--------------	----------

PERMETHRIN

CREAM;TOPICAL

ELIMITE

+ @ MYLAN	5%	N019855	001	Aug 25, 1989	Feb DISC
AB ! PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb CHRS

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB ZYDUS PHARMS	2MG	A205232	001	Apr 06, 2020	Mar NEWA
AB	4MG	A205232	002	Apr 06, 2020	Mar NEWA
AB	8MG	A205232	003	Apr 06, 2020	Mar NEWA
AB	16MG	A205232	004	Apr 06, 2020	Mar NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

AA	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017	Mar CAHN
AA		35MG	A203600	001	Dec 27, 2017	Mar CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

>D>	+ @ CONCORDIA	10MG	N008708	001	Jun CMFD
>A> AB	+	10MG	N008708	001	Jun CMFD

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR	15MG	A090591	001	Mar 18, 2010	Mar DISC
@	30MG	A090591	002	Mar 18, 2010	Mar DISC

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR	37.5MG	A090470	001	Aug 31, 2009	Mar DISC
--------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>A> AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Jun NEWA
>A> AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Jun NEWA
>A> AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Jun NEWA
>A> AP1	CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jun NEWA
>A> AP1		50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jun NEWA
>A> AP1		100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jun NEWA
>A> AP1	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A211920	001	Jun 05, 2020	Jun NEWA
>A> AP1		100MG/10ML (10MG/ML)	A211920	002	Jun 05, 2020	Jun NEWA
>D> AP1	RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jun CAHN
	AP1	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan NEWA
>D> AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jun CAHN
	AP1	50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan NEWA
>D> AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jun CAHN
	AP1	100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan NEWA
>A> AP1	SAGENT PHARMS INC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jun CAHN
>A> AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jun CAHN
>A> AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jun CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

>A> AA	! PHARM ASSOC	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Jun CAHN
>D> AA	! VINTAGE	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Jun CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

@ LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Apr DISC
-------------	----------------	---------	-----	--------------	----------

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Mar CMFD
	@	5MG	A212377	001	Aug 13, 2019	Feb DISC
AB		7.5MG	A212377	002	Aug 13, 2019	Mar CMFD
	@	7.5MG	A212377	002	Aug 13, 2019	Feb DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

@ MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
@	EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
@	EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr CMFD
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Apr CMFD
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr CMFD

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar CAHN
AB		20MG	A206136	002	Jun 20, 2017	Mar CAHN

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT	+! TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan CAHN
----	-----------------------	------	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

@ GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan CMS1
XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN

POSACONAZOLE

SUSPENSION; ORAL

NOXAFL

AB	+! SCHERING	40MG/ML	N022003	001	Sep 15, 2006	May CFTG
AB	HIKMA	40MG/ML	A208773	001	May 15, 2020	May NFTG

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

+ @ NESHER PHARMS	8MEQ	N018238	001		May DISC
MICRO-K 10		N018238	002	May 14, 1984	May DISC
+ @ NESHER PHARMS	10MEQ				
POTASSIUM CHLORIDE					
AB STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Mar CAHN
	10MEQ	A205549	002	Dec 08, 2015	Mar CAHN

AB	FOR SUSPENSION, EXTENDED RELEASE; ORAL					
	MICRO-K LS					
+ @ KV PHARM	20MEQ/PACKET	N019561	003	Aug 26, 1988	Feb CRLD	
AB1	TABLET, EXTENDED RELEASE; ORAL					
	POTASSIUM CHLORIDE					
AB1	AMNEAL	10MEQ	A212861	001	May 08, 2020	Apr NEWA
AB1		15MEQ	A212861	002	May 08, 2020	Apr NEWA
AB1		20MEQ	A212861	003	May 08, 2020	Apr NEWA
AB2	GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb NEWA
AB2		10MEQ	A211797	002	Mar 04, 2020	Feb NEWA
	@ STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb CAHN
	@	10MEQ	A206881	002	Jan 22, 2019	Feb CAHN
	@	10MEQ	A210097	001	Jun 17, 2019	Feb CAHN
	@	20MEQ	A210098	001	Apr 26, 2019	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

>A> AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Jun NEWA
		15MEQ	A212799	002	Jun 29, 2020	Jun NEWA
AB	RISING	5MEQ	A077440	001	Jun 09, 2006	Apr CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Apr CAHN

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

>D>	+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun CTNA
>A>		PRALIDOXIME CHLORIDE (AUTOINJECTOR)					
>A>	+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun CTNA
>A>		SOLUTION;INTRAMUSCULAR					
>A>		PRALIDOXIME CHLORIDE (AUTOINJECTOR)					
>A>	+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun CDFR
>A>	+!		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Jun CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GRAVITI PHARMS	0.25MG	A211088	001	Oct 03, 2018	May CAHN
AB			0.5MG	A211088	002	Oct 03, 2018	May CAHN
AB			0.75MG	A211088	003	Oct 03, 2018	May CAHN
AB			1MG	A211088	004	Oct 03, 2018	May CAHN
AB			1.5MG	A211088	005	Oct 03, 2018	May CAHN
	@	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	Apr DISC
	@		0.25MG	A077724	002	Feb 19, 2008	Apr DISC
	@		0.5MG	A077724	003	Feb 19, 2008	Apr DISC
	@		1MG	A077724	004	Feb 19, 2008	Apr DISC
	@		1.5MG	A077724	005	Feb 19, 2008	Apr DISC
>D> AB		MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012	Jun DISC
>A>	@		0.125MG	A202164	001	Sep 20, 2012	Jun DISC
>D> AB			0.25MG	A202164	002	Sep 20, 2012	Jun DISC
>A>	@		0.25MG	A202164	002	Sep 20, 2012	Jun DISC
>D> AB			0.5MG	A202164	003	Sep 20, 2012	Jun DISC
>A>	@		0.5MG	A202164	003	Sep 20, 2012	Jun DISC
>D> AB			1MG	A202164	004	Sep 20, 2012	Jun DISC
>A>	@		1MG	A202164	004	Sep 20, 2012	Jun DISC
>D> AB			1.5MG	A202164	005	Sep 20, 2012	Jun DISC
>A>	@		1.5MG	A202164	005	Sep 20, 2012	Jun DISC
	@	MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan DISC
	@		0.25MG	A077854	002	Oct 08, 2010	Jan DISC
	@		0.5MG	A077854	003	Oct 08, 2010	Jan DISC
	@		0.75MG	A090764	001	Apr 09, 2010	Jan DISC
	@		1MG	A077854	004	Oct 08, 2010	Jan DISC
	@		1.5MG	A077854	005	Oct 08, 2010	Jan DISC
AB		ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Feb CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Feb CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Feb CAHN
AB			1MG	A090151	004	Apr 30, 2012	Feb CAHN
AB			1.5MG	A090151	005	Apr 30, 2012	Feb CAHN

PRASTERONE

INSERT; VAGINAL

INTRAROSA

>D>	+!	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	Jun CAHN
>A>	+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016	Jun CAHN

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+ @ VALEANT BERMUDA 0.1%

N020279 001 Oct 29, 1993 Apr DISC

PREDNICARBATE

@ FOUGERA PHARMS 0.1%

A077287 001 Sep 19, 2006 Apr DISC

OINTMENT; TOPICAL

DERMATOP

+ @ VALEANT PHARMS NORTH 0.1%

N019568 001 Sep 23, 1991 Feb DISC

PREDNICARBATE

! FOUGERA PHARMS 0.1%

A077236 001 Mar 09, 2007 Feb CTEC

AB ! 0.1%

A077236 001 Mar 09, 2007 Feb CHRS

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
OMNIPRED

AB	+!	NOVARTIS	1%	N017469	001	Jan CHRS
AB	+		1%	N017469	001	Jan CRLD

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

>D>	AA	PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb NEWA
>A>		VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	Jun DISC
>A>		@	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	Jun DISC

PREDNISONE

TABLET; ORAL
PREDNISONE

>A>	AB	AMNEAL	1MG	A213385	001	Jun 16, 2020	Jun NEWA
>A>	AB		5MG	A213385	002	Jun 16, 2020	Jun NEWA
>A>	AB		10MG	A213386	001	Jun 24, 2020	Jun NEWA
>A>	AB		20MG	A213386	002	Jun 24, 2020	Jun NEWA

TABLET, DELAYED RELEASE; ORAL
PREDNISONE

@	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr DISC
@		2MG	A204867	002	Apr 25, 2017	Apr DISC
@		5MG	A204867	003	Apr 25, 2017	Apr DISC
RAYOS						
+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr CTEC
+		2MG	N202020	002	Jul 26, 2012	Apr CTEC
+		5MG	N202020	003	Jul 26, 2012	Apr CTEC

PREGABALIN

CAPSULE; ORAL
LYRICA

>D>	AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jun CAHN
>D>	AB	+		50MG	N021446	002	Dec 30, 2004	Jun CAHN
>D>	AB	+		75MG	N021446	003	Dec 30, 2004	Jun CAHN
>D>	AB	+		100MG	N021446	004	Dec 30, 2004	Jun CAHN
>D>	AB	+		150MG	N021446	005	Dec 30, 2004	Jun CAHN
>D>	AB	+		200MG	N021446	006	Dec 30, 2004	Jun CAHN
>D>	AB	+		225MG	N021446	007	Dec 30, 2004	Jun CAHN
>D>	AB	+		300MG	N021446	008	Dec 30, 2004	Jun CAHN
>A>	AB	+	PFIZER	25MG	N021446	001	Dec 30, 2004	Jun CAHN
>A>	AB	+		50MG	N021446	002	Dec 30, 2004	Jun CAHN
>A>	AB	+		75MG	N021446	003	Dec 30, 2004	Jun CAHN
>A>	AB	+		100MG	N021446	004	Dec 30, 2004	Jun CAHN
>A>	AB	+		150MG	N021446	005	Dec 30, 2004	Jun CAHN
>A>	AB	+		200MG	N021446	006	Dec 30, 2004	Jun CAHN
>A>	AB	+		225MG	N021446	007	Dec 30, 2004	Jun CAHN
>A>	AB	+		300MG	N021446	008	Dec 30, 2004	Jun CAHN

PREGABALIN

AB		CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar NEWA
AB			75MG	A212865	002	Mar 20, 2020	Mar NEWA
AB			100MG	A212865	003	Mar 20, 2020	Mar NEWA
AB			150MG	A212865	004	Mar 20, 2020	Mar NEWA
AB		HIKAL	25MG	A213423	001	Mar 23, 2020	Mar NEWA
AB			50MG	A213423	002	Mar 23, 2020	Mar NEWA
AB			75MG	A213423	003	Mar 23, 2020	Mar NEWA
AB			100MG	A213423	004	Mar 23, 2020	Mar NEWA
AB			150MG	A213423	005	Mar 23, 2020	Mar NEWA
AB			200MG	A213423	006	Mar 23, 2020	Mar NEWA
AB			225MG	A213423	007	Mar 23, 2020	Mar NEWA
AB			300MG	A213423	008	Mar 23, 2020	Mar NEWA
		MYLAN	25MG	A091228	001	Sep 20, 2019	Feb DISC
			50MG	A091228	002	Sep 20, 2019	Feb DISC
			75MG	A091228	003	Sep 20, 2019	Feb DISC
			100MG	A091228	004	Sep 20, 2019	Feb DISC
			150MG	A091228	005	Sep 20, 2019	Feb DISC
			200MG	A091228	006	Sep 20, 2019	Feb DISC
			225MG	A091228	007	Sep 20, 2019	Feb DISC
			300MG	A091228	008	Sep 20, 2019	Feb DISC

SOLUTION;ORAL
LYRICA

>D> AA	+! PF PRISM CV	20MG/ML	N 022488	001	Jan 04, 2010	Jun CAHN
>A> AA	+! PFIZER	20MG/ML	N 022488	001	Jan 04, 2010	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL						
LYRICA CR						
>D>	+ PF PRISM CV	82.5MG	N 209501	001	Oct 11, 2017	Jun CAHN
>D>	+	165MG	N 209501	002	Oct 11, 2017	Jun CAHN
>D>	+!	330MG	N 209501	003	Oct 11, 2017	Jun CAHN
>A>	+ PFIZER	82.5MG	N 209501	001	Oct 11, 2017	Jun CAHN
>A>	+	165MG	N 209501	002	Oct 11, 2017	Jun CAHN
>A>	+!	330MG	N 209501	003	Oct 11, 2017	Jun CAHN

PROCHLORPERAZINE MALEATE

TABLET;ORAL						
COMPАЗИНЕ						
+ @ GLAXOSMITHKLINE	EQ 5MG BASE	N 010571	001	Mar CRLD		
+ @	EQ 10MG BASE	N 010571	002	Mar CRLD		
+ @	EQ 25MG BASE	N 010571	003	Mar CRLD		
PROCHLORPERAZINE MALEATE						
@ SANDOZ	EQ 5MG BASE	A 040101	001	Jul 19, 1996	Mar DISC	
@	EQ 10MG BASE	A 040101	002	Jul 19, 1996	Mar DISC	
PROCOMP						
AB ! JUBILANT CADISTA	EQ 10MG BASE	A 040268	002	Feb 27, 1998	Mar CHRS	

PROGESTERONE

SYSTEM;VAGINAL						
MILPROSA						
+! FERRING PHARMS INC	1.78GM	N 201110	001	Apr 29, 2020	Apr NEWA	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION						
PROMETHAZINE HYDROCHLORIDE						
AP XGEN PHARMS	25MG/ML	A 040737	001	Apr 24, 2008	Feb CAHN	
AP	50MG/ML	A 040737	002	Apr 24, 2008	Feb CAHN	
SUPPOSITORY;RECTAL						
PROMETHAZINE HYDROCHLORIDE						
@ WATSON LABS INC	12.5MG	A 040479	001	Jun 24, 2003	Mar DISC	
@	25MG	A 040479	002	Jun 24, 2003	Mar DISC	
SYRUP;ORAL						
PROMETHAZINE HYDROCHLORIDE						
>A> @ PHARM ASSOC	6.25MG/5ML	A 040643	001	Apr 26, 2006	Jun CAHN	
>D> AA VINTAGE	6.25MG/5ML	A 040643	001	Apr 26, 2006	Jun DISC	
>A> @	6.25MG/5ML	A 040643	001	Apr 26, 2006	Jun DISC	

PROPafenone HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
PROPAFENONE HYDROCHLORIDE						
>A> AB TWI PHARMS	225MG	A 212928	001	Jun 18, 2020	Jun NEWA	
>A> AB	325MG	A 212928	002	Jun 18, 2020	Jun NEWA	
>A> AB	425MG	A 212928	003	Jun 18, 2020	Jun NEWA	
>A> AB UPSHER SMITH LABS	225MG	A 212744	001	Jun 25, 2020	Jun NEWA	
>A> AB	325MG	A 212744	002	Jun 25, 2020	Jun NEWA	
>A> AB	425MG	A 212744	003	Jun 25, 2020	Jun NEWA	

PYRAZINAMIDE

TABLET;ORAL						
PYRAZINAMIDE						
! AKORN	500MG	A 081319	001	Jun 30, 1992	Feb CHRS	
	500MG	A 081319	001	Jun 30, 1992	Feb CTEC	
@ DAVA PHARMS INC	500MG	A 080157	001		Feb DISC	

PYRIMETHAMINE

TABLET;ORAL						
DARAPRIM						
AB +! VYERA PHARMS LLC	25MG	N 008578	001		Feb CFTG	
AB CEROVENE INC	25MG	A 207127	001	Feb 28, 2020	Feb NFTG	

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012	Feb CAHN
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Feb CAHN
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012	Feb CAHN
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012	Feb CAHN
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012	Feb CAHN
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012	Feb CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ MYLAN	EQ 5MG BASE	A076694	001	Dec 23, 2004	Mar DISC
@	EQ 10MG BASE	A076694	002	Dec 23, 2004	Mar DISC
@	EQ 20MG BASE	A076694	003	Dec 23, 2004	Mar DISC
@	EQ 40MG BASE	A076694	004	Dec 23, 2004	Mar DISC

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

! SANDOZ	200MG	A088072	002	May CHRS
	200MG	A088072	002	May CTEC
!	300MG	A088072	001	Sep 26, 1983
	300MG	A088072	001	Sep 26, 1983
@ WATSON LABS	200MG	A083288	001	Apr DISC
@	300MG	A085583	001	Apr DISC

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar NEWA
----	-----------	-----	---------	-----	--------------	----------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008	Mar DISC
@	2.5MG	A077470	002	Jun 18, 2008	Mar DISC
@	5MG	A077470	003	Jun 18, 2008	Mar DISC
@	10MG	A077470	004	Jun 18, 2008	Mar DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

>D> AB	AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018	Jun DISC
>A>	@	EQ 150MG BASE	A209859	001	Sep 27, 2018	Jun DISC
>D> AB		EQ 300MG BASE	A209859	002	Sep 27, 2018	Jun DISC
>A>	@	EQ 300MG BASE	A209859	002	Sep 27, 2018	Jun DISC
	@ APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019	May DISC
	@	EQ 300MG BASE	A211893	002	Apr 05, 2019	May DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008	Apr DISC
@ HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	May DISC
@ TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan DISC
@	EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan DISC
@ HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Apr DISC
@	EQ 300MG BASE	A075165	002	Sep 30, 1998	Apr DISC
@ STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Apr DISC
@	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan DISC
@	EQ 300MG BASE	A205512	002	Aug 22, 2016	Apr DISC
AB !	EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan CHRS
@	EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan CAHN
AB		1GM	A210482	002	Oct 29, 2019	Jan CAHN
AB	MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan NEWA
AB		1GM	A212284	002	Feb 12, 2020	Jan NEWA
AB	MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb NEWA
AB		1GM	A211745	002	Feb 27, 2020	Feb NEWA
AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Mar NEWA
AB		1GM	A212781	002	Mar 23, 2020	Mar NEWA
AB	SUNSHINE LAKE	500MG	A211865	001	Mar 23, 2020	Mar NEWA
AB		1GM	A211865	002	Mar 23, 2020	Mar NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Mar DISC
@	EQ 1MG BASE	A201823	002	Jul 01, 2013	Mar DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

@ ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Mar DISC
@	1MG	A090008	002	Jan 22, 2014	Mar DISC
@	2MG	A090008	003	Jan 22, 2014	Mar DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

@ KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Feb DISC
RIBAVIRIN	200MG	A076277	001	Oct 04, 2004	Mar DISC

TABLET;ORAL

RIBAVIRIN

@ BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb DISC
@	400MG	A202546	002	Aug 12, 2014	Feb DISC
@	500MG	A202546	003	Aug 12, 2014	Feb DISC
@	600MG	A202546	004	Aug 12, 2014	Feb DISC
@ KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Feb DISC
@	400MG	A077456	002	Dec 05, 2005	Feb DISC
@	600MG	A077456	003	Dec 05, 2005	Feb DISC
@ ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb DISC
@	500MG	A077094	004	Apr 18, 2008	Feb DISC
@	600MG	A077094	003	Mar 16, 2007	Feb DISC

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

@ EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	May DISC
---------------------	------------	---------	-----	--------------	----------

RILUZOLE

TABLET;ORAL

RILUZOLE

AB	KENTON	50MG	A206045	001	Dec 09, 2019	Mar CAHN
----	--------	------	---------	-----	--------------	----------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb NEWA
-------------------	--------------	---------	-----	--------------	----------

RIPRETTINIB

TABLET;ORAL

QINLOCK

+! DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020	May NEWA
---------------------	------	---------	-----	--------------	----------

RISPERIDONE

TABLET;ORAL

RISPERIDONE

>D> AB	MYLAN	0.25MG	A076288	001	Sep 15, 2008	Jun DISC
>A>	@	0.25MG	A076288	001	Sep 15, 2008	Jun DISC
TABLET, ORALLY DISINTEGRATING;ORAL						
	RISPERIDONE					
	@ ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar DISC
	@	1MG	A076996	002	Apr 19, 2011	Mar DISC
	@	2MG	A076996	003	Apr 19, 2011	Mar DISC
	@	3MG	A076996	004	Apr 19, 2011	Mar DISC
	@	4MG	A076996	005	Apr 19, 2011	Mar DISC
	@ HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	Apr DISC
	@	1MG	A076908	002	Mar 12, 2012	Apr DISC
	@	2MG	A076908	003	Mar 12, 2012	Apr DISC

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

YUTOPAR

@ ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan CMS1
---------------	---------	---------	-----	--------------	----------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

@ APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	May DISC
@	EQ 3MG BASE	A091072	002	May 16, 2013	May DISC
@	EQ 4.5MG BASE	A091072	003	May 16, 2013	May DISC
@	EQ 6MG BASE	A091072	004	May 16, 2013	May DISC

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb DISC
@	EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

@ TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008	Mar DISC
@	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008	Mar DISC

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

>D> AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Jun DISC
>A>	@	500MCG	A208180	001	Mar 22, 2019	Jun DISC
AB	STRIDES PHARMA	500MCG	A208247	001	Mar 30, 2020	Mar NEWA

ROMIDEPSIN

SOLUTION; INTRAVENOUS

ROMIDEPSIN

+ TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574	001	Mar 13, 2020	Mar NEWA
+!	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Mar NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

@ HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb DISC
@	EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb DISC
@	EQ 1MG BASE	A077852	003	May 05, 2008	Feb DISC
@	EQ 2MG BASE	A077852	004	May 05, 2008	Feb DISC
@	EQ 3MG BASE	A077852	005	May 05, 2008	Feb DISC
@	EQ 4MG BASE	A077852	006	May 05, 2008	Feb DISC
@	EQ 5MG BASE	A077852	007	May 19, 2008	Feb DISC

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

+ @ GLAXOSMITHKLINE LLC	EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar DISC
-------------------------	-------------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

@ WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	Mar DISC
@	EQ 4MG BASE	A200431	002	Jun 06, 2012	Mar DISC
@	EQ 6MG BASE	A200431	003	Jun 06, 2012	Mar DISC

**TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE**

@	EQ 8MG BASE	A200431	004	Jun 06, 2012	Mar DISC
@	EQ 12MG BASE	A200431	005	Jun 06, 2012	Mar DISC

ROPIVACAINE HYDROCHLORIDE

**SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE**

AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020	Mar NEWA
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020	Mar NEWA
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020	Mar NEWA
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020	Mar NEWA

ROSUVASTATIN CALCIUM

**TABLET;ORAL
ROSUVASTATIN CALCIUM**

>D> AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jun DISC
>A>	@	5MG	A079145	001	Jul 19, 2016	Jun DISC
>D> AB		10MG	A079145	002	Jul 19, 2016	Jun DISC
>A>	@	10MG	A079145	002	Jul 19, 2016	Jun DISC
>D> AB		20MG	A079145	003	Jul 19, 2016	Jun DISC
>A>	@	20MG	A079145	003	Jul 19, 2016	Jun DISC
>D> AB		40MG	A079145	004	Jul 19, 2016	Jun DISC
>A>	@	40MG	A079145	004	Jul 19, 2016	Jun DISC
AB	SUNSHINE LAKE	5MG	A210667	001	Apr 01, 2020	Mar NEWA
AB		10MG	A210667	002	Apr 01, 2020	Mar NEWA
AB		20MG	A210667	003	Apr 01, 2020	Mar NEWA
AB		40MG	A210667	004	Apr 01, 2020	Mar NEWA
	@ ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr DISC
	@	10MG	A212059	002	Nov 04, 2019	Apr DISC
	@	20MG	A212059	003	Nov 04, 2019	Apr DISC
	@	40MG	A212059	004	Nov 04, 2019	Apr DISC

SELEGILINE HYDROCHLORIDE

**CAPSULE;ORAL
SELEGILINE HYDROCHLORIDE**

@ DAVA PHARMS INC	5MG	A075352	001	Nov 30, 1998	Feb DISC
TABLET;ORAL SELEGILINE HYDROCHLORIDE					
@ MIV	5MG	A074672	001	Apr 01, 1997	Mar CAHN

SELEXIPAG

TABLET;ORAL UPTRAVI					
+! ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
+	1.6MG	N207947	008	Dec 21, 2015	Jan CHRS

SELPERCATINIB

CAPSULE;ORAL RETEVMO					
+ LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020	May NEWA
+!	80MG	N213246	002	May 08, 2020	May NEWA

SELUMETINIB SULFATE

CAPSULE;ORAL KOSELUGO					
+ ASTRAZENECA PHARMS	EQ 10MG BASE	N213756	001	Apr 10, 2020	Apr NEWA
+!	EQ 25MG BASE	N213756	002	Apr 10, 2020	Apr NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS OZEMPIC					
+! NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan NEWA

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL ZOLOFT					
>D> AA +! PFIZER	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jun CAHN
>A> AA +! UPJOHN	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jun CAHN

TABLET;ORALSERTRALINE HYDROCHLORIDE

AB	VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB		EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
	ZOLOFT					
>D> AB	+ PFIZER	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jun CAHN
>D> AB	+	EQ 50MG BASE	N019839	001	Dec 30, 1991	Jun CAHN
>D> AB	+!	EQ 100MG BASE	N019839	002	Dec 30, 1991	Jun CAHN
>D>	+ @	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jun CAHN
>D>	+ @	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jun CAHN
>A> AB	+ UPJOHN	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jun CAHN
>A> AB	+	EQ 50MG BASE	N019839	001	Dec 30, 1991	Jun CAHN
>A> AB	+!	EQ 100MG BASE	N019839	002	Dec 30, 1991	Jun CAHN
>A>	+ @	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jun CAHN
>A>	+ @	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jun CAHN

SEVELAMER CARBONATETABLET;ORALSEVELAMER CARBONATE

AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar NEWA
----	-------	-------	---------	-----	--------------	----------

SILDENAFIL CITRATEFOR SUSPENSION;ORALREVATIO

>D> AB	+! PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Jun CAHN
>A> AB	+! UPJOHN	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Jun CAHN

SILDENAFIL CITRATE

AB	TEVA PHARMS USA	EQ 10MG BASE/ML	A211534	001	May 29, 2020	May NEWA
	SOLUTION;INTRAVENOUS					
	REVATIO					

>D> AP	+! PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Jun CAHN
>A> AP	+! UPJOHN	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Jun CAHN

TABLET;ORALREVATIO

>D> AB	+! PFIZER	EQ 20MG BASE	N021845	001	Jun 03, 2005	Jun CAHN
>A> AB	+! UPJOHN	EQ 20MG BASE	N021845	001	Jun 03, 2005	Jun CAHN

SILDENAFIL CITRATE

AB	APPCO	EQ 25MG BASE	A207178	001	Mar 02, 2020	Apr CPOT
AB		25MG	A207178	001	Mar 02, 2020	Feb NEWA
AB		EQ 50MG BASE	A207178	002	Mar 02, 2020	Apr CPOT
AB		50MG	A207178	002	Mar 02, 2020	Feb NEWA
AB		EQ 100MG BASE	A207178	003	Mar 02, 2020	Apr CPOT
AB		100MG	A207178	003	Mar 02, 2020	Feb NEWA
AB	PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020	Apr NEWA
AB		EQ 50MG BASE	A205791	002	Apr 23, 2020	Apr NEWA
>A> AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Jun NEWA
>A> AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Jun NEWA
>A> AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Jun NEWA
>A> AB	SUNSHINE LAKE	EQ 25MG BASE	A213032	001	Jun 11, 2020	Jun NEWA
>A> AB		EQ 50MG BASE	A213032	002	Jun 11, 2020	Jun NEWA
>A> AB		EQ 100MG BASE	A213032	003	Jun 11, 2020	Jun NEWA

VIAGRA

>D> AB	+ PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	Jun CAHN
>D> AB	+	EQ 50MG BASE	N020895	002	Mar 27, 1998	Jun CAHN
>D> AB	+!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Jun CAHN
>A> AB	+ UPJOHN	EQ 25MG BASE	N020895	001	Mar 27, 1998	Jun CAHN
>A> AB	+	EQ 50MG BASE	N020895	002	Mar 27, 1998	Jun CAHN
>A> AB	+!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Jun CAHN

SILODOSINCAPSULE;ORALSILODOSIN

AB	HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb NEWA
AB		8MG	A204793	002	Feb 14, 2020	Feb NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

AMMONIUM

>A> AP +! BAUSCH	10%;10% (5GM/50ML;5GM/50ML)
>D> AP +! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)

N020645 001	Feb 17, 2005	Jun CAHN
N020645 001	Feb 17, 2005	Jun CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP NEPHRON	9MG/ML
------------	--------

A211968 001	Apr 23, 2020	Apr NEWA
-------------	--------------	----------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA CURIUM	100uCi
AA	200uCi

A071909 001	Feb 28, 1989	Feb CAHN
A071910 001	Feb 28, 1989	Feb CAHN

SODIUM IODIDE I-131

SOLUTION; ORAL

HICON

AA +! JUBILANT DRAXIMAGE	250-1000mCi
	SODIUM IODIDE I 131
AA INTL ISOTOPES	250-1000mCi

N021305 007	Dec 05, 2011	Jan CFTG
A209166 001	Feb 05, 2020	Jan NFTG

>D> SODIUM LACTATE

>D> INJECTABLE; INJECTION

>D> SODIUM LACTATE IN PLASTIC CONTAINER

>D> +! HOSPIRA	5MEQ/ML
>A> + @	5MEQ/ML

N018947 001	Sep 05, 1984	Jun DISC
N018947 001	Sep 05, 1984	Jun DISC

SODIUM PHENYLBUTYRATE

TABLET; ORAL

SODIUM PHENYLBUTYRATE

@ ALVOGEN 500MG

A090910 001	Nov 18, 2011	Jan DISC
-------------	--------------	----------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ HIKMA 15GM/60ML

A089049 001	Nov 17, 1986	Feb DISC
-------------	--------------	----------

SOFOSBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

+ GILEAD SCIENCES INC 200MG;50MG

N208341 002	Mar 19, 2020	Mar NEWA
-------------	--------------	----------

SOLIFENACIN SUCCINATE

SUSPENSION; ORAL

VESICARE LS

+! ASTELLAS 1MG/ML

N209529 001	May 26, 2020	May NEWA
-------------	--------------	----------

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB GRAVITI PHARMS	5MG
AB	10MG
AB SUNSHINE LAKE	5MG
AB	10MG

A211423 001	Dec 11, 2019	May CAHN
A211423 002	Dec 11, 2019	May CAHN
A213346 001	Apr 13, 2020	Mar NEWA
A213346 002	Apr 13, 2020	Mar NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET; ORAL

SUNOSI

+ JAZZ EQ 75MG BASE

N211230 001	Jun 17, 2019	Jan CPOT
-------------	--------------	----------

+ 75MG

N211230 001	Jun 17, 2019	Jan CAIN
-------------	--------------	----------

+! EQ 150MG BASE

N211230 002	Jun 17, 2019	Apr CHRS
-------------	--------------	----------

+ EQ 150MG BASE

N211230 002	Jun 17, 2019	Jan CPOT
-------------	--------------	----------

+ 150MG

N211230 002	Jun 17, 2019	Jan CAIN
-------------	--------------	----------

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
! XGEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998 Feb CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE
+ @ HOSPIRA 50MG/ML N008845 002 Apr CRLD
+ @ 100MG/ML N008845 004 Apr CRLD
SUCCINYLCHOLINE CHLORIDE
AP ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020 May NEWA
>A> AP AMPHASTAR PHARMS INC 20MG/ML A213432 001 Jun 08, 2020 Jun NEWA
AP ASPIRO 20MG/ML A213810 001 May 04, 2020 Apr NEWA
>A> AP GLAND PHARMA LTD 20MG/ML A214246 001 Jun 16, 2020 Jun NEWA
>A> AP HIKMA 20MG/ML A213229 001 Jun 12, 2020 Jun NEWA
AP INDOCO REMEDIES 20MG/ML A214308 001 May 22, 2020 May NEWA
AP NIVAGEN PHARMS INC 20MG/ML A211625 001 May 19, 2020 May NEWA
SUCOSTRIN
+ @ APOTHECON 20MG/ML N008847 001 Apr CRLD
+ @ 100MG/ML N008847 003 Apr CRLD

SUCRALFATE

TABLET; ORAL
SUCRALFATE
AB NOSTRUM LABS INC 1GM A074415 001 Jun 08, 1998 May CMFD

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON
AB +! BAUSCH 10% N019931 001 Dec 23, 1996 Mar CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AP TEVA PHARMS USA 80MG/ML;16MG/ML A073303 001 Oct 31, 1991 Mar CMFD

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE
AB COREPHARMA EQ 25MG BASE A200263 001 Jun 19, 2012 Feb CAHN
AB EQ 50MG BASE A200263 002 Jun 19, 2012 Feb CAHN
AB EQ 100MG BASE A200263 003 Jun 19, 2012 Feb CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
TAMSULOSIN HYDROCHLORIDE
@ ANBISON LAB 0.4MG A211885 001 Oct 17, 2019 Apr DISC

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL
NUCYNTA
+ @ COLLEGIUM PHARM INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 Feb CAHN
TABLET; ORAL
NUCYNTA
+ COLLEGIUM PHARM INC EQ 50MG BASE N022304 001 Nov 20, 2008 Feb CAHN
+ EQ 75MG BASE N022304 002 Nov 20, 2008 Feb CAHN
+! EQ 100MG BASE N022304 003 Nov 20, 2008 Feb CAHN
TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER
+ COLLEGIUM PHARM INC EQ 50MG BASE N200533 001 Aug 25, 2011 Feb CAHN
+ EQ 100MG BASE N200533 002 Aug 25, 2011 Feb CAHN
+ EQ 150MG BASE N200533 003 Aug 25, 2011 Feb CAHN
+ EQ 200MG BASE N200533 004 Aug 25, 2011 Feb CAHN
+! EQ 250MG BASE N200533 005 Aug 25, 2011 Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL

TAZVERIK

+! EPIZYME INC

EQ 200MG BASE

N211723 001 Jan 23, 2020 Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

@ SUN PHARM INDs INC N/A

N018467 001 Mar 16, 1982 Apr CAHN

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE;INJECTION

TECHNETIUM TC-99M MEBROFENIN

AP SUN PHARM INDs INC N/A

A078242 001 Jan 29, 2008 Apr CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

CIS-MDP

SUN PHARM INDs INC N/A

N018124 001 Apr CAHN

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP SOMMER PHARMS II LLC N/A

A206489 001 Feb 06, 2020 Jan NEWA

AP SUN PHARM INDs INC N/A

A208994 001 Jul 12, 2019 Apr CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION

CIS-PYRO

AP SUN PHARM INDs INC N/A

N019039 001 Jun 30, 1987 Apr CAHN

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP CURIUM N/A

A078098 001 Sep 22, 2008 Feb CAHN

AP SUN PHARM INDs INC 10-30mCi

A079157 001 Jul 10, 2009 Apr CAHN

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

AN-SULFUR COLLOID

+! SUN PHARM INDs INC N/A

N017858 001 Apr CAHN

TELmisartan

TABLET;ORAL

TELmisartan

@ JUBILANT GENERICS 20MG

A204164 001 Aug 22, 2016 Jan DISC

@ 40MG

A204164 002 Aug 22, 2016 Jan DISC

@ 80MG

A204164 003 Aug 22, 2016 Jan DISC

AB MICRO LABS 20MG

A207016 001 Oct 03, 2017 Apr CMFD

AB 40MG

A207016 002 Oct 03, 2017 Apr CMFD

AB 80MG

A207016 003 Oct 03, 2017 Apr CMFD

TEMozolomide

CAPSULE;ORAL

TEMOZOLOMIDE

>A> AB	CHARTWELL	5MG	A206413 001 Apr 12, 2016	Jun CAHN
>A> AB		20MG	A206413 002 Apr 12, 2016	Jun CAHN
>A> AB		100MG	A206413 003 Apr 12, 2016	Jun CAHN
>A> AB		140MG	A206413 004 Apr 12, 2016	Jun CAHN
>A> AB		180MG	A206413 005 Apr 12, 2016	Jun CAHN
>A> AB		250MG	A206413 006 Apr 12, 2016	Jun CAHN
>D> AB	IDT AUSTRALIA LTD	5MG	A206413 001 Apr 12, 2016	Jun CAHN
>D> AB		20MG	A206413 002 Apr 12, 2016	Jun CAHN
>D> AB		100MG	A206413 003 Apr 12, 2016	Jun CAHN
>D> AB		140MG	A206413 004 Apr 12, 2016	Jun CAHN
>D> AB		180MG	A206413 005 Apr 12, 2016	Jun CAHN
>D> AB		250MG	A206413 006 Apr 12, 2016	Jun CAHN

TENAPANOR HYDROCHLORIDE

TABLET;ORAL
IBSRELA
+ @ ARDELYX INC EQ 50MG BASE N211801 001 Sep 12, 2019 Mar DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE
@ MYLAN 150MG A206569 001 Nov 27, 2018 Feb DISC
@ 200MG A206569 002 Nov 27, 2018 Feb DISC
@ 250MG A206569 003 Nov 27, 2018 Feb DISC
@ 300MG A206569 004 Nov 27, 2018 Feb DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE
@ HERITAGE PHARMA EQ 1MG BASE A075614 002 Jan 30, 2001 Feb DISC
@ EQ 2MG BASE A075614 001 Jan 30, 2001 Feb DISC
@ EQ 5MG BASE A075614 003 Jan 30, 2001 Feb DISC
@ EQ 10MG BASE A075614 004 Jan 30, 2001 Feb DISC

TERBUTALINE SULFATE

TABLET;ORAL
TERBUTALINE SULFATE
>A> AB TWI PHARMS 2.5MG A211832 001 Jun 19, 2020 Jun NEWA
>A> AB 5MG A211832 002 Jun 19, 2020 Jun NEWA

TERIFLUNOMIDE

TABLET;ORAL
TERIFLUNOMIDE
>A> AB IMPAX 14MG A209677 001 Jun 17, 2020 Jun NEWA
@ MYLAN 7MG A209702 001 Feb 28, 2020 Mar DISC
AB 7MG A209702 001 Feb 28, 2020 Feb NEWA
AB @ 14MG A209702 002 Feb 28, 2020 Mar DISC
AB 14MG A209702 002 Feb 28, 2020 Feb NEWA

TERIPARATIDE

INJECTABLE;SUBCUTANEOUS
FORTEO
+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CAIN
@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CAIN
SOLUTION;SUBCUTANEOUS
BONSITY
ALVOGEN 0.62MG/2.48ML (0.25MG/ML) N211939 001 Oct 04, 2019 Jan CAIN
FORTEO
+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CDFR
@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CDFR

TESTOSTERONE

GEL, METERED;TRANSDERMAL
ANDROGEL
+ @ ABBVIE TESTOSTERONE 12.5MG/1.25GM ACTUATION N021015 003 Sep 26, 2003 Mar DISC
BX ! ACTAVIS LABS UT INC 12.5MG/1.25GM ACTUATION A076737 003 Mar 09, 2015 Mar CHRS
BX 12.5MG/1.25GM ACTUATION A076737 003 Mar 09, 2015 Mar CTEC
AB XIROMED 1.62% (20.25MG/1.25GM ACTUATION) A210835 001 Apr 16, 2020 Apr NEWA

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE
AB APOTEX 12.5MG A206093 001 Mar 17, 2020 Mar NEWA
AB 25MG A206093 002 Mar 17, 2020 Mar NEWA
AB PIRAMAL HLTHCARE UK 12.5MG A213316 001 Jan 22, 2020 Jan NEWA
AB 25MG A213316 002 Jan 22, 2020 Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE
AB STRIDES PHARMA 250MG A212635 001 Mar 03, 2020 Feb NEWA
AB 500MG A212635 002 Mar 03, 2020 Feb NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

@ CURIUM

2mCi/ML

A077698 001 Nov 09, 2006 Feb CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>D> AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	Jun CTEC
>A>		300MG	A090430	001	Oct 27, 2010	Jun CTEC
>D> AB	HERITAGE PHARMA	300MG	A089763	001	Apr 30, 1990	Jun DISC
>A>	@	300MG	A089763	001	Apr 30, 1990	Jun DISC

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB	MYLAN	10MG	A088004	002	Mar 15, 1983	Mar CTEC
AB		25MG	A088004	003	Mar 15, 1983	Mar CTEC
AB		50MG	A088004	004	Mar 15, 1983	Mar CTEC
AB	!	100MG	A088004	001	Nov 18, 1983	Mar CTEC
AB	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar CMFD
AB		25MG	A089953	003	Aug 01, 1986	Mar CMFD
AB		50MG	A089953	002	Aug 01, 1986	Mar CMFD
AB		100MG	A089953	001	Oct 07, 1988	Mar CMFD

THIOTEP APOWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
TEPADINA

AP	+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	May CPOT
AP	+!	100MG/VIAL	N208264	002	Jan 26, 2017	May CPOT
	THIOTEP A					
AP	MSN	15MG/VIAL	A213049	001	Mar 04, 2020	May CPOT
AP		100MG/VIAL	A213049	002	Mar 04, 2020	May CPOT
	POWDER; INTRAVENOUS					
	TEPADINA					
AP	+! ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Feb CFTG
AP	+!	100MG/VIAL	N208264	002	Jan 26, 2017	Feb CFTG
	THIOTEP A					
AP	MSN	15MG/VIAL	A213049	001	Mar 04, 2020	Feb NFTG
AP		100MG/VIAL	A213049	002	Mar 04, 2020	Feb NFTG

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AB	HEC PHARM CO LTD	90MG	A208508	001	Apr 06, 2020	Mar NEWA
AB	SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar NEWA
AB		EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar NEWA
AB		EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar NEWA
AB	RUBICON	EQ 2MG BASE	A213798	001	May 27, 2020	May NEWA
AB		EQ 4MG BASE	A213798	002	May 27, 2020	May NEWA
AB		EQ 6MG BASE	A213798	003	May 27, 2020	May NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

@ MYLAN

300MG/5ML

A209554 001 Oct 13, 2017 Feb DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	! XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001	Feb CAHN
----	---------------	--------------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@ MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar DISC
@	500MG	A070259	003	Mar 17, 1986	Mar DISC

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	May NEWA
AB		4MG	A213397	002	May 19, 2020	May NEWA
	TABLET;ORAL					
	DETROL					
>D> AB	+ PHARMACIA AND UPJOHN	1MG	N020771	001	Mar 25, 1998	Jun CAHN
>D> AB	+!	2MG	N020771	002	Mar 25, 1998	Jun CAHN
>A> AB	+ UPJOHN	1MG	N020771	001	Mar 25, 1998	Jun CAHN
>A> AB	+!	2MG	N020771	002	Mar 25, 1998	Jun CAHN
	TOLTERODINE TARTRATE					
	@ MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012	Jan DISC
	@	2MG	A202641	002	Nov 27, 2012	Jan DISC
AB	UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020	Jan NEWA
AB		2MG	A204721	002	Jan 24, 2020	Jan NEWA

TOLVAPTAN

TABLET;ORAL

SAMSCA

AB	+! OTSUKA AMERICA PHARM	30MG	N022275	002	May 19, 2009	May CFTG
	TOLVAPTAN					
AB	ALKEM LABS LTD	30MG	A211891	001	May 19, 2020	May NEWA
AB		60MG	A211891	002	May 19, 2020	May NFTG
AB	APOTEX	30MG	A207605	001	May 19, 2020	May NFTG

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB	VIWIT PHARM	25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB		25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB		50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB		50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB		100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB		100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB		200MG	A077733	004	Mar 27, 2009	Mar CAHN
AB		200MG	A077733	004	Mar 27, 2009	Mar CAHN

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB	COREPHARMA	5MG	A076894	001	May 31, 2005	Feb CAHN
AB		10MG	A076894	002	May 31, 2005	Feb CAHN
AB		20MG	A076894	003	May 31, 2005	Feb CAHN
AB		100MG	A076894	004	May 31, 2005	Feb CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@ MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	May DISC
-----------------------	------	---------	-----	--------------	----------

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP	@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan DISC
	XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb CAHN
	TABLET;ORAL					
	TRANEXAMIC ACID					
	@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan CAHN

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan NEWA
AB		100MG	A204852	002	Feb 05, 2020	Jan NEWA
AB		150MG	A204852	003	Feb 05, 2020	Jan NEWA
AB		300MG	A204852	004	Feb 05, 2020	Jan NEWA

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	May NEWA
AP		2.5MG/ML	A210214	002	May 22, 2020	May NEWA
AP		5MG/ML	A210214	003	May 22, 2020	May NEWA
AP		10MG/ML	A210214	004	May 22, 2020	May NEWA

TRIAMCINOLONE ACETONIDE

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	QUAGEN	0.025%	A213559	001	Jul 01, 2020	Jun NEWA
>A>	AT		0.1%	A213559	002	Jul 01, 2020	Jun NEWA
AT		SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN
		OINTMENT;TOPICAL					
		TRIAMCINOLONE ACETONIDE					
AT		MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
AT			0.1%	A209828	002	Nov 23, 2018	Mar CTNA
AT			0.5%	A209828	003	Nov 23, 2018	Mar CTNA
AT		STRIDES PHARMA	0.05%	A212356	001	Jun 01, 2020	May NEWA
AT			0.1%	A211315	001	Mar 18, 2020	Mar NEWA
AT			0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

@	MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan DISC
@		0.25MG	A074031	002	Mar 25, 1994	Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	LUPIN LTD	250MG	A211637	001	May 21, 2020	May NEWA
AB	RISING	250MG	A212238	001	Feb 20, 2020	Feb NEWA

TRIFAROTENE

CREAM;TOPICAL

AKLIEF

+!	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019	May CAHN
----	------------------	--------	---------	-----	--------------	----------

TROMETHAMINE

INJECTABLE;INJECTION

THAM

>D>	+ @ HOSPIRA	3.6GM/100ML	N013025	002		Jun CMFD
>A>	+! HOSPIRA	18GM/500ML (3.6GM/100ML)	N013025	002		Jun CMFD

TROSPiUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPiUM CHLORIDE

AB	GRANULES PHARMS	60MG	A213185	001	Apr 23, 2020	Apr NEWA
----	-----------------	------	---------	-----	--------------	----------

TUCATINIB

TABLET;ORAL

TUKYSA

+	SEATTLE GENETICS	50MG	N213411	001	Apr 17, 2020	Apr NEWA
+		150MG	N213411	002	Apr 17, 2020	Apr NEWA

URSODIOL

CAPSULE;ORAL

URSODIOL

NEXGEN PHARMA INC	200MG	A205789	001	May 08, 2020	Apr NFTG
	400MG	A205789	002	May 08, 2020	Apr NFTG
AB RISING	300MG	A213200	001	Feb 12, 2020	Jan NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

@ TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan DISC
@	EQ 1GM BASE	A077655	002	May 24, 2010	Jan DISC
AB YILING PHARM LTD	EQ 500MG BASE	A209553	001	Mar 18, 2020	Mar NEWA
	EQ 1GM BASE	A209553	002	Mar 18, 2020	Mar NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan NEWA
--------------------	---------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL

FIRVANQ KIT

>A>	+! AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jun CAHN
>A>	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jun CAHN
>D>	+! RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jun CAHN
>D>	+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jun CAHN

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	@ HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jun CMFD
>A> AP		EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jun CMFD
>D>	@	EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jun CMFD
>A> AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jun CMFD
AP	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CAHN

SOLUTION;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	May CPOT
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	May NEWA
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	May CPOT
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	May NEWA
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	May CPOT
+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	May NEWA
+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	May CPOT

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb NEWA
------------------------	------	---------	-----	--------------	----------

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+!	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr NEWA
+!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

>A> AB	+ UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jun CAHN
>A> AB	+	EQ 75MG BASE	N020699	002	Oct 20, 1997	Jun CAHN
>A>	@	EQ 100MG BASE	N020699	003	Oct 20, 1997	Jun CAHN
>A> AB	+!	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jun CAHN
>D> AB	+	WYETH PHARMS	N020699	001	Oct 20, 1997	Jun CAHN
>D> AB	+	EQ 75MG BASE	N020699	002	Oct 20, 1997	Jun CAHN
>D>	@	EQ 100MG BASE	N020699	003	Oct 20, 1997	Jun CAHN
>D> AB	+	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE					
AB	INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020
AB		EQ 75MG BASE	A203332	002	Mar 12, 2020
AB		EQ 150MG BASE	A203332	003	Mar 12, 2020
VERAPAMIL HYDROCHLORIDE					
SOLUTION;INTRAVENOUS VERAPAMIL HYDROCHLORIDE					
AP	AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020
AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020
AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020
VIGABATRIN					
FOR SOLUTION;ORAL VIGABATRIN					
AA	GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020
VILAZODONE HYDROCHLORIDE					
TABLET;ORAL VILAZODONE HYDROCHLORIDE					
@	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019
@		20MG	A208212	002	Sep 30, 2019
@		40MG	A208212	003	Sep 30, 2019
VINCRISTINE SULFATE					
INJECTABLE;INJECTION VINCRISTINE SULFATE PFS					
AP	! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999
VORICONAZOLE					
INJECTABLE;INTRAVENOUS VORICONAZOLE					
AP	GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020
ZALEPLON					
CAPSULE;ORAL ZALEPLON					
@	TEVA PHARMS	5MG	A077239	001	Jun 06, 2008
@		10MG	A077239	002	Jun 06, 2008
ZIDOVUDINE					
TABLET;ORAL ZIDOVUDINE					
@	MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011
ZINC SULFATE					
SOLUTION;INTRAVENOUS ZINC SULFATE					
AM REGENT		EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020
ZIPRASIDONE HYDROCHLORIDE					
CAPSULE;ORAL GEODON					
>D> AB	+! PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001
>D> AB	+	EQ 40MG BASE	N020825	002	Feb 05, 2001
>D> AB	+	EQ 60MG BASE	N020825	003	Feb 05, 2001
>D> AB	+	EQ 80MG BASE	N020825	004	Feb 05, 2001
>A> AB	+! UPJOHN	EQ 20MG BASE	N020825	001	Feb 05, 2001
>A> AB	+	EQ 40MG BASE	N020825	002	Feb 05, 2001
>A> AB	+	EQ 60MG BASE	N020825	003	Feb 05, 2001
>A> AB	+	EQ 80MG BASE	N020825	004	Feb 05, 2001
ZIPRASIDONE HYDROCHLORIDE					
AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR
GEODON

>D> AP +! PFIZER EQ 20MG BASE/ML N020919 001 Jun 21, 2002 Jun CAHN
>A> AP +! UPJOHN EQ 20MG BASE/ML N020919 001 Jun 21, 2002 Jun CAHN

ZOLEDRONIC ACID

**INJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID**

@	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr DISC
AP	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb NEWA
AP	PUNISKA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN

ZOLMITRIPTAN

**TABLET; ORAL
ZOLMITRIPTAN**

AB	APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar CAHN
AB		5MG	A206973	002	Jun 30, 2017	Mar CAHN
TABLET, ORALLY DISINTEGRATING;ORAL						
ZOLMITRIPTAN						
@	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb DISC
@		5MG	A202855	002	Sep 20, 2019	Feb DISC

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

>D>	AB	VINTAGE	5MG	A078616	001	Nov 21, 2008	Jun	DISC
>A>	@		5MG	A078616	001	Nov 21, 2008	Jun	DISC
>D>	AB		10MG	A078616	002	Nov 21, 2008	Jun	DISC
>A>	@		10MG	A078616	002	Nov 21, 2008	Jun	DISC
	@ YUNG SHIN PHARM		5MG	A077990	001	Apr 23, 2007	Apr	DISC
	@		10MG	A077990	002	Apr 23, 2007	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

A213592 001 Jun 04, 2020 Jun NEWA
A213592 002 Jun 04, 2020 Jun NEWA

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE

AB	AUROBINDO PHARMA LTD	25MG	A 077645	002	Sep 29, 2006	Mar CMFD
AB		50MG	A 077645	003	Sep 29, 2006	Mar CMFD
AB		100MG	A 077645	001	Dec 22, 2005	Mar CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN
+! GLAXOSMITHKLINE 250MG;125MG
+! PFIZER INC 250MG;125MG

N211733 001 Feb 28, 2020 Apr CAHN
N211733 001 Feb 28, 2020 Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS 0.1%
P AND L 0.1%

A091314 001 Jul 01, 2010 Mar CMS1
A090962 001 Jun 02, 2010 Apr CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
PERRIGO R AND D 5MG;120MG

A210719 001 Nov 16, 2018 Mar CMFD

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

PERRIGO UK FINCO 1%
VOLTAREN ARTHRITIS PAIN
+! GLAXOSMITHKLINE CONS 1%
+! 1%

A211253 001 May 16, 2019 Apr CMS1
N022122 001 Oct 17, 2007 Mar CTNA
N022122 001 Oct 17, 2007 Mar CMS1

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

HETERO LABS LTD III EQ 20MG BASE
EQ 20MG BASE
SUN PHARM EQ 20MG BASE

A208939 001 May 28, 2020 May NEWA
A212507 001 Jun 02, 2020 May NEWA
A212866 001 May 04, 2020 Apr NEWA

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

DR REDDYS LABS LTD EQ 20MG BASE
MYLAN EQ 20MG BASE

A211571 001 May 14, 2020 May NEWA
A212088 001 Jun 25, 2020 Jun NEWA

>A>

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

DR REDDYS LABS LTD 10MG
@ MYLAN 10MG
@ TEVA 10MG

A077367 002 Aug 17, 2001 Jan CMS1
A075674 001 Dec 21, 2001 Jan DISC
A075312 001 May 31, 2001 Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO 60MG
180MG

A212971 001 Feb 24, 2020 Feb NEWA
A212971 002 Feb 24, 2020 Feb NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

@ GRANULES INDIA LTD 60MG
@ 180MG

A211075 001 Oct 18, 2019 May DISC
A211075 002 Oct 18, 2019 May DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

GRANULES INDIA LTD 600MG
1.2GM

A213420 001 May 08, 2020 Apr NEWA
A213420 002 May 08, 2020 Apr NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 600MG;60MG
1.2GM;120MG
SUN PHARM INDNS INC 600MG;60MG
1.2GM;120MG

A213203 001 Mar 25, 2020 Mar NEWA
A213203 002 Mar 25, 2020 Mar NEWA
A212542 001 Apr 28, 2020 Apr NEWA
A212542 002 Apr 28, 2020 Apr NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>D>	ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020	Jun DISC
>A>	@	200MG	A209076	001	Jan 06, 2020	Jun DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

BAYSHORE PHARMS LLC EQ 0.025% BASE

A204059 001 Jun 01, 2020 May NEWA

LEVO CETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVO CETIRIZINE DIHYDROCHLORIDE

HETERO LABS LTD III 5MG
PERRIGO R AND D 5MGA213513 001 Apr 29, 2020 Apr NEWA
A211983 001 Mar 28, 2019 Feb CMFDLEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D>	@ ACCORD HLTHCARE	1.5MG	A207660	001	May 02, 2019	Jun CAHN
	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan CMFD
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan CAHN
>A>	@ NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Jun CAHN
	XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

BIONPHARMA INC 10MG

A202538 001 Dec 21, 2018 May CMFD

SYRUP;ORAL

LORATADINE

@ TEVA 1MG/ML

A075505 001 Nov 07, 2003 Apr DISC

TABLET;ORAL

LORATADINE

@ MYLAN 10MG
@ 10MGA075790 001 Nov 07, 2008 Jan DISC
A078447 001 Aug 12, 2011 Jan DISC

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ ACTAVIS LABS FL INC 10MG

A075990 001 Nov 03, 2003 Apr DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ YICHANG HUMANWELL 220MG

A212033 001 Aug 30, 2019 Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

DR REDDYS LABS SA EQ 2MG BASE
EQ 4MG BASE
P AND L EQ 2MG BASE
EQ 4MG BASEA212983 001 Feb 21, 2020 Feb NEWA
A212983 002 Feb 21, 2020 Feb NEWA
A212057 001 May 14, 2020 May NEWA
A212057 002 May 14, 2020 May NEWANONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ @ MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Mar DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A>	GLAND PHARMA LTD	EQ 0.2% BASE	A209752	001	May 20, 2020	May NFTG
	MICRO LABS LTD INDIA	EQ 0.2% BASE	A204620	001	Jun 16, 2020	Jun NEWA
	PATADAY ONCE DAILY RELIEF					
+!	NOVARTIS	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar CTNA
+!		EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar CMS1
	PATADAY TWICE DAILY RELIEF					
+!	NOVARTIS	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar CTNA
+!		EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar CMS1

OMEПRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEПRAZOLE MAGNESIUM

HETERO LABS LTD III EQ 20MG BASE
P AND L EQ 20MG BASEA211732 001 Mar 25, 2020 Mar NEWA
A206582 001 Jun 01, 2020 May NEWAOMEПRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEПRAZOLE AND SODIUM BICARBONATE

@ ACTAVIS ELIZABETH 20MG;1.1GM

A204137 001 Jul 15, 2016 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

LANNETT CO INC 17GM/PACKET
17GM/SCOOPFULA090600 001 Oct 06, 2009 Jan CMFD
A090600 002 Oct 06, 2009 Jan CMFDRANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ APOTEX INC EQ 75MG BASE
@ EQ 150MG BASE
@ STRIDES PHARMA EQ 75MG BASE
@ EQ 75MG BASE
@ EQ 150MG BASE
@ EQ 150MG BASEA075167 001 May 04, 2000 May DISC
A200172 001 May 31, 2012 Apr DISC
A201745 001 Feb 29, 2012 Apr DISC
A209160 001 Mar 05, 2018 Apr DISC
A200536 001 Jun 28, 2011 Apr DISC
A209161 001 Feb 22, 2018 Apr DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2020

NO JUNE 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115 001					CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001					NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10588895	Jul 07, 2020	U-2772		M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10588895	Jan 14, 2022	U-2772			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10561808	Jan 01, 2032	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10561808	Jan 01, 2032	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGITALER</u>						
N 205636 002	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>ALCAFTADINE - LASTACAF</u>						
N 022134 001	10617695	Mar 19, 2027	DP U-1493			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	>A> 10420763	Jun 11, 2030	DP U-2825		>A> NP	May 21, 2023
	>A> 10449146	Apr 19, 2036	U-2825			
	>A> 8414922	Dec 16, 2031	DP U-2825			
	>A> 8603514	Apr 03, 2024	DP			
	>A> 8663687	Feb 02, 2023	DP			
	>A> 8765167	Feb 20, 2024	DP			
	>A> 8846074	Dec 16, 2031	DP U-2825			
	>A> 9044475	Jun 11, 2030	DP			
	>A> 9283219	Jun 11, 2030	DP U-2825			
	>A> 9326981	Jun 11, 2030	U-2825			
	>A> 9669019	Jun 11, 2030	DP U-2825			
	>A> 9669021	Jun 11, 2030	U-2825			
	>A> 9855221	Feb 14, 2022	DP			
	>A> 9931305	Feb 14, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	>A> 10420763	Jun 11, 2030	DP U-2825		>A> NP	May 21, 2023
	>A> 10449146	Apr 19, 2036	U-2825			
	>A> 8414922	Dec 16, 2031	DP U-2825			
	>A> 8603514	Apr 03, 2024	DP			
	>A> 8663687	Feb 02, 2023	DP			
	>A> 8765167	Feb 20, 2024	DP			
	>A> 8846074	Dec 16, 2031	DP U-2825			
	>A> 9044475	Jun 11, 2030	DP			
	>A> 9283219	Jun 11, 2030	DP U-2825			
	>A> 9326981	Jun 11, 2030	U-2825			
	>A> 9669019	Jun 11, 2030	DP U-2825			
	>A> 9669021	Jun 11, 2030	U-2825			
	>A> 9855221	Feb 14, 2022	DP			
	>A> 9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	>A> 10420763	Jun 11, 2030	DP U-2825		>A> NP	May 21, 2023
	>A> 10449146	Apr 19, 2036	U-2825			
	>A> 8414922	Dec 16, 2031	DP U-2825			
	>A> 8603514	Apr 03, 2024	DP			
	>A> 8663687	Feb 02, 2023	DP			
	>A> 8765167	Feb 20, 2024	DP			
	>A> 8846074	Dec 16, 2031	DP U-2825			
	>A> 9044475	Jun 11, 2030	DP			
	>A> 9283219	Jun 11, 2030	DP U-2825			
	>A> 9326981	Jun 11, 2030	U-2825			
	>A> 9669019	Jun 11, 2030	DP U-2825			
	>A> 9669021	Jun 11, 2030	U-2825			
	>A> 9855221	Feb 14, 2022	DP			
	>A> 9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	>A> 10420763	Jun 11, 2030	DP U-2825		>A> NP	May 21, 2023
	>A> 10449146	Apr 19, 2036	U-2825			
	>A> 8414922	Dec 16, 2031	DP U-2825			
	>A> 8603514	Apr 03, 2024	DP			
	>A> 8663687	Feb 02, 2023	DP			
	>A> 8765167	Feb 20, 2024	DP			
	>A> 8846074	Dec 16, 2031	DP U-2825			
	>A> 9044475	Jun 11, 2030	DP			
	>A> 9283219	Jun 11, 2030	DP U-2825			
	>A> 9326981	Jun 11, 2030	U-2825			
	>A> 9669019	Jun 11, 2030	DP U-2825			
	>A> 9669021	Jun 11, 2030	U-2825			
	>A> 9855221	Feb 14, 2022	DP			
	>A> 9931305	Feb 14, 2022	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					M-257	Apr 10, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 003					M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10624850	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001					NCE	May 26, 2025
					ODE-290	May 26, 2027
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENNU</u>						
N 209381 001	10646512	Mar 25, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AXITINIB - INLYTA</u>						
N 202324 001 >A> 10570202		Feb 03, 2035	U-2844			
<u>AXITINIB - INLYTA</u>						
N 202324 002 >A> 10570202		Feb 03, 2035	U-2844			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001				PC		Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10633397	Apr 27, 2036	U-2816			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10633397	Apr 27, 2036	U-2816			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002 >A> 7498343		Dec 01, 2026	DS DP U-1321			
	>A> 8546428	Mar 19, 2029	DS DP U-1321			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002	>A> 7498343	Dec 01, 2026	DS DP U-1321			
	>A> 8546428	Mar 19, 2029	DS DP U-1321			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10624918	Jun 03, 2029	U-916			
<u>BEPOVASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Jan 13, 2025	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
	>A> 10660908	Jun 10, 2031	DP U-2627			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	>A> 6579968	Jun 28, 2021	DS DP			
	>A> 6794489	Jun 28, 2021	DS DP			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	>A> 10385078	Nov 10, 2035	DS DP U-2837		>A> ODE-300	May 22, 2027
	>A> 9273077	May 21, 2029	U-2837			
	>A> 9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	>A> 10385078	Nov 10, 2035	DS DP U-2837		>A> ODE-300	May 22, 2027
	>A> 9273077	May 21, 2029	U-2837			
	>A> 9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	>A> 10385078	Nov 10, 2035	DS DP U-2837		>A> ODE-300	May 22, 2027
	>A> 9273077	May 21, 2029	U-2837			
	>A> 9611283	Apr 10, 2034	U-2837			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	>A> 10385078	Nov 10, 2035	DS DP U-2837		>A> ODE-300	May 22, 2027
	>A> 9273077	May 21, 2029		U-2837		
	>A> 9611283	Apr 10, 2034		U-2837		
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586 002					CGT	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031		U-2489		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10592168	Jun 06, 2031		U-2489		
<u>CABAZITAXEL - JEVXTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030		U-2753		
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001					NPP	Nov 05, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025		U-2441		
	8222219	Apr 11, 2025		U-2632		
	8222219	Apr 11, 2025		U-493		
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025		U-2441		
	8222219	Apr 11, 2025		U-2632		
	8222219	Apr 11, 2025		U-493		
	8513202	Dec 03, 2027	DS DP U-2441			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001 >A>	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002 >A>	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	10376527	May 27, 2036	DP U-2718		NP	May 05, 2023
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBABAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRI</u>						
N 212819 001 >A>	8487093	Nov 19, 2029	DS DP U-2586			
	>A> 8487093	Nov 19, 2029	DS DP U-2587			
	>A> 8487093	Nov 19, 2029	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001				>A> NP		May 22, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 001	>A> 8337890 >A> 8623409	Apr 17, 2027 Sep 08, 2031	DP			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 002	>A> 8337890 >A> 8623409	Apr 17, 2027 Sep 08, 2031	DP			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	6642245 6642245 7803788 7803788 8148374 8148374 8148374 8148374 8148374 8148374 8754065 8754065 9296769 9296769	Nov 04, 2020 Nov 04, 2020 Feb 02, 2022 Feb 02, 2022 Sep 03, 2029 Sep 03, 2029 Sep 03, 2029 Sep 03, 2029 Sep 03, 2029 Sep 03, 2029 Aug 15, 2032 Aug 15, 2032 Aug 15, 2032 Aug 15, 2032	U-2352 U-2765 U-2352 U-2765 DS DP U-2353 DS DP U-2364 DS DP U-2365 DS DP U-2766 DS DP U-2767 DS DP U-2768 DS DP U-2352 DS DP U-2765 DS DP U-2352 DS DP U-2765			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	>A> 10383820 >A> 10383821	Nov 22, 2036 Nov 22, 2036	DP U-2814 DP			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451 8039451*PED 8168614 8168614*PED 8501712 8501712*PED 9682092 9682092*PED	Jun 11, 2026 Dec 11, 2026 Jan 20, 2030 Jul 20, 2030 Feb 16, 2027 Aug 16, 2027 Feb 16, 2027 Aug 16, 2027	DS DP U-1932 U-1932		NCE NPP PED PED	Dec 14, 2021 Mar 23, 2023 Jun 14, 2022 Sep 23, 2023
<u>CYSTEAMINE BITARTRATE - PROCYSB</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSB</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSB</u>						
N 213491 001	10143665 10328037 10548859 8026284 9173851 9192590 9198882 9233077 9925156 9925157 9925158	Aug 16, 2036 Aug 16, 2036 Aug 16, 2036 Sep 22, 2027 Jun 17, 2034 Jan 26, 2027 Jan 26, 2027 Jun 17, 2034 Jan 26, 2027 Jan 26, 2027 Jan 26, 2027	U-1399 U-1399 U-1399 U-1399 DP U-1399 U-1399 DP DP U-1399 DP U-1399 DP U-1399		M-216 PED	Dec 22, 2020 Jun 22, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001					ODE-287	Aug 03, 2024
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					>A> I-834	May 05, 2023
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					>A> I-834	May 05, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	>A> 7049328	Jun 28, 2021	U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP ODE-279	Jan 10, 2023
	8895546	Mar 27, 2029	DP			Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP ODE-279	Jan 10, 2023
	8895546	Mar 27, 2029	DP			Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286 001					CGT	Nov 18, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907 001					CGT	Nov 19, 2020
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					M-260	Feb 05, 2023
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001 >A> 8129385		Oct 05, 2027	DS DP			
>A> 9242986		Dec 08, 2029	DS DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP			
<u>DOXEPPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
>A> 10653660		Jul 20, 2027	U-620			
>A> 10653662		May 18, 2027	U-620			
<u>DOXEPPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
>A> 10653660		Jul 20, 2027	U-620			
>A> 10653662		May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001 >A> 10603281		Jun 08, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFFINAConazole - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	>A> 6872728	Jan 25, 2021	DS DP	>A> NCE		Jul 23, 2023
	>A> 7056927	Sep 10, 2024	DS DP	>A> NP		May 29, 2023
	>A> 7179815	Mar 07, 2021	U-2842			
	>A> 7419983	Jul 06, 2024	DS DP			
	>A> 7462625	Jan 25, 2021	DS DP U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 10646481	Aug 13, 2029	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	>A> 7741356	Jun 24, 2026	DS DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	>A> 7741356	Jun 24, 2026	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027	U-1652	Y	M-252	Mar 20, 2023
	9173859	May 04, 2027	DP U-1772	Y	M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027	U-1652	Y	M-252	Mar 20, 2023
	9173859	May 04, 2027	DP U-1772	Y	M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10610489	Sep 30, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
					ODE-284	Sep 28, 2024
					ODE-285	Sep 28, 2024
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-826	Apr 08, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10258622	Nov 21, 2032	U-2802			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9474754	Aug 05, 2033	DP U-2802			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPINEPHRINE - ADRENACCLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENAClick</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 10675287	May 06, 2025	U-2041			
	>A> 10675287	May 06, 2025	U-2831			
	>A> 10695354	May 06, 2025	U-2501			
	>A> 10695354	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 10675287	May 06, 2025	U-2041			
	>A> 10675287	May 06, 2025	U-2831			
	>A> 10695354	May 06, 2025	U-2501			
	>A> 10695354	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 10675287	May 06, 2025	U-2041			
	>A> 10675287	May 06, 2025	U-2831			
	>A> 10695354	May 06, 2025	U-2501			
	>A> 10695354	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 10675287	May 06, 2025	U-2041			
	>A> 10675287	May 06, 2025	U-2831			
	>A> 10695354	May 06, 2025	U-2501			
	>A> 10695354	May 06, 2025	U-2831			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	>A> 10668082	Jun 18, 2033	U-2316			
	>A> 10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	>A> 10668082	Jun 18, 2033	U-2316			
	>A> 10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10639375	Nov 21, 2032	DP			
	>A> 10675288	Nov 21, 2032	U-2439			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039		U-2786		
	10632066	Feb 01, 2039		U-2787		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP	U-2588		
	6515117	Oct 04, 2020	DS DP	U-2588		
	6872700	Jan 14, 2020		U-2588		
	6872700	Jan 14, 2020		U-2589		
	6872700	Jan 14, 2020		U-2590		
	6872700	Jan 14, 2020		U-2591		
	6936590	Oct 04, 2020		U-2588		
	7456254	Jun 30, 2025	DP	U-2588		
	7456254	Jun 30, 2025	DP	U-2589		
	7456254	Jun 30, 2025	DP	U-2590		
	7456254	Jun 30, 2025	DP	U-2592		
	7612176	Apr 13, 2025	DP	U-2588		
	7612176	Apr 13, 2025	DP	U-2589		
	7612176	Apr 13, 2025	DP	U-2590		
	7612176	Apr 13, 2025	DP	U-2592		
	8329648	Aug 18, 2026		U-2588		
	8329648	Aug 18, 2026		U-2589		
	8329648	Aug 18, 2026		U-2590		
	8329648	Aug 18, 2026		U-2593		
	8329648	Aug 18, 2026		U-2594		
	8329648	Aug 18, 2026		U-2595		
	8329648	Aug 18, 2026		U-2596		
	8361972	Mar 21, 2028		U-2588		
	8431685	Apr 13, 2025	DP	U-2588		
	8431685	Apr 13, 2025	DP	U-2589		
	8431685	Apr 13, 2025	DP	U-2590		
	8431685	Apr 13, 2025	DP	U-2598		
	8461105	Apr 13, 2025	DP	U-2588		
	8461105	Apr 13, 2025	DP	U-2589		
	8461105	Apr 13, 2025	DP	U-2590		
	8461105	Apr 13, 2025	DP	U-2598		
	8501698	Jun 20, 2027	DP	U-2588		
	8906851	Aug 18, 2026		U-2588		
	8906851	Aug 18, 2026		U-2589		
	8906851	Aug 18, 2026		U-2590		
	8906851	Aug 18, 2026		U-2593		
	9198925	Oct 04, 2020		U-2588		
	9238076	Apr 15, 2024	DP	U-2588		
	9238076	Apr 15, 2024	DP	U-2589		
	9238076	Apr 15, 2024	DP	U-2590		
	9238076	Apr 15, 2024	DP	U-2599		
	9884092	Aug 18, 2026		U-2588		
	9884092	Aug 18, 2026		U-2589		
	9884092	Aug 18, 2026		U-2590		
	9884092	Aug 18, 2026		U-2593		
	9884092	Aug 18, 2026		U-2594		
	9884092	Aug 18, 2026		U-2595		
	9884092	Aug 18, 2026		U-2596		
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP	U-2588		
	6515117	Oct 04, 2020	DS DP	U-2588		
	6872700	Jan 14, 2020		U-2588		
	6872700	Jan 14, 2020		U-2589		
	6872700	Jan 14, 2020		U-2590		
	6872700	Jan 14, 2020		U-2591		
	6936590	Oct 04, 2020		U-2588		
	7456254	Jun 30, 2025	DP	U-2588		
	7456254	Jun 30, 2025	DP	U-2589		
	7456254	Jun 30, 2025	DP	U-2590		
	7456254	Jun 30, 2025	DP	U-2592		
	7612176	Apr 13, 2025	DP	U-2588		
	7612176	Apr 13, 2025	DP	U-2589		
	7612176	Apr 13, 2025	DP	U-2590		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS	U-2709		
	10519252	Oct 20, 2023	DS	U-2710		
	10519252	Oct 20, 2023	DS	U-2711		
	10519252	Oct 20, 2023	DS	U-2712		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021		DP U-1577		
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP	U-2734		
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS	U-2801		
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027		U-2719		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 001	>A> 8932557	May 19, 2029	DS		>A> NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 002	>A> 8932557	May 19, 2029	DS		>A> NCE	May 28, 2025
<u>FLUORESTRADIOL F-18 - CERIANNA</u>						
N 212155 001					>A> NCE	May 20, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 004	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Sep 03, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10624911	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	>A> 10208073	May 23, 2032	U-2301			
	>A> 10624911	Jun 02, 2037	DP			
	>A> 8426450	May 23, 2032	DS DP			
	>A> 8895586	May 23, 2032	U-2301			
	>A> 9186357	Nov 18, 2030	U-2301			
	>A> 9403772	May 23, 2032	DS U-2301			
	>A> 9908907	May 23, 2032	DS DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					M-259	Apr 10, 2023
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 10653696	Jun 03, 2031	U-1456			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	>A> 10653696	Jun 03, 2031	U-1456			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 10653696	Jun 03, 2031	U-1456			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002 >A> 10653696		Jun 03, 2031		U-1456		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003 >A> 10653696		Jun 03, 2031		U-1456		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004 >A> 10653696		Jun 03, 2031		U-1456		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001 10555924		Jun 28, 2033		U-2743		
	10555925	Jun 28, 2033		U-2744		
	10568861	Jun 28, 2033		U-2756		
	10576054	Jun 28, 2033		U-2762		
>A> 10668042		Jun 28, 2033		U-2841		
	8518929	Feb 09, 2030		U-1287		
	8524698	Feb 09, 2030		U-1287		
	8546372	Feb 09, 2030		U-1287		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002 10555924		Jun 28, 2033		U-2743		
	10555925	Jun 28, 2033		U-2744		
	10568861	Jun 28, 2033		U-2756		
	10576054	Jun 28, 2033		U-2762		
>A> 10668042		Jun 28, 2033		U-2841		
	8518929	Feb 09, 2030		U-1287		
	8524698	Feb 09, 2030		U-1287		
	8546372	Feb 09, 2030		U-1287		
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001 10631746		Aug 04, 2035		DP U-2815		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001 >A> 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002 >A> 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003 >A> 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001 >A> 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002 >A> 10646481		Aug 13, 2029		DP		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001 10597384		Dec 04, 2028	DS DP	U-2777		
>A> 10646481		Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002 10597384		Dec 04, 2028	DS DP	U-2777		
>A> 10646481		Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001 10597384		Dec 04, 2028	DS DP	U-2778		
>A> 10646481		Aug 13, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778			
>A> 10646481 Aug 13, 2029 DP						
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784			
10610125 Jun 21, 2030 U-2785						
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
8748459 Mar 27, 2023 U-1719						
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
8748459 Mar 27, 2023 U-1719						
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
10588901 Mar 14, 2034 DS DP U-2773						
>A> 10654844 Nov 10, 2030 DS DP U-1524						
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
8268848 Sep 20, 2031 DS DP U-2791						
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
8268848 Sep 20, 2031 DS DP U-2791						
<u>LETHERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	May 22, 2024	DS DP			
<u>LETHERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	May 22, 2024	DS DP			
<u>LETHERMOVIR - PREVYMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP			
7196086 May 22, 2024 DS DP Y						
RE46791 May 22, 2024 DS DP						
<u>LETHERMOVIR - PREVYMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP			
7196086 May 22, 2024 DS DP Y						
RE46791 May 22, 2024 DS DP						
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001					I-829	May 01, 2023
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE; TETRACAIN - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	>A> 10675325	Aug 11, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10555938	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10555938	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10555938	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10555938	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10555938	Mar 07, 2025		U-1316		
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP	U-2764		
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001 >A>	10646437	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029		U-543		
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029		U-2713		
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029		DP		
	9956227	Dec 03, 2034		U-2714		
	RE39680	Jun 15, 2020	DS DP	U-543		
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001 >A>	7763615	Dec 13, 2024	DS DP	U-2836		
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP	U-2750	NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP	U-2750		
	8512727	Dec 25, 2022	DP	U-2750		
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031		U-2490		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 022270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 022270 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 022270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 022270 003					M-244	Aug 12, 2022
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10610485	Jan 02, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10617651	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10617651	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10617651	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10617651	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10617651	Mar 23, 2032		U-2357		
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP	U-2357		
>A> 10688060		Oct 30, 2035	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	>A> 6770262	Mar 29, 2021		U-2843		
	>A> 8334281	May 16, 2030	DP	U-2843		
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10596155	Jun 28, 2032	DP			
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 001					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 002					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMEINE</u>						
N 021506 002				I-821		Dec 20, 2022
				PED		Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMEINE</u>						
N 021506 003				I-821		Dec 20, 2022
				PED		Jun 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10660904	Apr 20, 2036		U-1643		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028		U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEO</u>						
N 212379 001	10517882	Oct 01, 2030		U-2647		
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	>A> 10213512	Oct 01, 2030	DP	U-1631		
	>A> 10265404	Oct 01, 2030	DP			
	>A> 10322186	Oct 01, 2030		U-1631		
	>A> 8865139	Oct 01, 2030	DP	U-1631		
	>A> 8945516	Oct 01, 2030	DP			
	>A> 8992896	Oct 01, 2030	DP	U-1631		
	>A> 9675700	Oct 01, 2030	DP	U-1631		
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10098863	Feb 27, 2035	DP	U-1384		
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP	U-1384		
	10105337	Feb 27, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035		U-1384		
	9511043	Feb 27, 2035		U-1384		
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035		U-1384		
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035		U-1384		
	9814692	Feb 27, 2035		U-1384		
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP	U-1384		
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026		U-1524		
	10588901	Mar 14, 2034	DS	DP U-1524		
	>A> 10654844	Nov 10, 2030	DS	DP U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	6297375	Mar 17, 2023	DS			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	10342787	Apr 16, 2038	DP	U-2804		
	10576070	Apr 16, 2038	DP	U-2804		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001					I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002					I-825	Mar 09, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8071579	Aug 12, 2027	U-2480		>A> I-831	May 08, 2023
	>A> 8071579	Aug 12, 2027	U-2819		>A> I-832	May 19, 2023
	>A> 8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2481			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8143241	Aug 12, 2027	U-2832			
	>A> 8143241	Aug 12, 2027	U-2833			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	>A> 9169235	Mar 12, 2024	U-2832			
	>A> 9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP	U-2811		
	8524746	Jul 14, 2029		U-2811		
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026		U-2811		
	9550759	Jul 26, 2026		U-2817		
	9550759	Jul 26, 2026		U-2818		
	9630955	Dec 12, 2032	DS DP	U-2811		
	9745290	Oct 10, 2027	DP	U-2811		
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029		U-2811		
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026		U-2811		
	9550759	Jul 26, 2026		U-2817		
	9550759	Jul 26, 2026		U-2818		
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP	U-2811		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1819			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1819			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1819			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10646485 >A> 10668060	Sep 02, 2036 Dec 10, 2030	DP U-1556 DP U-1819			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 10675278 >A> 10696684	Nov 20, 2023 Mar 30, 2025	DP DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573 8796318 9382217	May 14, 2029 May 14, 2029 May 14, 2029	DS DP U-2774 DS DP U-2774		NCE	Mar 25, 2025
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573 8796318 9382217	May 14, 2029 May 14, 2029 May 14, 2029	DS DP U-2774 DS DP U-2774		NCE	Mar 25, 2025
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573 8796318 9382217	May 14, 2029 May 14, 2029 May 14, 2029	DS DP U-2774 DS DP U-2774		NCE	Mar 25, 2025
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612 7208489	Jan 16, 2023 Jan 16, 2023	DS DP DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612 7208489	Jan 16, 2023 Jan 16, 2023	DS DP DS DP		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10646480	Aug 27, 2038	DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	>A> 8354430	Feb 06, 2026	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	>A> 8354430	Feb 06, 2026	U-1101			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP		>A> ODE-296 >A> ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP		>A> ODE-296 >A> ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		>A> ODE-296 >A> ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		>A> ODE-296 >A> ODE-297	May 14, 2027 May 14, 2027
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	>A> 10314828	Jul 24, 2029	U-1481			
	>A> 10335397	Jul 24, 2029	U-2579			
	>A> 9421195	Jul 24, 2029	U-1481			
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	>A> 10662188	Feb 18, 2034	DS DP U-2834			
	>A> 10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	>A> 10662188	Feb 18, 2034	DS DP U-2834			
	>A> 10662188	Feb 18, 2034	DS DP U-2835			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	>A> 10662188	Feb 18, 2034	DS DP U-2834			
	>A> 10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	>A> 10662188	Feb 18, 2034	DS DP U-2834			
	>A> 10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	>A> 10662188	Feb 18, 2034	DS DP U-2834			
	>A> 10662188	Feb 18, 2034	DS DP U-2835			
<u>RIPRETTINIB - OINLOCK</u>						
N 213973 001	>A> 8188113	Jul 27, 2030	DS DP			
	>A> 8461179	Jun 07, 2032	DS DP			
	>A> 8940756	Jun 07, 2032	U-2829			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004				I-824		Oct 11, 2021
<u>RUCAPARIB CAMSYLIATE - RUBRACA</u>						
N 209115 001	>A> 10130636	Aug 17, 2035	U-2012			
	>A> 10130636	Aug 17, 2035	U-2101			
	>A> 10130636	Aug 17, 2035	U-2273			
	>A> 10130636	Aug 17, 2035	U-2830			
	>A> 7351701	Jul 23, 2024	U-2012			
	>A> 7351701	Jul 23, 2024	U-2101			
	>A> 7351701	Jul 23, 2024	U-2273			
	>A> 7351701	Jul 23, 2024	U-2830			
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 7531530	Jul 23, 2024	U-2101			
	>A> 7531530	Jul 23, 2024	U-2273			
	>A> 7531530	Jul 23, 2024	U-2830			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2273			
	>A> 8071579	Aug 12, 2027	U-2830			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2273			
	>A> 8143241	Aug 12, 2027	U-2830			
	>A> 8859562	Aug 04, 2031	U-2012			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2273			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001 >A> 8859562		Aug 04, 2031	U-2830			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002 >A> 10130636		Aug 17, 2035	U-2012		>A> I-830	May 15, 2023
>A> 10130636		Aug 17, 2035	U-2101			
>A> 10130636		Aug 17, 2035	U-2273			
>A> 10130636		Aug 17, 2035	U-2830			
>A> 7351701		Jul 23, 2024	U-2012			
>A> 7351701		Jul 23, 2024	U-2101			
>A> 7351701		Jul 23, 2024	U-2273			
>A> 7351701		Jul 23, 2024	U-2830			
>A> 7531530		Jul 23, 2024	U-2012			
>A> 7531530		Jul 23, 2024	U-2101			
>A> 7531530		Jul 23, 2024	U-2273			
>A> 7531530		Jul 23, 2024	U-2830			
>A> 8071579		Aug 12, 2027	U-2012			
>A> 8071579		Aug 12, 2027	U-2101			
>A> 8071579		Aug 12, 2027	U-2273			
>A> 8071579		Aug 12, 2027	U-2830			
>A> 8143241		Aug 12, 2027	U-2012			
>A> 8143241		Aug 12, 2027	U-2101			
>A> 8143241		Aug 12, 2027	U-2273			
>A> 8143241		Aug 12, 2027	U-2830			
>A> 8859562		Aug 04, 2031	U-2012			
>A> 8859562		Aug 04, 2031	U-2101			
>A> 8859562		Aug 04, 2031	U-2273			
>A> 8859562		Aug 04, 2031	U-2830			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003 >A> 10130636		Aug 17, 2035	U-2012		>A> I-830	May 15, 2023
>A> 10130636		Aug 17, 2035	U-2101			
>A> 10130636		Aug 17, 2035	U-2273			
>A> 10130636		Aug 17, 2035	U-2830			
>A> 7351701		Jul 23, 2024	U-2012			
>A> 7351701		Jul 23, 2024	U-2101			
>A> 7351701		Jul 23, 2024	U-2273			
>A> 7351701		Jul 23, 2024	U-2830			
>A> 7531530		Jul 23, 2024	U-2012			
>A> 7531530		Jul 23, 2024	U-2101			
>A> 7531530		Jul 23, 2024	U-2273			
>A> 7531530		Jul 23, 2024	U-2830			
>A> 8071579		Aug 12, 2027	U-2012			
>A> 8071579		Aug 12, 2027	U-2101			
>A> 8071579		Aug 12, 2027	U-2273			
>A> 8071579		Aug 12, 2027	U-2830			
>A> 8143241		Aug 12, 2027	U-2012			
>A> 8143241		Aug 12, 2027	U-2101			
>A> 8143241		Aug 12, 2027	U-2273			
>A> 8143241		Aug 12, 2027	U-2830			
>A> 8859562		Aug 04, 2031	U-2012			
>A> 8859562		Aug 04, 2031	U-2101			
>A> 8859562		Aug 04, 2031	U-2273			
>A> 8859562		Aug 04, 2031	U-2830			
SECNIDAZOLE - SOLOSEC						
N 209363 001 >A> 10682338		Sep 04, 2035	U-2583			
SELINEXOR - XPOVIO						
N 212306 001 10519139		Aug 14, 2035	DS DP U-2584			
10544108		Jul 26, 2032	U-2584			
SEPERCATINIB - RETEVMO						
N 213246 001 >A> 10112942		Oct 10, 2037	DS DP		NCE	May 08, 2025
>A> 10137124		Oct 10, 2037	U-2826			
>A> 10137124		Oct 10, 2037	U-2827			
>A> 10137124		Oct 10, 2037	U-2828			
>A> 10172851		Oct 10, 2037	U-2826			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10584124	Oct 10, 2038	DS	U-2826		
	>A> 10584124	Oct 10, 2038	DS	U-2827		
	>A> 10584124	Oct 10, 2038	DS	U-2828		
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	>A> 10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	>A> 10137124	Oct 10, 2037	U-2826			
	>A> 10137124	Oct 10, 2037	U-2827			
	>A> 10137124	Oct 10, 2037	U-2828			
	>A> 10172851	Oct 10, 2037	U-2826			
	>A> 10172851	Oct 10, 2037	U-2827			
	>A> 10172851	Oct 10, 2037	U-2828			
	>A> 10584124	Oct 10, 2038	DS	U-2826		
	>A> 10584124	Oct 10, 2038	DS	U-2827		
	>A> 10584124	Oct 10, 2038	DS	U-2828		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS	U-2800		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS	U-2800		
<u>SEMAGLUTIDE - OZEMPIK</u>						
N 209637 001				I-822		Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIK</u>						
N 209637 002				I-822		Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001				M-252		Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002				M-252		Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003				M-252		Jan 16, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001				M-261		Apr 24, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002				M-261		Apr 24, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001				NPP		Mar 19, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR: VELPATASVIR - EPCLUSA</u>						
N 208341 002	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9757406	Jan 30, 2034	DP			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001				>A> NP		May 26, 2023
				>A> PED		Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10512609	Sep 05, 2037	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10512609	Sep 05, 2037	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10624906	Oct 28, 2036	DP			
	>A> 10660907	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	>A> 10682376	Nov 13, 2028	DP			
	>A> 10695367	Nov 13, 2028	DP			
<u>SUMATRIPTAN - TOSYMRRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001				M-253		Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002				M-253		Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003				M-253		Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004				M-253		Jan 29, 2023
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001				ODE-294		May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002				ODE-294		May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003				ODE-294		May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001				ODE-294		May 24, 2025
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610510	Jan 25, 2033	U-2805			
	10610511	Oct 10, 2034	U-2806			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2737		>A> ODE-299	Jan 23, 2027
	10369155	Oct 16, 2035	U-2736			
	10420775	Apr 13, 2032	U-2736			
	8410088	Apr 13, 2032	DS DP			
	9090562	Apr 13, 2032	DS DP			
	9394283	Apr 11, 2033	DS DP			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2025	DS			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Apr 20, 2026	DS DP U-2507			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Apr 20, 2026	DS DP U-2507			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					M-255	Feb 04, 2023
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	>A> 10238662	Feb 19, 2035	DP U-2418			
	>A> 10279131	Jul 31, 2031	DP			
	>A> 10357609	Aug 21, 2031	DP			
	>A> 10478560	Jan 24, 2026	DP			
	>A> 10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	>A> 10238662	Feb 19, 2035	DP U-2418			
	>A> 10279131	Jul 31, 2031	DP			
	>A> 10357609	Aug 21, 2031	DP			
	>A> 10478560	Jan 24, 2026	DP			
	>A> 10646495	Aug 30, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	>A> 10238662	Feb 19, 2035	DP U-2418			
	>A> 10279131	Jul 31, 2031	DP			
	>A> 10357609	Aug 21, 2031	DP			
	>A> 10478560	Jan 24, 2026	DP			
	>A> 10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	>A> RE46276	Oct 30, 2024	DS DP U-1935			
	>A> RE46276	Oct 30, 2024	DS DP U-1936			
	>A> RE46276	Oct 30, 2024	DS DP U-1937			
	>A> RE46276	Oct 30, 2024	DS DP U-1938			
	>A> RE46276	Oct 30, 2024	DS DP U-2838			
	>A> RE46276	Oct 30, 2024	DS DP U-2839			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> RE46276	Oct 30, 2024	DS DP U-1935			
	>A> RE46276	Oct 30, 2024	DS DP U-1936			
	>A> RE46276	Oct 30, 2024	DS DP U-1937			
	>A> RE46276	Oct 30, 2024	DS DP U-1938			
	>A> RE46276	Oct 30, 2024	DS DP U-2838			
	>A> RE46276	Oct 30, 2024	DS DP U-2839			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOQ</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	10597400	Oct 17, 2036	U-2616			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022		PED		Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022		PED		Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022		PED		Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034		U-2676		
	9248199	Jan 29, 2034		U-2715		
	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm